Cells suitable for genetic engineering, cell engineering and cellular drugs and methods of making same

By modifying more than two alleles of the chromosomal genome in the MHC locus and using the CRISPR/Cas system for large-scale deletion or replacement, the difficulty of targeting and uncertainty in genome modification caused by repeat sequences of the MHC locus is solved, and the problem of targeting is achieved. The efficient modification of the MHC genome and the controllability of cell surface expression.

CN119072544APending Publication Date: 2024-12-03CO LTD LOGO FUSION
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032500.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-01-27
Filing Date
2023-03-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to effectively solve the problem of targeting difficulties and genomic modification uncertainty caused by repeat sequences of MHC loci, especially when making cells for regeneration medicine, it is difficult to ensure the deletion of specific genes of MHC and the ability of cell surface expression. Controlled.

Method used

By modifying more than 2 alleles of the chromosomal genome in the MHC locus, using the CRISPR/Cas system for large-scale deletion or replacement, ensuring specific deletion or replacement of the clustering region of HLA similar sequences, combined with homologous recombination technology of selected marker genes , realize accurate editing of the MHC genome.

Benefits of technology

The efficient transformation of the MHC genome is achieved, ensuring the loss of MHC expression in cells, reducing the uncertainty of genome modification, and is suitable for transplantation and cell engineering applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005070328160000891
    Figure BDA0005070328160000891
  • Figure BDA0005070328160000901
    Figure BDA0005070328160000901
  • Figure HDA0005070328170000011
    Figure HDA0005070328170000011
Patent Text Reader

Abstract

Provided are a cell suitable for genetic engineering, cell engineering, and cell drugs, and a method for producing the same. Provided is a technique for facilitating gene targeting or sequence decoding in a specific gene region by removing a repetitive sequence present in the region among two or more alleles.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to cells suitable for genetic engineering, cell engineering and cell medicine and a method for producing the same. Background Art

[0002] Since the CRISPR / Cas system was reported as a new genome editing tool, various studies have been conducted using the CRISPR / Cas system (e.g., Patent Document 1). In genome editing using the CRISPR / Cas system, the Cas9 nuclease double-strands the target region targeted by the guide RNA. It is known that the DNA after double-stranded cutting can be repaired by homologous recombination repair (Homologous Directed Repair: HDR) or non-homologous end joining repair (Non-Homologous End-Joining Repair: NHEJ). In HDR, by introducing a donor DNA with a sequence homologous to the surrounding region of the target region into the cell together with the CRISPR / Cas system, any sequence can be integrated into the target region.

[0003] A technique for simultaneously and efficiently modifying two or more alleles using HDR using genome modification technology has been developed (for example, Patent Document 2). Patent Document 2 discloses a technique capable of simultaneously and efficiently inducing large-scale deletions of several hundred kb in two or more alleles.

[0004] In order to deal with the problem of rejection of transplanted cells by recipients due to differences in the major histocompatibility gene complex, a technique for producing cells lacking expression and function of MHC class I has been developed (e.g., Patent Document 3). Patent Document 3 proposes a scheme for knocking out β2 microglobulin (B2M) in order to lack expression and function of MHC class I.

[0005] Prior art literature

[0006] Patent Literature

[0007] Patent Document 1: International Publication No. 2014 / 093661

[0008] Patent Document 2: International Publication No. 2021 / 206054

[0009] Patent Document 3: International Publication No. 2012 / 145384 Summary of the invention

[0010] MHC-deficient cells are being developed as an effective means to deal with the problem of immune rejection, and their methods are roughly divided into the following two kinds: a method for losing the cell surface expression of MHC by destroying molecules other than MHC and a method for destroying any molecule of MHC. However, the repetitive sequences of the MHC locus are extremely numerous, and it is very difficult to decode the locus by current sequence decoding technology. Even if the transformation of a specific part can be carried out, it is difficult to analyze whether the other parts of the repetitive sequence are maintained or also transformed. Therefore, with regard to the technology of targeting the specific gene of the MHC locus, the possibility of unpredictable transformation occurring in the genome cannot be ruled out, and it is difficult to be used in the production of cells for regenerative medicine, etc. In contrast, with regard to the method for losing the cell surface expression of MHC by destroying molecules other than MHC, the effect of the destroyed molecule (such as β2 microglobulin) is unclear, and the risk of unpredictable problems caused by destruction cannot be ruled out at present.

[0011] Therefore, the present invention provides a cell in which a large region of a repetitive sequence containing a specific region of MHC that is difficult to decode is deleted, or a specific gene of MHC is deleted while replacing it with a decodable region. The present invention also provides a method for producing the cell using a genome modification method that can efficiently modify more than two alleles and can modify a large region. The obtained cell is suitable for transplantation purposes or is also suitable for use in cell engineering.

[0012] As an example, the present invention includes the following aspects.

[0013] [1A] A cell (particularly a human cell) comprising genomic DNA (particularly human genomic DNA) having a deletion, wherein the deletion is a deletion of a part or the entire region (preferably a deletion of the entire region) comprising an HLA-like sequence cluster region located in one or more (preferably all) chromosomal regions, wherein the one or more (preferably all) chromosomal regions are selected from the group consisting of the chromosomal regions specified in (i) to (iv) below:

[0014] (i) a region containing HLA-F, HLA-G and HLA-A (e.g., a chromosomal region corresponding to chr6:29723464-29945455, preferably chr6:29723464-30010618, such as chr6:29722775-29945870 or chr6:29711000-30020000 of the hg38 genomic sequence);

[0015] (ii) a series of regions containing HLA-C and HLA-B (e.g., a chromosomal region corresponding to chr6:31269169-31357158 of the hg38 genomic sequence, preferably chr6:31269169-31463338 of the hg38 genomic sequence, such as chr6:31268749-31357179 or chr6:31176000-31534000);

[0016] (iii) a region containing HLA-DRA, HLA-DRB5 and HLA-DRB1 (e.g., a chromosomal region corresponding to chr6:32445000-32816951, preferably chr6:32439951-32817002 of the hg38 genomic sequence); and

[0017] (iv) a region containing HLA-DOA, HLA-DPA1 and HLA-DPB1 (e.g., a chromosomal region corresponding to the chromosomal region of chr6:33006838-33086238, preferably chr6:33006838-33131199, such as chr6:32934636-33089696 or chr6:33002000-33147000 of the hg38 genomic sequence),

[0018] The HLA similar sequence cluster region includes all of the HLA encoding genes and HLA similar sequences respectively contained in the above chromosome region.

[0019] The portion includes at least one continuous region, and the one continuous region includes 50% or more of genes selected from the group consisting of HLA encoding genes and HLA similar sequences respectively contained in the region.

[0020] [2A] The cell according to [1A] above, wherein the genomic DNA contains no or only one endogenous HLA and HLA-like sequence, or preferably none of the deletions (i) to (iv) specified in claim 1.

[0021] [3A] The cell according to [1A] or [2A] above, wherein the genomic DNA does not contain any one or preferably all of the deletions (i) to (iv) specified in claim 1 and does not contain endogenous HLA and HLA-like sequences.

[0022] [4A] A cell according to any one of [1A] to [3A] above, comprising (i) genomic DNA in which the entire HLA-like sequence cluster region in a series of regions containing HLA-F, HLA-G and HLA-A (for example, a chromosomal region corresponding to chr6:29723464-29945455 of the hg38 genomic sequence, preferably chr6:29723464-30010618, for example chr6:29722775-29945870 or chr6:29711000-30020000) is deleted.

[0023] [5A] The cell according to any one of [1A] to [4A] above, which has (ii) a series of regions containing HLA-C and HLA-B (for example, a chromosome corresponding to chr6:31269169-31357158 of the hg38 genomic sequence, preferably chr6:31269169-31463338 of the hg38 genomic sequence, for example, chr6:31268749-31357179 or chr6:31176000-31534000) The genomic DNA is deleted as a whole in a region where HLA similar sequence clusters are located in a series of regions containing HLA-C and HLA-B (for example, a chromosomal region corresponding to chr6:31269169-31357158 of the hg38 genomic sequence, preferably chr6:31269169-31463338 of the hg38 genomic sequence, for example chr6:31268749-31357179 or chr6:31176000-31534000).

[0024] [6A] A cell according to any one of [1A] to [5A] above, which has (iii) a series of regions containing HLA-DRA, HLA-DRB5 and HLA-DRB1 (for example, a chromosomal region corresponding to the chromosomal region of chr6:32445000-32816951, preferably chr6:32439951-32817002 of the hg38 genomic sequence) or a genomic DNA in which the HLA similar sequence cluster region in the chromosomal region corresponding to chr6:32445000-32821000 is completely deleted.

[0025] [7A] A cell according to any one of [1A] to [6A] above, which has genomic DNA in which the entire HLA similar sequence cluster region in (iv) a series of regions containing HLA-DOA, HLA-DPA1 and HLA-DPB1 (for example, a chromosomal region corresponding to the chromosomal region of chr6:33006838-33086238, preferably chr6:33006838-33131199, for example, chr6:32934636-33089696 or chr6:33002000-33147000 of the hg38 genomic sequence) is deleted.

[0026] [8A] A cell according to any one of [1A] to [7A] above, wherein the deletion is a deletion of a region having one end in a specific sequence (first sequence) in a chromosome region corresponding to chr6: 29701000 to 29723464 (e.g., Chr6: 29709000-29711000) of the hg38 genomic sequence and having the other end in a specific sequence (second sequence) in a chromosome region corresponding to chr6: 29945455-30030000 (e.g., Chr6: 30020000-30020000 and chr6: 30021500-30022800) of the hg38 genomic sequence.

[0027] [9A] A cell according to any one of [1A] to [8A] above, wherein the genomic DNA comprises an insertion of an endogenous or exogenous desired gene operably linked to a control sequence, and the insertion is located in any region of (i) to (iv) above or in a region outside of (i) to (iv) above.

[0028] [10A] A cell according to any one of [1A] to [9A] above, wherein the deletion is a deletion of a region having one end in a specific sequence (third sequence) in a chromosome region corresponding to chr6:31166000 to 31269169 (e.g., Chr6:31174000 to 31177000) of the hg38 genomic sequence and having the other end in a specific sequence (fourth sequence) in a chromosome region corresponding to chr6:31357158 to 31544000 (e.g., Chr6:31534000 to 31538000) of the hg38 genomic sequence.

[0029] [11A] A cell according to any one of [1A] to [10A] above, wherein the deletion is a deletion of a region having one end in a specific sequence (5th sequence) in a chromosome region corresponding to chr6: 32416000 to 33445000 (e.g., Chr6: 32440000 to 32448500) of the hg38 genome sequence, and having the other end in a specific sequence (6th sequence) in a chromosome region corresponding to chr6: 32439951-32831000 (e.g., Chr6: 32820500 to 32822500) of the hg38 genome sequence.

[0030] [12A] A cell according to any one of [1A] to [11A] above, wherein the above-mentioned deletion is a deletion of a region having one end in a specific sequence (7th sequence) in the chromosome region corresponding to chr6:32924000~33006838 (for example, Chr6:32999500~33002500) of the hg38 genome sequence, and having the other end in a specific sequence (8th sequence) in the chromosome region corresponding to chr6:33086238-33165000 (for example, Chr6:33147500~33150500) of the hg38 genome sequence.

[0031] [13A] The cell according to any one of [1A] to [12A] above, wherein the deletions in (i) to (iv) above do not have a repetitive sequence in the chromosomal region.

[0032] [14A] The cell according to any one of [1A] to [13A] above, which has either or both of functional β2-microglobulin and functional CIITA.

[0033] [15A] The cell according to any one of [1A] to [14A] above, wherein HLA class I and / or HLA class II are substantially not expressed on the cell surface.

[0034] [16A] The cell according to any one of [1A] to [15A] above, wherein the deletion is 100 kb to 400 kb in size.

[0035] [17A] A composition comprising the cell according to any one of [1A] to [16A] above.

[0036] [18A] A cell comprising a genome having a deletion, wherein the deletion is a deletion of a region in all alleles of the genome (two alleles in the case of diploid) (for example, a deletion of a region within 1 Mb or within 500 kb), and the deletion includes a portion or preferably all of a region containing a cluster of MHC-like sequences in a locus encoding an MHC molecule.

[0037] [19A] The cell according to [18A] above, wherein each MHC-like sequence cluster region contains only one or less gene encoding an MHC molecule.

[0038] [20A] The cell according to [18A] above, wherein each MHC-like sequence cluster region contains no more than 4 genes encoding MHC molecules.

[0039] [21A] The cell according to [18A] above, wherein each MHC-like sequence cluster region does not contain a gene encoding an MHC molecule.

[0040] [22A] The cell according to [18A] above, wherein the deletion is a deletion of a region containing all MHC-like sequence clustering regions of the gene locus encoding the MHC molecule.

[0041] [23A] The cell according to [22A] above, further comprising a control sequence and a desired gene operably linked to the control sequence.

[0042] [24A] The cell according to [23A] above, wherein the control sequence and the desired gene operably linked to the control sequence have sequences that do not exist naturally as a whole.

[0043] [25A] The cell according to [23A] above, wherein the control sequence and the desired gene operably linked to the control sequence have naturally occurring (or endogenous) sequences.

[0044] [1B] A cell comprising genomic DNA having a deletion, wherein the deletion is a deletion of a region including a portion or the entirety of an HLA-like sequence cluster region located in one or more (preferably all) chromosomal regions (preferably a deletion including the entirety of the region), wherein the one or more (preferably all) chromosomal regions are selected from the group consisting of the chromosomal regions specified in (i) to (iv) below:

[0045] (i) a region containing HLA-F, HLA-G and HLA-A (e.g., a chromosomal region corresponding to chr6:29723464-29945455, preferably chr6:29723464-30010618, such as chr6:29722775-29945870 or chr6:29711000-30020000 of the hg38 genomic sequence);

[0046] (ii) a series of regions containing HLA-C and HLA-B (e.g., a chromosomal region corresponding to chr6:31269169-31357158 of the hg38 genomic sequence, preferably chr6:31269169-31463338 of the hg38 genomic sequence, such as chr6:31268749-31357179 or chr6:31176000-31534000);

[0047] (iii) a region containing HLA-DRA, HLA-DRB5 and HLA-DRB1 (e.g., a chromosomal region corresponding to chr6:32445000-32816951, preferably chr6:32439951-32817002 of the hg38 genomic sequence); and

[0048] (iv) a region containing HLA-DOA, HLA-DPA1 and HLA-DPB1 (e.g., a chromosomal region corresponding to the chromosomal region of chr6:33006838-33086238, preferably chr6:33006838-33131199, such as chr6:32934636-33089696 or chr6:33002000-33147000 of the hg38 genomic sequence),

[0049] The HLA similar sequence cluster region includes all of the HLA encoding genes and HLA similar sequences respectively contained in the above chromosome region.

[0050] The portion includes at least one continuous region, and the one continuous region includes at least 50% of genes selected from the group consisting of HLA encoding genes and HLA similar sequences respectively contained in the region.

[0051] [2B] The cell according to [1B] above, wherein the genomic DNA contains no or only one endogenous HLA and HLA-like sequence in any one or all of the deletions (i) to (iv) specified in claim 1.

[0052] [3B] The cell according to [1B] or [2B] above, wherein in the genomic DNA, any one or all of the deletions (i) to (iv) specified in claim 1 do not contain endogenous HLA and HLA-like sequences.

[0053] [4B] A cell according to any one of [1B] to [3B] above, comprising (i) genomic DNA in which the entire HLA-like sequence cluster region in a series of regions containing HLA-F, HLA-G and HLA-A (for example, a chromosomal region corresponding to chr6:29723464-29945455 of the hg38 genomic sequence, preferably chr6:29723464-30010618, for example chr6:29722775-29945870 or chr6:29711000-30020000) is deleted.

[0054] [5B] The cell according to any one of [1B] to [4B] above, which has (ii) a series of regions containing HLA-C and HLA-B (for example, a chromosome corresponding to chr6:31269169-31357158 of the hg38 genomic sequence, preferably chr6:31269169-31463338 of the hg38 genomic sequence, for example, chr6:31268749-31357179 or chr6:31176000-31534000) The genomic DNA is deleted as a whole in a region where HLA similar sequence clusters are located in a series of regions containing HLA-C and HLA-B (for example, a chromosomal region corresponding to chr6:31269169-31357158 of the hg38 genomic sequence, preferably chr6:31269169-31463338 of the hg38 genomic sequence, for example chr6:31268749-31357179 or chr6:31176000-31534000).

[0055] [6B] A cell according to any one of [1B] to [5B] above, which has (iii) a series of regions containing HLA-DRA, HLA-DRB5 and HLA-DRB1 (for example, a chromosomal region corresponding to the chromosomal region of chr6:32445000-32816951, preferably chr6:32439951-32817002 of the hg38 genomic sequence) or a genomic DNA in which the HLA similar sequence cluster region in the chromosomal region corresponding to chr6:32445000-32821000 is entirely deleted.

[0056] [7B] A cell according to any one of [1B] to [6B] above, comprising genomic DNA in which the entire HLA similar sequence cluster region in (iv) a series of regions containing HLA-DOA, HLA-DPA1 and HLA-DPB1 (for example, a chromosomal region corresponding to the chromosomal region of chr6:33006838-33086238, preferably chr6:33006838-33131199, for example, chr6:32934636-33089696 or chr6:33002000-33147000 of the hg38 genomic sequence) is deleted.

[0057] [8B] A cell according to any one of [1B] to [7B] above, wherein the deletion is a deletion of a region having one end in a specific sequence (first sequence) in a chromosome region corresponding to chr6: 29701000 to 29723464 (e.g., Chr6: 29709000-29711000) of the hg38 genomic sequence and having the other end in a specific sequence (second sequence) in a chromosome region corresponding to chr6: 29945455-30030000 (e.g., Chr6: 30020000-30020000 and chr6: 30021500-30022800) of the hg38 genomic sequence.

[0058] [9B] A cell according to any one of [1B] to [8B] above, wherein the genomic DNA comprises a control sequence and an insertion of an endogenous or exogenous desired gene operably linked to the control sequence, and the insertion is located in any region of (i) to (iv) above or in a region outside of the regions of (i) to (iv) above.

[0059] [10B] A cell according to any one of [1B] to [9B] above, wherein the deletion is a deletion of a region having one end in a specific sequence (the third sequence) in a chromosome region corresponding to chr6:31166000 to 31269169 (e.g., Chr6:31174000 to 31177000) of the hg38 genomic sequence and having the other end in a specific sequence (the fourth sequence) in a chromosome region corresponding to chr6:31357158 to 31544000 (e.g., Chr6:31534000 to 31538000) of the hg38 genomic sequence.

[0060] [11B] A cell according to any one of [1B] to [10B] above, wherein the deletion is a deletion of a region having one end in a specific sequence (5th sequence) in a chromosome region corresponding to chr6: 32416000 to 33445000 (e.g., Chr6: 32440000 to 32448500) of the hg38 genome sequence, and having the other end in a specific sequence (6th sequence) in a chromosome region corresponding to chr6: 32439951-32831000 (e.g., Chr6: 32820500 to 32822500) of the hg38 genome sequence.

[0061] [12B] A cell according to any one of [1B] to [11B] above, wherein the deletion is a deletion of a region having one end in a specific sequence (the 7th sequence) in a chromosome region corresponding to chr6: 32924000 to 33006838 (e.g., Chr6: 32999500 to 33002500) of the hg38 genome sequence, and having the other end in a specific sequence (the 8th sequence) in a chromosome region corresponding to chr6: 33086238-33165000 (e.g., Chr6: 33147500 to 33150500) of the hg38 genome sequence.

[0062] [13B] The cell according to any one of [1B] to [12B] above, wherein the deletions in (i) to (iv) above do not have a repetitive sequence in the chromosomal region.

[0063] [14B] The cell according to any one of [1B] to [13B] above, which has either or both of functional β2 microglobulin and functional CIITA.

[0064] [15B] The cell according to any one of [1B] to [14B] above, wherein HLA class I and / or HLA class II are not substantially expressed on the cell surface.

[0065] [16B] The cell according to any one of [1B] to [15B] above, wherein the deletion is 100 kb to 400 kb in size.

[0066] [17B] A composition comprising the cell according to any one of [1B] to [16B] above.

[0067] [1C] A cell comprising genomic DNA having a deletion, wherein the deletion is a deletion of a region including the entire HLA-like sequence cluster region located in one or more (preferably all) chromosomal regions selected from the group consisting of the chromosomal regions specified in the following (i) to (iv):

[0068] (i) a region containing HLA-F, HLA-G and HLA-A (e.g., a chromosomal region corresponding to chr6:29723464-29945455, preferably chr6:29723464-30010618, such as chr6:29722775-29945870 or chr6:29711000-30020000 of the hg38 genomic sequence);

[0069] (ii) a series of regions containing HLA-C and HLA-B (e.g., a chromosomal region corresponding to chr6:31269169-31357158 of the hg38 genomic sequence, preferably chr6:31269169-31463338 of the hg38 genomic sequence, such as chr6:31268749-31357179 or chr6:31176000-31534000);

[0070] (iii) a region containing HLA-DRA, HLA-DRB5 and HLA-DRB1 (e.g., a chromosomal region corresponding to chr6:32445000-32816951, preferably chr6:32439951-32817002 of the hg38 genomic sequence); and

[0071] (iv) a region containing HLA-DOA, HLA-DPA1 and HLA-DPB1 (e.g., a chromosomal region corresponding to the chromosomal region of chr6:33006838-33086238, preferably chr6:33006838-33131199, such as chr6:32934636-33089696 or chr6:33002000-33147000 of the hg38 genomic sequence),

[0072] The HLA similar sequence cluster region includes all of the HLA encoding genes and HLA similar sequences respectively contained in the above chromosome region.

[0073] The genomic DNA may further comprise a deletion of the gene encoding HLA-E,

[0074] Any one of the regions having a deletion (for example, a region having a deletion of a gene encoding HLA-E) has a first allele and a second allele, and the first allele and the second allele each have a box containing a base sequence of one or more selectable marker genes for negative selection (and preferably a marker gene for positive selection) at the deletion site (respectively referred to as the first box and the second box), and the selectable marker gene for negative selection contained in the first box and the one or more selectable marker genes for negative selection contained in the second box are different from each other so as to be distinguishable, thereby, after the first box or the second box is further subjected to modification by removing or replacing it with another sequence, cells having the modification in the first box or the second box can be selected based on the fact that the selectable marker gene for negative selection contained in the first box or the second box is not expressed as an indicator.

[0075] [2C] A cell comprising genomic DNA having a deletion, wherein the deletion is a deletion of a region including the entire HLA-like sequence cluster region located in one or more (preferably all) chromosomal regions selected from the group consisting of the chromosomal regions specified in the following (i) to (iv):

[0076] (i) a region containing HLA-F, HLA-G and HLA-A (e.g., a chromosomal region corresponding to chr6:29723464-29945455, preferably chr6:29723464-30010618, such as chr6:29722775-29945870 or chr6:29711000-30020000 of the hg38 genomic sequence);

[0077] (ii) a series of regions containing HLA-C and HLA-B (e.g., a chromosomal region corresponding to chr6:31269169-31357158 of the hg38 genomic sequence, preferably chr6:31269169-31463338 of the hg38 genomic sequence, such as chr6:31268749-31357179 or chr6:31176000-31534000);

[0078] (iii) a region containing HLA-DRA, HLA-DRB5 and HLA-DRB1 (e.g., a chromosomal region corresponding to chr6:32445000-32816951, preferably chr6:32439951-32817002 of the hg38 genomic sequence); and

[0079] (iv) a region containing HLA-DOA, HLA-DPA1 and HLA-DPB1 (e.g., a chromosomal region corresponding to the chromosomal region of chr6:33006838-33086238, preferably chr6:33006838-33131199, such as chr6:32934636-33089696 or chr6:33002000-33147000 of the hg38 genomic sequence),

[0080] The HLA similar sequence cluster region includes all of the HLA encoding genes and HLA similar sequences respectively contained in the above chromosome region.

[0081] The genomic DNA also contained a deletion of the gene encoding HLA-E,

[0082] Any one of the regions with a deletion (for example, a region with a deletion of a gene encoding HLA-E) has a first allele and a second allele, the first allele having an exogenous target gene, and the second allele having a cassette (referred to as a second cassette) containing a base sequence of one or more selectable marker genes for negative selection (and preferably a marker gene for positive selection) at the deletion site, whereby, after the second cassette is further subjected to modification by removing or replacing it with another sequence, cells having the modification in the second cassette can be selected using the fact that the selectable marker gene for negative selection contained in the second cassette is not expressed as an indicator.

[0083] [3C] A cell comprising genomic DNA having a deletion, wherein the deletion is a deletion of a region including the entire HLA-like sequence cluster region located in one or more (preferably all) chromosomal regions selected from the group consisting of the chromosomal regions specified in the following (i) to (iv):

[0084] (i) a region containing HLA-F, HLA-G and HLA-A (e.g., a chromosomal region corresponding to chr6:29723464-29945455, preferably chr6:29723464-30010618, such as chr6:29722775-29945870 or chr6:29711000-30020000 of the hg38 genomic sequence);

[0085] (ii) a series of regions containing HLA-C and HLA-B (e.g., a chromosomal region corresponding to chr6:31269169-31357158 of the hg38 genomic sequence, preferably chr6:31269169-31463338 of the hg38 genomic sequence, such as chr6:31268749-31357179 or chr6:31176000-31534000);

[0086] (iii) a region containing HLA-DRA, HLA-DRB5 and HLA-DRB1 (e.g., a chromosomal region corresponding to chr6:32445000-32816951, preferably chr6:32439951-32817002 of the hg38 genomic sequence); and

[0087] (iv) a region containing HLA-DOA, HLA-DPA1 and HLA-DPB1 (e.g., a chromosomal region corresponding to the chromosomal region of chr6:33006838-33086238, preferably chr6:33006838-33131199, such as chr6:32934636-33089696 or chr6:33002000-33147000 of the hg38 genomic sequence),

[0088] The HLA similar sequence cluster region includes all of the HLA encoding genes and HLA similar sequences respectively contained in the above chromosome region.

[0089] The genomic DNA also contained a deletion of the gene encoding HLA-E,

[0090] Any of the regions having a deletion (for example, a region having a deletion of a gene encoding HLA-E) has a first allele and a second allele, and,

[0091] (1) The deletion sites of the first allele and the second allele respectively contain exogenous target genes, or

[0092] (2) Either one of the deletion sites of the first allele or the second allele has an exogenous target gene, and the other has a structure in which both ends of the deletion site are directly or indirectly (for example, indirectly via a spacer, etc.) linked.

[0093] [4C] The cell according to [2C] above, wherein the first allele contains an exogenous gene encoding any one, two, three or all of the genes selected from the group consisting of HLA-A, HLA-B, HLA-C and HLA-E.

[0094] [5C] The cell according to [3C] above, wherein the exogenous target gene contains exogenous genes encoding any one, two, three or all of the genes selected from the group consisting of HLA-A, HLA-B, HLA-C and HLA-E, and the exogenous target gene is contained in the first allele or the second allele, respectively.

[0095] [6C] The cell according to [2C] or [4C] above, wherein the exogenous gene further comprises an upstream sequence of the transcription start point, an intron, and a downstream sequence of the stop codon of the coding region of the gene.

[0096] [7C] The cell according to [3C] or [5C] above, wherein the exogenous gene further comprises an upstream sequence of the transcription start point, an intron, and a downstream sequence of the stop codon of the coding region of the gene.

[0097] [8C] The cell according to [6C] above, wherein the upstream sequence has a length of more than 1 kbp.

[0098] [9C] The cell according to [7C] above, wherein the upstream sequence has a length of more than 1 kbp.

[0099] [10C] A composition comprising the cell according to any one of [1C] to [9C] above.

[0100] [11C] A composition for analyzing the expression and / or function of the above-mentioned foreign gene, comprising the cell according to any one of [2C] to [9C] above.

[0101] As an example, the present invention includes the following aspects.

[0102] [1] A genome modification method, which is a genome modification method for modifying two or more alleles of a chromosomal genome at an MHC locus (particularly a method for deleting a specific gene group by modifying two or more alleles of a chromosomal genome), comprising:

[0103] (a) a step of introducing the following (i) and (ii) into a cell containing the above chromosome,

[0104] (i) a genome modification system comprising a sequence-specific nucleic acid cleavage molecule targeting the target region of the chromosome genome or a polynucleotide encoding the sequence-specific nucleic acid cleavage molecule,

[0105] (ii) two or more types of donor DNAs for selection markers, each containing a base sequence of a selection marker gene between an upstream homology arm having a base sequence homologous to a base sequence adjacent to the upstream side of the target region and a downstream homology arm having a base sequence homologous to a base sequence adjacent to the downstream side of the target region, wherein the two or more types of donor DNAs for selection markers have different selection marker genes, and the number of types of the donor DNAs for selection markers is equal to or greater than the number of the alleles to be the subject of genome modification; and

[0106] (b) After the step (a), the cells are selected based on all the selectable marker genes contained in the two or more selectable marker donor DNAs.

[0107] [2] The genome modification method according to [1], wherein the selection marker gene is a positive selection marker gene, and the step (b) is a step of selecting cells that express the positive selection marker gene in an amount equal to the amount of the allele.

[0108] [3] The genome modification method according to [2], wherein the selection marker donor DNA further comprises a negative selection marker gene between the upstream homology arm and the downstream homology arm.

[0109] [4] The genome modification method according to [3] further comprises: (c) a step of introducing into the above-mentioned cells a recombinant donor DNA containing a desired base sequence between an upstream homologous arm having a homologous base sequence adjacent to the upstream side of the above-mentioned target region and a downstream homologous arm having a homologous base sequence adjacent to the downstream side of the above-mentioned target region after the above-mentioned step (b); and (d) a step of selecting cells that do not express the above-mentioned negative selection marker gene after the above-mentioned step (c).

[0110] [5] The genome modification method according to [3] or [4], wherein the positive selection marker gene is a drug resistance gene and the negative selection marker gene is a fluorescent protein gene.

[0111] [6] The genome modification method according to any one of [1] to [5], wherein the sequence-specific nucleic acid cleavage molecule is a sequence-specific endonuclease.

[0112] [7] The genome modification method according to [6], wherein the genome modification system contains a Cas protein and a guide RNA having a base sequence homologous to the base sequence in the target region.

[0113] [8] A genome modification kit for modifying two or more alleles of a chromosomal genome, comprising the following (i) and (ii):

[0114] (i) a genome modification system comprising a sequence-specific nucleic acid cleavage molecule targeting the target region of the above-mentioned chromosomal genome or a polynucleotide encoding the above-mentioned sequence-specific nucleic acid cleavage molecule;

[0115] (ii) two or more types of donor DNAs for selection markers, which contain the base sequence of a selection marker gene between an upstream homology arm having a homologous base sequence to the base sequence adjacent to the upstream side of the above-mentioned target region and a downstream homology arm having a homologous base sequence to the base sequence adjacent to the downstream side of the above-mentioned target region, wherein the above-mentioned two or more types of donor DNAs for selection markers have different selection marker genes, and the number of types of the above-mentioned donor DNAs for selection markers is greater than or equal to the number of the above-mentioned alleles to be the object of genome modification.

[0116] [9] The genome modification kit according to [8], wherein the selection marker gene is a positive selection marker gene.

[0117]

[10] The genome modification kit according to [9], wherein the selection marker donor DNA further comprises a negative selection marker gene between the upstream homology arm and the downstream homology arm.

[0118]

[11] The genome modification kit according to any one of [8] to

[10] , wherein the sequence-specific nucleic acid cleavage molecule is a sequence-specific endonuclease.

[0119]

[12] A genome modification kit according to any one of [8] to

[11] , wherein the genome modification system contains a Cas protein and a guide RNA having a base sequence homologous to the base sequence in the target region.

[0120] As an example, the present invention includes the following aspects.

[0121] [1] A method for producing a cell in which two or more alleles of a chromosome genome are modified, comprising:

[0122] (a) a step of introducing the following (i) and (ii) into a cell containing two or more alleles and introducing a selectable marker gene into each of the two or more alleles,

[0123] (i) a genome modification system comprising a sequence-specific nucleic acid cleavage molecule or a polynucleotide encoding the sequence-specific nucleic acid cleavage molecule that can target and cleave a target region in two or more alleles of the above-mentioned chromosomal genome,

[0124] (ii) two or more types of donor DNAs for selection markers, each of which has an upstream homology arm having a base sequence capable of homologously recombination with a base sequence on the upstream side of the target region and a downstream homology arm having a base sequence capable of homologously recombination with a base sequence on the downstream side of the target region, and contains a base sequence of a selection marker gene between the upstream homology arm and the downstream homology arm, the two or more types of donor DNAs for selection markers respectively have different selection marker genes that can be distinguished from each other, the selection marker gene is unique to each type of donor DNA for selection markers, and the number of types of donor DNA for selection markers is greater than or equal to the number of alleles to be the subject of genome modification; and

[0125] (b) a step of introducing, after the above step (a), different unique selectable marker genes that can be distinguished into the two or more alleles by causing different types of selectable marker donor DNAs to undergo homologous recombination with each other, and selecting cells that express all of the introduced different selectable marker genes that can be distinguished (a step for positive selection).

[0126] [2] A method for modifying two or more alleles of a chromosome genome, comprising:

[0127] (a) a step of introducing the following (i) and (ii) into a cell containing two or more alleles to introduce a selectable marker gene into each of the two or more alleles,

[0128] (i) a genome modification system comprising a sequence-specific nucleic acid cleavage molecule or a polynucleotide encoding the sequence-specific nucleic acid cleavage molecule that can target and cleave a target region in two or more alleles of the above-mentioned chromosomal genome,

[0129] (ii) two or more types of donor DNAs for selection markers, each of which has an upstream homology arm having a base sequence capable of homologously recombination with a base sequence on the upstream side of the target region and a downstream homology arm having a base sequence capable of homologously recombination with a base sequence on the downstream side of the target region, and contains a base sequence of a selection marker gene between the upstream homology arm and the downstream homology arm, the two or more types of donor DNAs for selection markers respectively have different selection marker genes that can be distinguished from each other, the selection marker gene is unique to each type of donor DNA for selection markers, and the number of types of donor DNA for selection markers is greater than or equal to the number of alleles to be the subject of genome modification; and

[0130] (b) a step of introducing, after the above step (a), different unique selectable marker genes that can be distinguished into the two or more alleles by causing different types of selectable marker donor DNAs to undergo homologous recombination with each other, and selecting cells that express all of the introduced different selectable marker genes that can be distinguished (a step for positive selection).

[0131] [3] The method according to [1] or [2] above, wherein the target region has a length of 5 kbp or more.

[0132] [4] The method according to [3] above, wherein the target region has a length of 8 kbp or more.

[0133] [5] The method according to any one of [1] to [4] above, wherein the two or more selectable marker donor DNAs respectively have a selectable marker gene for positive selection, a marker gene for negative selection, and a target sequence between the upstream homology arm and the downstream homology arm, wherein when the selectable marker gene can be used for both positive selection and negative selection, it is not necessary to have another selectable marker gene for negative selection.

[0134] The method further comprises:

[0135] (c) after the above step (b), a step of introducing the following (iii) and (iv) into the selected cells to introduce a donor DNA for recombination into the above two or more alleles,

[0136] (iii) a genome engineering system comprising a sequence-specific nucleic acid cleavage molecule capable of targeting the target sequence and cleaving the target sequence or a polynucleotide encoding the sequence-specific nucleic acid cleavage molecule,

[0137] (iv) a donor DNA for recombination containing a desired base sequence, which has an upstream homology arm having a base sequence capable of homologously recombination with the base sequence on the upstream side of the target region and a downstream homology arm having a base sequence capable of homologously recombination with the base sequence on the downstream side of the target region; and

[0138] (d) A step of selecting cells that do not express the marker gene for negative selection after the above step (c) (a step for negative selection).

[0139] [6] The method according to [3] above, wherein the two or more selectable marker donor DNAs respectively have a selectable marker gene for positive selection, a marker gene for negative selection and a target sequence between the upstream homology arm and the downstream homology arm, wherein when the selectable marker gene can be used for both positive selection and negative selection, it is not necessary to have another selectable marker gene for negative selection.

[0140] The method further comprises:

[0141] (c) after the above step (b), a step of introducing the following (iii) and (iv) into the selected cells to introduce a donor DNA for recombination into the above two or more alleles,

[0142] (iii) a genome engineering system comprising a sequence-specific nucleic acid cleavage molecule capable of targeting the target sequence and cleaving the target sequence or a polynucleotide encoding the sequence-specific nucleic acid cleavage molecule,

[0143] (iv) a donor DNA for recombination containing a desired base sequence, which has an upstream homology arm having a base sequence capable of homologously recombination with the base sequence on the upstream side of the target region and a downstream homology arm having a base sequence capable of homologously recombination with the base sequence on the downstream side of the target region; and

[0144] (d) A step of selecting cells that do not express the marker gene for negative selection after the above step (c) (a step for negative selection).

[0145] [7] The method according to [4] above, wherein the two or more selectable marker donor DNAs respectively have a selectable marker gene for positive selection, a marker gene for negative selection and a target sequence between the upstream homology arm and the downstream homology arm, wherein when the selectable marker gene can be used for both positive selection and negative selection, it is not necessary to have another selectable marker gene for negative selection.

[0146] The method further comprises:

[0147] (c) after the above step (b), a step of introducing the following (iii) and (iv) into the selected cells to introduce a donor DNA for recombination into the above two or more alleles,

[0148] (iii) a genome engineering system comprising a sequence-specific nucleic acid cleavage molecule capable of targeting the target sequence and cleaving the target sequence or a polynucleotide encoding the sequence-specific nucleic acid cleavage molecule,

[0149] (iv) a donor DNA for recombination containing a desired base sequence, which has an upstream homology arm having a base sequence capable of homologously recombination with the base sequence on the upstream side of the target region and a downstream homology arm having a base sequence capable of homologously recombination with the base sequence on the downstream side of the target region; and

[0150] (d) A step of selecting cells that do not express the marker gene for negative selection after the above step (c) (a step for negative selection).

[0151] [8] The method according to any one of [5] to [7] above, wherein the region between the upstream homology arm and the downstream homology arm of the recombination donor DNA has a length of 5 kbp or more.

[0152] [9] The method according to [6] or [7] above, wherein the region between the upstream homology arm and the downstream homology arm of the recombination donor DNA has a length of 5 kbp or more.

[0153]

[10] The method according to [7] above, wherein the region between the upstream homology arm and the downstream homology arm of the recombination donor DNA has a length of 5 kbp or more.

[0154]

[11] The method according to [8] above, wherein the region between the upstream homology arm and the downstream homology arm of the recombination donor DNA has a length of 8 kbp or more.

[0155]

[12] A genome modification kit for modifying two or more alleles of a chromosomal genome, comprising the following (i) and (ii):

[0156] (i) a genome modification system, which contains a sequence-specific nucleic acid cleavage molecule or a polynucleotide encoding the sequence-specific nucleic acid cleavage molecule that can target and cleave the target region of the above-mentioned chromosomal genome;

[0157] (ii) two or more types of donor DNAs for selection markers, which have an upstream homology arm having a base sequence that can undergo homologous recombination with a base sequence on the upstream side of the above-mentioned target region, and a downstream homology arm having a base sequence that can undergo homologous recombination with a base sequence on the downstream side of the above-mentioned target region, and the base sequence of the selection marker gene is contained between the upstream homology arm and the downstream homology arm, the above-mentioned two or more types of donor DNAs for selection markers have different selection marker genes that can be distinguished from each other, the above-mentioned selection marker genes are unique to each type of donor DNA for selection markers, and the number of types of the above-mentioned donor DNA for selection markers is greater than or equal to the number of the above-mentioned alleles to be the object of genome modification.

[0158]

[13] The kit according to

[12] above, wherein the target region has a length of 5 kbp or more.

[0159]

[14] The kit according to

[13] above, wherein the target region has a length of 8 kbp or more.

[0160]

[15] The kit according to any one of

[12] to

[14] above, further comprising a donor DNA for recombination.

[0161]

[16] The kit according to any one of

[12] to

[15] above, wherein the region between the upstream homology arm and the downstream homology arm of the recombination donor DNA has a length of 5 kbp or more.

[0162]

[17] The kit according to any one of

[12] to

[16] above, wherein the region between the upstream homology arm and the downstream homology arm of the recombination donor DNA has a length of 8 kbp or more.

[0163]

[18] The kit according to

[12] above, wherein the target region has a length of 5 kbp or more, and the region between the upstream homology arm and the downstream homology arm of the recombination donor DNA has a length of 5 kbp or more.

[0164]

[19] The kit according to

[18] above, wherein the target region has a length of 8 kbp or more, and the region between the upstream homology arm and the downstream homology arm of the recombination donor DNA has a length of 8 kbp or more.

[0165]

[20] A method according to the above-mentioned [5], wherein the recombinant donor DNA does not have a base sequence in the region between the upstream homologous arm and the downstream homologous arm of the recombinant donor DNA, and in the above-mentioned two or more alleles of the chromosomal genome obtained after the transformation, the sequences upstream and downstream of the target region are seamlessly connected in a manner without insertion, substitution or deletion of bases.

[0166]

[21] A method according to the above-mentioned [6] or [7], wherein the recombinant donor DNA does not have a base sequence in the region between the upstream homologous arm and the downstream homologous arm of the recombinant donor DNA, and in the above-mentioned two or more alleles of the chromosomal genome obtained after the transformation, the sequences upstream and downstream of the target region are seamlessly connected in a manner without insertion, substitution or deletion of bases.

[0167]

[22] The method according to [3] above, wherein the target sequence of the site-specific recombinase does not exist in the above two or more alleles of the chromosomal genome obtained after the transformation.

[0168]

[23] The method according to [4] above, wherein the target sequence of the site-specific recombinase does not exist in the above two or more alleles of the chromosomal genome obtained after the transformation.

[0169]

[24] The method according to [5] above, wherein the target sequence of the site-specific recombinase does not exist in the above two or more alleles of the chromosomal genome obtained after the transformation.

[0170]

[25] The method according to [6] or [7] above, wherein the target sequence of the site-specific recombinase does not exist in the above two or more alleles of the chromosomal genome obtained after the transformation.

[0171]

[26] A method according to any one of [1] to

[11] and

[20] to

[25] above, wherein in step (b), single cell cloning is not performed until cells in which two or more alleles have been modified are selected.

[0172]

[27] A cell having two or more alleles on a chromosome genome with respect to a target region, wherein the target region of each of the two or more alleles is deleted, and the sequences upstream and downstream of the target region are seamlessly connected without insertion, substitution or deletion of bases.

[0173]

[28] The cell according to

[27] above, wherein the target region has a length of 5 kbp or more.

[0174]

[29] The cell according to

[27] or

[28] above, which does not have a target sequence for a site-specific recombinase in its genome.

[0175]

[30] The method according to [6] or [7] above, wherein the region between the upstream homology arm and the downstream homology arm of the donor DNA for recombination has a length of more than 8 kbp.

[0176]

[31] The kit according to

[15] above, wherein the donor DNA for recombination has no base sequence in the region between the upstream homology arm and the downstream homology arm of the donor DNA for recombination.

[0177] As an example, the present invention includes the following aspects. [1D] A cell (particularly a human cell) containing genomic DNA (particularly human genomic DNA) having a deletion, wherein the deletion is a deletion of a part or the entirety of a region containing an HLA-like sequence cluster region located in one or more chromosomal regions selected from the group consisting of chromosomal regions specified in the following (i) to (iv): (i) a chromosomal region corresponding to the chromosomal region of chr6: 29711000-30020000 of the hg38 genomic sequence; (ii) a chromosomal region corresponding to the chromosomal region of chr6: 31176000-31534000 of the hg38 genomic sequence; ( iii) a chromosomal region corresponding to the chr6:32445000-32821000 chromosomal region of the hg38 genomic sequence; and (iv) a chromosomal region corresponding to the chr6:33002000-33147000 chromosomal region of the hg38 genomic sequence, wherein the HLA similar sequence clustering region contains all of the HLA coding genes and HLA similar sequences respectively contained in the above chromosomal region, and the above part contains at least one continuous region, and the above one continuous region contains more than 50% of the genes selected from the group consisting of the HLA coding genes and HLA similar sequences respectively contained in the above region. [2D] A cell according to the above [1D], wherein in the above genomic DNA, any one or preferably all of the deletions (i) to (iv) specified in claim 1 do not contain or contain only one endogenous HLA and HLA similar sequence. [3D] The cell according to [1D] or [2D], wherein the genomic DNA contains no endogenous HLA and HLA-like sequences in any one or preferably all of the deletions (i) to (iv) specified in claim 1. [4D] The cell according to any one of [1D] to [3D], which has (i) a genomic DNA in which the entire HLA-like sequence cluster region in the chromosome region of chr6:29711000-30020000 is deleted. [5D] The cell according to any one of [1D] to [4D], which has (ii) a genomic DNA in which the entire HLA-like sequence cluster region in the chromosome region of chr6:31176000-31534000 is deleted. [6D] The cell according to any one of [1D] to [5D], which has (iii) a genomic DNA in which the entire HLA-like sequence cluster region in the chromosome region of chr6:32445000-32821000 is deleted. [7D] The cell according to any one of [1D] to [6D] above, which has (iv) genomic DNA in which the entire HLA-like sequence cluster region in the chromosome region of chr6:33002000-33147000 is deleted.[8D] The cell according to any one of [1D] to [7D] above, wherein the deletion is a deletion of a region having one end in a specific sequence (first sequence) in the chromosomal region of Chr6:29709000-29711000 and the other end in a specific sequence (second sequence) in the chromosomal region of Chr6:30020000-30020000 and a chromosomal region of Chr6:30021500-30022800. [9D] The cell according to any one of [1D] to [8D] above, wherein the genomic DNA comprises an insertion of an endogenous or exogenous desired gene operably linked to a control sequence, and the insertion is located in any region of (i) to (iv) above or in a region other than the regions of (i) to (iv) above. [10D] The cell according to any one of [1D] to [9D] above, wherein the deletion is a deletion of a region having one end in a specific sequence (third sequence) in a chromosomal region of Chr6:31174000 to 31177000 and having the other end in a specific sequence (fourth sequence) in a chromosomal region of Chr6:31534000 to 31538000. [11D] The cell according to any one of [1D] to [10D] above, wherein the deletion is a deletion of a region having one end in a specific sequence (fifth sequence) in a chromosomal region of Chr6:32446000 to 32448500 and having the other end in a specific sequence (sixth sequence) in a chromosomal region of Chr6:32820500 to 32822500. [12D] The cell according to any one of [1D] to [11D], wherein the deletion is a deletion of a region having one end in a specific sequence (sequence 7) in the chromosomal region of Chr6:32999500-33002500 and the other end in a specific sequence (sequence 8) in the chromosomal region of Chr6:33147500-33150500. [13D] The cell according to any one of [1D] to [12D], wherein the deletions in (i) to (iv) do not have a repetitive sequence in the chromosomal region. [14D] The cell according to any one of [1D] to [13D], which has either or both of functional β2 microglobulin and functional CIITA. [15D] The cell according to any one of [1D] to [14D], wherein HLA class I and / or HLA class II are not substantially expressed on the cell surface. [16D] The cell according to any one of [1D] to [15D] above, wherein the deletion is 100 kb to 400 kb in size. [17D] A composition comprising the cell according to any one of [1D] to [16D] above.[18D] A cell comprising a genome having a deletion, wherein the deletion is a deletion of a region in all alleles (two alleles in the case of diploid) of the genome (e.g., a deletion of a region within 1 Mb or within 500 kb), and the deletion includes a portion or preferably all of the region containing the MHC similar sequence cluster region of the locus encoding the MHC molecule. [19D] The cell according to [18D] above, wherein each MHC similar sequence cluster region contains only one or less gene encoding the MHC molecule. [20D] The cell according to [18D] above, wherein each MHC similar sequence cluster region contains only four or less genes encoding the MHC molecule. [21D] The cell according to [18D] above, wherein each MHC similar sequence cluster region does not contain a gene encoding the MHC molecule. [22D] The cell according to [18D] above, wherein the deletion is a deletion of a region containing all the MHC similar sequence cluster regions of the locus encoding the MHC molecule. [23D] The cell according to [22D] above, further comprising a control sequence and a desired gene operably linked to the control sequence. [24D] The cell according to [23D] above, wherein the control sequence and the desired gene operably linked to the control sequence have sequences that do not exist naturally as a whole. [25D] The cell according to [23D] above, wherein the control sequence and the desired gene operably linked to the control sequence have sequences that occur naturally (or endogenous).

[0178] Effects of the Invention

[0179] According to the present invention, a genome modification method and the genome modification kit as well as cells having the modification can be provided, which are capable of efficiently modifying more than two alleles and modifying larger regions (particularly large-scale deletions of HLA class I and HLA class II regions).

[0180] Simple description of the picture

[0181] Figure 1 The figure shows the gene map of the chromosome 6 region where the HLA class I region and the HLA class II region are located. The cluster where the HLA genes are located is highlighted with arrows.

[0182] Figure 2 The results of searching for similar sequences of the HLA-A gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0183] Figure 3 The results of searching for similar sequences of the HLA-B gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0184] Figure 4 The results of searching for similar sequences of the HLA-C gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0185] Figure 5 The results of searching for similar sequences of the HLA-E gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0186] Figure 6 The results of searching for similar sequences of the HLA-F gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0187] Figure 7 The results of searching for similar sequences of the HLA-G gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0188] Figure 8 The results of searching for similar sequences of the HLA-H gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0189] Fig. 9 The results of searching for similar sequences of the HLA-J gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0190] Fig.10 The results of searching for similar sequences of the HLA-W gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0191] Fig.11 The results of searching for similar sequences of the MICA gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0192] Fig.12 The results of searching for similar sequences of the MICB gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0193] Fig.13 The results of searching for similar sequences of the HLA-DRA gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0194] Fig.14 The results of searching for similar sequences of the HLA-DRB1 gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0195] Fig.15 The results of searching for similar sequences of the HLA-DRB5 gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0196] Fig.16 The results of searching for similar sequences of the HLA-DRB6 gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0197] Fig.17 The results of searching for similar sequences of the HLA-DRB9 gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0198] Fig.18 The results of searching for similar sequences of the HLA-DQA1 gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0199] Fig.19 The results of searching for similar sequences of the HLA-DQA2 gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0200] Fig. 20 The results of searching for similar sequences of the HLA-DQB1 gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0201] Fig.21 The results of searching for similar sequences of the HLA-DPA1 gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0202] Fig. 22 The results of searching for similar sequences of the HLA-DPB1 gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0203] Fig.23 The results of searching for similar sequences of the HLA-DMB gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0204] Fig.24 The results of searching for similar sequences of the HLA-DOA gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0205] Fig.25 The results of searching for similar sequences of the HLA-DOB gene in the chromosome 6 region where the HLA class I region and the HLA class II region are located are shown.

[0206] Fig.26 The positions of four HLA-similar sequence (sequence) clustering regions (i) to (iv) in the HLA class I region and the HLA class II region are shown.

[0207] Fig. 27 An example of Blat search results for identifying terminal candidates on the telomere side of the HLA-like sequence cluster region (i) is shown.

[0208] Fig.28 An example of Blat search results for identifying the terminal candidates on the centromere side of the HLA-like sequence cluster region (i) is shown.

[0209] Fig.29 An example of Blat search results for identifying terminal candidates on the telomere side of the HLA-like sequence cluster region (ii) is shown.

[0210] Fig.30 An example of Blat search results for identifying the terminal candidates on the centromere side of the HLA-like sequence cluster region (ii) is shown.

[0211] Fig.31 An example of Blat search results for identifying terminal candidates on the telomere side of the HLA-like sequence cluster region (iii) is shown.

[0212] Fig.32 An example of Blat search results for identifying the terminal candidates on the centromere side of the HLA-like sequence cluster region (iii) is shown.

[0213] Fig.33 An example of Blat search results for identifying terminal candidates on the telomere side of the HLA-like sequence cluster region (iv) is shown.

[0214] Fig.34 An example of Blat search results for identifying the terminal candidates on the centromere side of the HLA-like sequence cluster region (iv) is shown.

[0215] Fig.35 Show Figure 27 to Figure 34 A summary of the results.

[0216] Fig.36 Shown is a scheme of a method for removing the entirety of a series of regions containing HLA-F, HLA-G, and HLA-A by the method of the present invention and its results.

[0217] Fig.37The present invention shows a method for removing a series of regions containing HLA-C and HLA-B in their entirety by the method of the present invention and the results thereof. The obtained cells lack HLA-F, HLA-G and HLA-A, as well as HLA-C and HLA-B.

[0218] Fig.38 The figure is a scattergram showing that the obtained cells are all negative for HLA-A, HLA-B and HLA-C.

[0219] Fig.39 The obtained cells were shown to express pluripotent stem cell markers comparable to those of unmodified iPS cells.

[0220] Fig.40 The scheme of a method for further deleting the HLA-E region and its results are shown.

[0221] Fig.41 The scheme of a method for further deleting the HLA-E region and its results are shown.

[0222] Fig.42 Shown is a scheme for introducing HLA-E to which a signal sequence is added instead of HLA-E and the results thereof.

[0223] Fig.43 The present invention also shows a method for removing the entire series of regions containing HLA-DRA, HLA-DRBs, HLA-DQAs, HLA-DQB1, and HLA-DOB by the method of the present invention and its results. The obtained cells lack HLA-F, HLA-G, and HLA-A; HLA-C and HLA-B; and HLA-DRA, HLA-DRBs, HLA-DQAs, HLA-DQB1, and HLA-DOB.

[0224] Fig.44 This is to show the scheme and results of the method of removing the entire series of regions containing HLA-DRA, HLA-DRBs, HLA-DQAs, HLA-DQB1 and HLA-DOB by the method of the present invention. The obtained cells lack HLA-F, HLA-G and HLA-A; HLA-C and HLA-B; and HLA-DRA, HLA-DRBs, HLA-DQAs, HLA-DQB1 and HLA-DOB.

[0225] Fig.45 A scheme for introducing an arbitrary target gene into a region having an HLA-E deletion is shown.

[0226] Fig.46A scheme for introducing foreign genes (eg, HLA-A, HLA-B, HLA-C, and HLA-E) into the HLA-E defective site is shown.

[0227] Fig.47 The present invention shows a scheme and results of cells in which HLA-A and B are integrated in cells lacking a series of regions containing HLA-F, HLA-G and HLA-A and a series of regions containing HLA-C and HLA-B and replaced with UKiS marker.

[0228] Fig.48 The results show that the cells lacking a series of regions containing HLA-F, HLA-G and HLA-A and a series of regions containing HLA-C and HLA-B (ref. Fig.37 )'s HLA-E was replaced with the UKiS marker to obtain cells integrating HLA-C and E and its results.

[0229] Fig.49 The cells into which HLA-A and B were reintroduced (ref. Fig.47 ) and cells reintroduced with HLA-C and E (ref. Fig.48 ) in the cell surface expression of HLA.

[0230] Fig.50 It was shown that HLA-deficient cells can avoid cell killing by T cells. DETAILED DESCRIPTION

[0231] [definition]

[0232] The terms "polynucleotide" and "nucleic acid" are used interchangeably and refer to nucleotide polymers formed by nucleotides bonded by phosphodiester bonds. "Polynucleotide" and "nucleic acid" can be DNA, RNA, or a combination of DNA and RNA. In addition, "polynucleotide" and "nucleic acid" can be polymers of natural nucleotides, polymers of natural nucleotides and non-natural nucleotides (analogs of natural nucleotides, nucleotides in which at least one of the base part, sugar part and phosphate part is modified (e.g., phosphorothioate backbone), etc.), and polymers of non-natural nucleotides.

[0233] The base sequence of a "polynucleotide" or "nucleic acid" is described using generally recognized single-letter symbols unless otherwise specified. The base sequence is described from the 5' side to the 3' side unless otherwise specified. The nucleotide residues constituting a "polynucleotide" or "nucleic acid" are sometimes described using only adenine, thymine, cytosine, guanine, or uracil or their single-letter symbols.

[0234] The term "gene" refers to a polynucleotide containing at least one open reading frame encoding a specific protein. A gene may contain both exons and introns.

[0235] The terms "polypeptide", "peptide" and "protein" are used interchangeably and refer to polymers of amino acids bonded by amide bonds. "Polypeptide", "peptide" or "protein" may be a polymer of natural amino acids, a polymer of natural amino acids and non-natural amino acids (chemical analogs, modified derivatives, etc. of natural amino acids), or a polymer of non-natural amino acids. Unless otherwise specified, the amino acid sequence is recorded from the N-terminal side to the C-terminal side.

[0236] The term "allele" refers to a base sequence group present at the same locus on a chromosome genome. In one embodiment, there are two alleles at the same locus in a diploid cell, and three alleles at the same locus in a triploid cell. In addition, in one embodiment, additional alleles are sometimes formed due to an abnormal copy of a chromosome or an abnormal additional copy of the locus.

[0237] The terms "genome modification" or "genome editing" are used interchangeably and refer to the induction of mutations at desired locations (target regions) on the genome. Genome modification may include the use of sequence-specific nucleic acid cutting molecules designed to cut the DNA in the target region. In a preferred embodiment, genome modification may include the use of nucleases that operate in a manner that cuts the DNA in the target region. In a preferred embodiment, genome modification may include the use of nucleases (e.g., TALEN, ZFN) that operate in a manner that cuts a target sequence having a specific base sequence in the target region. In a preferred embodiment, in genome modification, in order to cut a target sequence having a specific base sequence in the target region, restriction enzymes such as meganucleases that have only one cutting site in the genome (e.g., a restriction enzyme with a sequence specificity of 16 bases (theoretically, a restriction enzyme with a sequence specificity of 4 bases) may sometimes be used. 16 bases), restriction enzymes with a sequence specificity of 17 bases (theoretically, 17 bases) and restriction enzymes with sequence specificity of 18 bases (theoretically, 18Typically, a site-specific nuclease is used to induce a double-stranded cut (DSB) in the DNA of the target region, followed by cellular endogenous processes such as homologous recombination repair (Homologous Directed Repair: HDR) and non-homologous end-joining repair (Non-Homologous End-Joining Repair: NHEJ) to repair the genome. NHEJ is a repair method that connects the ends of double-stranded cuts without using donor DNA, and can induce insertions and / or deletions (indels) at a high frequency during repair. HDR is a repair mechanism that uses donor DNA, and it is also possible to introduce desired mutations into the target region. As a genome modification technology, the CRISPR / Cas system can be preferably exemplified.As a meganuclease, for example, a nucleic acid selected from the group consisting of I-SceI, I-SceII, I-SceIII, I-SceIV, I-SceV, I-SceVI, I-SceVII, I-CeuI, I-CeuAIIP, I-CreI, I-CrepsbIP, I-CrepsbIIP, I-CrepsbIIIP, I-CrepsbIVP, I-TliI, I-PpoI, PI-PspI, F-SceI, F- -SceII, F-SuvI, F-TevI, F-TevII, I-AmaI, I-AniI, I-ChuI, I-CmoeI, I-CpaI, I-CpaII, I-CsmI, I-CvuI, I-CvuAIP, I-DdiI, I-DdiII, I-DirI, I-DmoI, I-HmuI, I-HmuII, I-HsNIP, I-LlaI, I-MsoI, I-NaaI, I-Nan I, I-NclIP, I-NgrIP, I-NitI, I-NjaI, I-Nsp236IP, I-PakI, I-PboIP, I-PcuIP, I-PcuAI, I-PcuVI, I-Pgr IP, I-PobIP, I-PorI, I-PorIIP, I-PbpIP, I-SpBetaIP, I-ScaI, I-SexIP, I-SneIP, I-SpomI, I-SpomCP, I -SpomIP, I-SpomIIP, I-SquIP, I-Ssp68031, I-SthPhiJP, I-SthPhiST3P, I-SthPhiSTe3bP, I-TdeIP, I-T evI, I-TevII, I-TevIII, I-UarAP, I-UarHGPAIP, I-UarHGPA13P, I-VinIP, I-ZbiIP, PI-Mtul, PI-MtuHIP Meganucleases and their cleavage sites (or recognition sites) in the group consisting of PI-MtuHIIP, PI-PfuI, PI-PfuII, PI-PkoI, PI-PkoII, PI-Rma43812IP, PI-SpBetaIP, PI-SceI, PI-TfuI, PI-TfuII, PI-ThyI, PI-TliI and PI-TliII, and their functional derivative restriction enzymes, preferably meganucleases and their cleavage sites (or recognition sites) that are restriction enzymes with sequence specificity of more than 18 bases, in particular meganucleases and their cleavage sites that do not cut the genome of the cell at one or more places can be used.

[0238] The term "target region" refers to the genomic region that is the object of genome modification. "Deletion" includes deletions of more than 1 base relative to the reference genome and deletions of more than 1 gene. Deletion can be a deletion of more than 100bp, a deletion of more than 200bp, a deletion of more than 300bp, a deletion of more than 400bp, a deletion of more than 500bp, a deletion of more than 600bp, a deletion of more than 700bp, a deletion of more than 800bp, a deletion of more than 900bp, a deletion of more than 1kbp, a deletion of more than 10kbp, a deletion of more than 50kbp, a deletion of more than 100kbp, a deletion of more than 200kbp, a deletion of more than 300kbp, a deletion of more than 400kbp, a deletion of more than 500kbp, or a deletion of more than 1Mbp or a deletion below it. Deletion can be a deletion below 1Mbp. Deletion can be a deletion below 700kbp. Deletion can be a deletion below 600kbp. Deletion can be a deletion below 500kbp. Deletion can be a deletion of more than 10kbp and less than 600kbp. The deletion may be greater than 100 kbp and less than 600 kbp. The deletion may be greater than 100 kbp and less than 500 kbp.

[0239] The term "donor DNA" refers to a DNA that is used in the repair of double-stranded cutting of DNA and can undergo homologous recombination with the DNA around the target region. The donor DNA contains the base sequence upstream and the base sequence downstream of the target region as homology arms (e.g., the base sequence adjacent to the upstream side). In this specification, the homology arm composed of the base sequence on the upstream side of the target region (e.g., the base sequence adjacent to the upstream side) is sometimes referred to as the "upstream homology arm", and the homology arm composed of the base sequence on the downstream side of the target sequence (e.g., the base sequence adjacent to the downstream side) is referred to as the "downstream homology arm". In the donor DNA, the desired base sequence can be contained between the upstream homology arm and the downstream homology arm. The length of each homology arm is preferably more than 300bp, usually about 500 to 3000bp. The lengths of the upstream homology arm and the downstream homology arm can be the same or different from each other. After sequence-dependent cleavage, once homologous recombination is successfully induced between the target region and the donor DNA, the sequence between the base sequence upstream and downstream of the target region will be replaced by the sequence of the donor DNA.

[0240] The "upstream" of the target region refers to the DNA region located at the 5' side of the nucleotide chain that serves as the benchmark in the double-stranded DNA of the target region. The "downstream" of the target region refers to the DNA located at the 3' side of the nucleotide chain that serves as the benchmark. When the target region contains a protein coding sequence, the nucleotide chain that serves as the benchmark is usually the sense strand. Usually, the promoter is located upstream of the protein coding sequence. The terminator is located downstream of the protein coding sequence.

[0241] The term "sequence-specific nucleic acid cleavage molecule" refers to a molecule that can recognize a specific nucleic acid sequence and cleave nucleic acid at the specific nucleic acid sequence. A sequence-specific nucleic acid cleavage molecule is a molecule that has an activity of sequence-specifically cleaving nucleic acid (sequence-specific nucleic acid cleavage activity).

[0242] The term "target sequence" refers to a DNA sequence in the genome that is the target of cleavage by a sequence-specific nucleic acid cleavage molecule. When the sequence-specific nucleic acid cleavage molecule is a Cas protein, the target sequence refers to a DNA sequence in the genome that is the target of cleavage by the Cas protein. When using the Cas9 protein as the Cas protein, the target sequence must be a sequence adjacent to the 5' side of the protoplast adjacent motif (PAM). The target sequence generally selects a sequence of 17 to 30 bases (preferably 18 to 25 bases, more preferably 19 to 22 bases, and further preferably 20 bases) next to the 5' side of the PAM. When designing the target sequence, well-known design tools such as CRISPR DESIGN (crispr.mit.edu / ) can be used.

[0243] The term "Cas protein" refers to CRISPR-associated proteins. In a preferred embodiment, the Cas protein forms a complex with the guide RNA and exhibits endonuclease activity or nickase activity. There are no particular limitations on the Cas protein, and examples thereof include Cas9 protein, Cpf1 protein, C2c1 protein, C2c2 protein, and C2c3 protein. As long as the Cas protein is linked to the guide RNA and exhibits endonuclease activity or nickase activity, it includes wild-type Cas proteins and homologs thereof (paralogs and orthologs), and their mutants.

[0244] In a preferred embodiment, the Cas protein is a Cas protein associated with a type 2 CRISPR / Cas system, more preferably a Cas protein associated with a type II CRISPR / Cas system. As a preferred example of a Cas protein, a Cas9 protein can be exemplified. As a preferred example of a Cas protein, a Cas3 protein can be exemplified.

[0245] The term "Cas9 protein" refers to the Cas protein associated with the type II CRISPR / Cas system. The Cas9 protein forms a complex with the guide RNA and is linked with the guide RNA to show the activity of cutting the DNA in the target region. As long as the Cas9 protein has the above-mentioned activity, it contains wild-type Cas9 protein and its homologs (paralogs and orthologs), and their mutants. The wild-type Cas9 protein has a RuvC domain and an HNH domain as a nuclease domain, and the Cas9 protein in this specification can be a protein in which any one of the RuvC domain and the HNH domain has been inactivated. The Cas9 inactivated in the RuvC domain and the HNH domain introduces single-stranded cutting (nicking) to double-stranded DNA. Therefore, the transformation system can be constructed in the following manner: when the Cas9 inactivated in the RuvC domain and the HNH domain is used for cutting of double-stranded DNA, the target sequence of Cas9 is set for the sense strand and the antisense strand respectively, so that the nicks of the sense strand and the antisense difference are generated at a sufficiently close position, thereby inducing double-stranded cutting.

[0246] The source species of Cas9 protein is not particularly limited, and preferably, bacteria belonging to the genus Streptococcus, Staphylococcus, Neisseria or Treponema can be exemplified. More specifically, Cas9 proteins from Streptococcus pyogenes, Streptococcus thermophilus, Staphylococcus aureus, Neisseria meningitidis or Treponema denticola can be exemplified. In a preferred embodiment, Cas9 protein is Cas9 protein from Streptococcus pyogenes.

[0247] The amino acid sequences of various Cas proteins and information on their coding sequences can be obtained from various databases such as GenBank, UniProt, and Addgene. For example, the amino acid sequence of the Cas9 protein of Streptococcus pyogenes can be a sequence registered in Addgene with plasmid number 42230. An example of the amino acid sequence of the Cas9 protein of Streptococcus pyogenes is shown in sequence number 1.

[0248] The terms "guide RNA" and "gRNA" are used interchangeably and refer to RNA that can form a complex with the Cas protein and induce the Cas protein to the target region. In a preferred embodiment, the guide RNA contains CRISPR RNA (crRNA) and trans-activating CRISPR RNA (tracrRNA). CrRNA is involved in binding to the target region on the genome, and tracrRNA is involved in binding to the Cas protein. In a preferred embodiment, crRNA contains a spacer sequence and a repeat sequence, and the spacer sequence binds to the complementary strand of the target sequence in the target region. In a preferred embodiment, tracrRNA contains an inverted repeat sequence and a 3' tail sequence. The inverted repeat sequence has a sequence complementary to the repeat sequence of crRNA, forms a base pair with the repeat sequence, and the 3' tail sequence generally forms 3 stem loops.

[0249] The guide RNA may be a single guide RNA (sgRNA) in which the 5' end of tracrRNA is connected to the 3' end of crRNA, or a type in which crRNA and tracrRNA are different RNA molecules and base pairs are formed by repeat sequences and inverted repeat sequences. In a preferred embodiment, the guide RNA is sgRNA.

[0250] The repeat sequence of crRNA and the sequence of tracrRNA can be appropriately selected according to the type of Cas protein, and those from the same bacterial species as the Cas protein can be used.

[0251] For example, when using the Cas9 protein from Streptococcus pyogenes, the length of sgRNA can be set to about 50 to 220 nucleotides (nt), preferably about 60 to 180 nt, and more preferably about 80 to 120 nt. When containing a spacer sequence, the length of crRNA can be set to about 25 to 70 bases, preferably about 25 to 50 nt. The length of tracrRNA can be set to about 10 to 130 nt, preferably about 30 to 80 nt.

[0252] The repetitive sequence of crRNA may be the same as the sequence in the bacterial species from which the Cas protein is derived, or it may be a sequence from which a portion of the 3' end is removed. The tracrRNA may have the same sequence as the mature tracrRNA in the bacterial species from which the Cas protein is derived, or it may be an end-cleavage type in which the 5' end and / or 3' end of the mature tracrRNA are cut. For example, the tracrRNA may be an end-cleavage type in which about 1 to 40 nucleotide residues are removed from the 3' end of the mature tracrRNA. In addition, the tracrRNA may be an end-cleavage type in which about 1 to 80 nucleotide residues are removed from the 5' end of the mature tracrRNA. In addition, the tracrRNA may be, for example, an end-cleavage type in which about 1 to 20 nucleotide residues are removed from the 5' end and about 1 to 40 nucleotide residues are removed from the 3' end.

[0253] Various proposals have been made for designing the crRNA repeat sequence and tracrRNA sequence of sgRNA, and those skilled in the art can design sgRNA based on known techniques (e.g., Jinek et al. (2012) Science, 337, 816-21; Mali et al. (2013) Science, 339: 6121, 823-6; Cong et al. (2013) Science, 339: 6121, 819-23; Hwang et al. (2013) Nat. Biotechnol. 31: 3, 227-9; Jinek et al. (2013) eLife, 2, e00471).

[0254] The terms "protospacer adjacent motif" and "PAM" can be used interchangeably and refer to the sequence recognized by the Cas protein when the Cas protein is used to cut DNA. The sequence and position of the PAM vary depending on the type of Cas protein. For example, in the case of Cas9 protein, the PAM needs to be adjacent to the 3' side of the target sequence. The PAM sequence corresponding to the Cas9 protein varies depending on the bacterial species from which the Cas9 protein is derived. For example, the PAM corresponding to the Cas9 protein of Streptococcus pyogenes is "NGG", the PAM corresponding to the Cas9 protein of Streptococcus thermophilus is "NNAGAA", the PAM corresponding to the Cas9 protein of Staphylococcus aureus is "NNGRRT" or "NNGRR(N)", the PAM corresponding to the Cas9 protein of Neisseria meningitidis is "NNNNGATT", and the PAM corresponding to the Cas9 protein of Treponema denticola is "NAAAAC" ("R" is A or G; "N" is A, T, G or C).

[0255] The terms "spacer sequence" and "guide sequence" can be used interchangeably and refer to a sequence contained in the guide RNA that is capable of binding to the complementary strand of the target sequence. Typically, the spacer sequence is the same sequence as the target sequence (wherein T in the target sequence is changed to U in the spacer sequence). In an embodiment of the present invention, the spacer sequence may contain a mismatch of 1 base or more than two bases relative to the target sequence. When it contains mismatches of two or more bases, the mismatches may be at adjacent positions or at more distant positions. In a preferred embodiment, the spacer sequence may contain a mismatch of 1 to 5 bases relative to the target sequence. In a particularly preferred embodiment, the spacer sequence may contain a mismatch of 1 base relative to the target sequence.

[0256] In the guide RNA, the spacer sequence is placed on the 5' side of the crRNA.

[0257] The term "functionally linked" used in relation to a polynucleotide means that a first base sequence is arranged in a manner sufficiently close to a second base sequence, and the first base sequence can be affected by the second base sequence or a region controlled by the second base sequence. For example, a polynucleotide being functionally linked to a promoter means that the polynucleotide is linked in a manner such that it can be expressed under the control of the promoter.

[0258] The term "expressible state" means that the polynucleotide is in a state in which transcription of the polynucleotide is possible in a cell into which the polynucleotide has been introduced.

[0259] The term "expression vector" refers to a vector that contains a target polynucleotide and has a system that is in a state where the target polynucleotide can be expressed in a cell into which the vector is introduced. For example, a "Cas protein expression vector" refers to a vector that can express a Cas protein in a cell into which the vector is introduced. In addition, for example, a "guide RNA expression vector" refers to a vector that can express a guide RNA in a cell into which the vector is introduced.

[0260] The term "HLA similar sequence" refers to a continuous base sequence that has an identity value of 80% or more with at least one HLA gene derived from a BLAT search in the UCSC Genome Browser. There are regions in the HLA locus where HLA and HLA similar sequences are clustered, and these are called HLA similar sequence cluster regions.

[0261] The term "MHC similar sequence" refers to a continuous base sequence that shows an identity value of 80% or more with at least one MHC gene derived from a BLAT search in the UCSC genome browser. In the MHC locus, there are regions where MHC and MHC similar sequences are clustered, and these are called MHC similar sequence cluster regions.

[0262] The term "intrinsic sequence" refers to a unique sequence in which no other similar sequences exist, and specifically, refers to a sequence having a consistency value of 80% or more based on BLAT search for its entire length, which exists only in one place on the genome having the inherent sequence. The inherent sequence is more preferably a sequence having a consistency value of 75% or more based on BLAT search, which exists only in one place on the genome having the inherent sequence, and further preferably a sequence having a consistency value of 70% or more based on BLAT search, which exists only in one place on the genome having the inherent sequence, and further preferably a sequence having a consistency value of 65% or more based on BLAT search, which exists only in one place on the genome having the inherent sequence, and preferably a sequence having a consistency value of 60% or more based on BLAT search, which exists only in one place on the genome having the inherent sequence. "Intrinsic sequence" and "unique sequence" can be used interchangeably.

[0263] HLA class I (such as HLA-A ~ HLA-C, etc.) bury endogenous peptides with about 9 amino acid residues in the groove to form a complex presented to killer T cells. When non-self peptides in infected cells, cancer cells, etc. are presented in the form of a complex, killer T cells destroy each cell presenting it. HLA class II (HLA-DR, DQ, DP, etc.) bury exogenous peptides with about 15 amino acid residues taken in by phagocytosis in the groove and present them to helper T cells. Immune checkpoint molecules are factors related to immune checkpoints that suppress immunity. As immune checkpoint molecules, for example, PD-L1, PD-L2, B7 (CD80 / CD86), CD275, CD276, VISTA, galectin 9, HVEM and HLA class II molecules can be cited.

[0264] The cell of the present invention can be an iPS cell. The cell of the present invention can be an iPS cell (human iPS cell) from a human cell. The cell of the present invention can be used, for example, after differentiation into an immune cell. Therefore, the cell of the present invention can be an immune cell (particularly an immune cell from an iPS cell). The immune cell can be, for example, one or more immune cells selected from the group consisting of T cells (e.g., CD4 positive T cells alone and CD8 positive T cells alone), natural killer T cells (NKT cells), natural killer cells (NK cells), regulatory T cells (Treg), αβT cells, γδT cells, and macrophages. The immune cell can be a T cell receptor (TCR) with antigen specificity. The immune cell may not express a T cell receptor with antigen specificity (e.g., it may have a TCRα chain defect). The immune cell may express a chimeric antigen receptor (CAR). For example, the immune cell may be a T cell, NKT cell, NK cell, or γδT cell that expresses CAR but may not express a TCR with antigen specificity. The cell can be, for example, a primary cell (e.g., a primary immune cell). The cell can be, for example, a cell strain (e.g., an immune cell strain). The cell can be a non-cancerous cell. Cells expressing CAR, for example, can express any one or both of endogenous or exogenous interleukin-7 (IL-7) and endogenous or exogenous CCL19. Endogenous or exogenous IL-7 and endogenous or exogenous CCL19 are operably connected to control sequences, and cells expressing CAR have any one or preferably both of the IL-7 and CCL19. Cells expressing CAR can express endogenous or exogenous internal β-D-glucuronidase (HPSE). These immune cells can have an autologous or allogeneic relationship with the object to which the cell is administered. Immune cells can additionally express endogenous or exogenous CD3. In addition, cells may express or not express one or more endogenous or exogenous factors selected from the group consisting of HLA-E, HLA-G, HACD16, 41BBL, CD3, CD4, CD8, CD47, CD137, CD80, PDL1, A2AR, CAR and TCR. In one embodiment, the cell has a nucleic acid encoding one or more endogenous or exogenous factors selected from the group consisting of HLA-E, HLA-G, CD16, 41BBL, CD3, CD4, CD8, CD47, CD137, CD80, PDL1, A2AR, CAR and TCR, and the nucleic acid is operably connected to a control sequence. In one embodiment, cells expressing CAR can be used in combination with antibody therapy. In this combined use, the target molecule (tumor antigen) of the antibody in the cell expressing CAR can be knocked out. In one embodiment, as such a tumor antigen, CD38 and CD52 can be listed. As anti-CD38 antibodies, for example, daratumumab and isatuximab (treatment target disease, for example, can be multiple myeloma) can be listed.In addition, as anti-CD52 antibodies, for example, alentuzumab can be cited (the target disease for treatment can be, for example, leukemia, lymphocytic leukemia, or chronic lymphocytic leukemia). NLRC5 can also be knocked out in one form of cells (such as immune cells or non-immune cells), thereby suppressing the onset of, for example, graft-versus-host disease (GVHD). One form of cells (such as immune cells or non-immune cells) can express factors selected from the group consisting of PD1, CD52, CTLA4, dCK, GGH, HPRT, and β2 microglobulin, as well as CAR or TCR. In a preferred embodiment, the cells of the present invention have functional β2 microglobulin and / or functional CIITA. The cells of the present invention can, for example, express IL-15:IL15Rα fusion protein.

[0265] In this specification, "chimeric antigen receptor" (CAR) is a chimeric molecule having an antigen binding fragment (especially scFv) of an antibody and an immune cell activation domain. CAR is generally a molecule formed by connecting scFv, an extracellular hinge domain, a transmembrane domain (such as CD8α or CD28) and an activation signal transduction domain (such as CD3ζ). CAR can be introduced into cells and expressed on the cell surface. Cells expressing CAR can target specific antigens. CAR, for example, can be introduced into immune cells such as T cells or NK cells and target immune cells such as T cells or NK cells to cancer. The first generation CAR is formed by connecting scFv, an extracellular hinge domain, a transmembrane domain (such as CD8α or CD28) and an activation signal transduction domain (such as CD3ζ), and the second generation CAR also contains a costimulatory molecule signal transduction domain for activating immune cells introduced into CAR. As a costimulatory molecule signal transduction domain, costimulatory factors such as CD28, 4-1BB, OX40, CD27 and ICOS can be used. The third generation CAR incorporates two or more co-stimulatory factors. In this way, improvements are added to CAR to allow the immune cells introduced with CAR to continue to proliferate in vivo. Preferably, any domain other than the scFv portion is derived from human protein.

[0266] In one embodiment, the endogenous or exogenous gene contains any one or more of the endogenous or exogenous HLA genes. The HLA gene is not particularly limited, and examples thereof include HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, HLA-J, HLA-W, MICA, MICB, HLA-DRA, HLA-DRB1, HLA-DRB5, HLA-DRB6, HLA-DRB9, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DPA1, HLA-DPB1, HLA-DMB, HLA-DOA, and HLA-DOB. In one embodiment, the HLA gene may be one or more selected from the group consisting of HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ, and HLA-DP. In one embodiment, the HLA gene may be one or more selected from the group consisting of HLA-A, HLA-B, and HLA-C. In one embodiment, the HLA gene may be one or more selected from the group consisting of HLA-DR, HLA-DQ, and HLA-DP.

[0267] In one embodiment, the HLA gene may be, for example, HLA-A. HLA-A may be any allele of HLA-A. HLA-A is not particularly limited, and examples thereof include A*01:01, A*02:01, A*02:03, A*02:05, A*02:06, A*02:07, A*02:10, A*02:11, A*02:15N, A*02:18, A*02:28, A*02:42, A*02:53N, A*02:59, A*02:72, A*03:01, A*03:02, A*11:01, A*11:02, A*11:13, A*23:01, A*24:02, A*24:03, A*24:04, A*24: 05. A*24:07, A*24:08, A*24:10, A*24:20, A*24:25, A*24:28, A*24:46, A*25:01, A*26:01, A*26:02, A*26:03, A*26:04, A*26:05, A* 26:06, A*29:01, A*29:02, A*30:01, A*30:02, A*30:04, A*31:01, A*31:11, A*32:01, A*33:01, A*33:03, A*33:08, A*34:01 and A*68:01. In addition, the HLA gene may be, for example, HLA-B. The HLA-B may be any allele of HLA-B.HLA-B is not particularly limited, and examples thereof include B*07:02, B*07:05, B*08:01, B*13:01, B*13:02, B*14:01, B*14:02, B*15:01, B*15:02, B*15:03, B*15:05, B*15:07, B*15:11, B*15:12, B*15:13, B*15:17, B*15:18, B*15:21, B*15:25, B*1 5:26N, B*15:27, B*15:28, B*15:35, B*15:38, B*15:46, B*18:01, B*18:02, B*27:04, B*27:05, B*27:06, B *27:11、B*35:01、B*35:02、B*35:03、B*35:05、B*35:08、B*35:11、B*35:51、B*35:64、B*37:01、B*38:01、B *38:02, B*39:01, B*39:02, B*39:04, B*39:05, B*39:23, B*40:01, B*40:02, B*40:03, B*40:06, B*40:07, B*40:11、B*40:50、B*40:52、B*41:01、B*44:02、B*44:03、B*45:01、B*46:01、B*48:01、B*48:03、B*49:01 B*50:01, B*51:01, B*51:02, B*51:03, B*51:06, B*52:01, B*53:01, B*54:01, B*54:21, B*55:01, B*55:02, B*55:04, B*55:10, B*55:12, B*56:01, B*56:03, B*56:04, B*56:05, B*57:01, B*58:01, B*59:01 and B*67:01.

[0268] In one embodiment, the HLA gene may be HLA-C. HLA-C may be any allele of HLA-C. HLA-C is not particularly limited, and examples thereof include C*01:02, C*01:03, C*01:55, C*02:02, C*03:02, C*03:03, C*03:04, C*03:23N, C*03:28, C*03:29, C*03:43, C*04:01, C*04:03, C*05:01, C*06:02, C*07:0 1. C*07:02, C*07:02N, C*07:04, C*08:01, C*08:02, C*08:03, C*08:39, C*12:02, C*12:0 3. C*12:04, C*14:02, C*14:03, C*15:02, C*15:05, C*15:10, C*16:01, C*16:02 and C*17:01.

[0269] In one embodiment, the HLA gene may be HLA-DR. HLA-DR may be any allele of HLA-DR. HLA-DR is not particularly limited, and examples thereof include DRB1*01:01, DRB1*01:02, DRB1*01:03, DRB1*03:01, DRB1*04:01, DRB1*04:02, DRB1*04:03, DRB1*04:04, DRB1*04:05, DRB1*04:06, DRB1*04:07, DRB1*04:08, DRB1*04:09, DRB1*04:10 0. DRB1*04: 11, DRB1*07: 01, DRB1*08: 01, DRB1*08: 02, DRB1*08: 03, DRB1*08: 09, DRB1*08: 23, DRB1*09 :01, DRB1*10:01, DRB1*11:01, DRB1*11:04, DRB1*11:06, DRB1*11:08, DRB1*11:19, DRB1*11:23, DRB1*1 2:01, DRB1*12:02, DRB1*12:05, DRB1*13:01, DRB1*13:02, DRB1*13:03, DRB1*13:07, DRB1*13:12, DRB1 *14:02, DRB1*14:03, DRB1*14:04, DRB1*14:05, DRB1*14:06, DRB1*14:07, DRB1*14:12, DRB1*14:29, DRB 1*14:45, DRB1*14:54, DRB1*15:01, DRB1*15:02, DRB1*15:04, DRB1*16:01, DRB1*16:02, DRB3*01:01, D RB3*02:02, DRB3*03:01, DRB4*01:01, DRB4*01:02, DRB4*01:03, DRB5*01:01, DRB5*01:02 and DRB5*02:02.

[0270] In one embodiment, the HLA gene may be HLA-DQ. HLA-DQ may be any allele of HLA-DQ. HLA-DQ is not particularly limited, and examples thereof include DQB1*02:01, DQB1*02:02, DQB1*03:01, DQB1*03:02, DQB1*03:03, DQB1*04:01, DQB1*04:02, DQB1*05:01, DQB1*05:02, DQB1*05:03, DQB1*06:01, DQB1*06:02, DQB1*06:03, DQB1*06:04, DQB1*0 6:09, DQA1*01:01, DQA1*01:02, DQA1*01:03, DQA1*01:04, DQA1*01:05, DQA1*02:01, DQA1*03:01, DQA1*03: 02, DQA1*03:03, DQA1*04:01, DQA1*05:01, DQA1*05:03, DQA1*05:05, DQA1*05:06 and DQA1*05:08, DQA1*06:01.

[0271] In one embodiment, the HLA gene may be HLA-DP. HLA-DP may be any allele of HLA-DP. HLA-DP is not particularly limited, and examples thereof include DPB1*02:01, DPB1*02:02, DPB1*03:01, DPB1*04:01, DPB1*04:02, DPB1*05:01, DPB1*06:01, DPB1*09:01, DPB1*13:01, DPB1*14:01, DPB1*17:01, DPB1*19:01, DPB1*36:01, DPB1*38:01, DPB1*41:01, DPA1*01:03, DPA1*02:01, DPA1*02:02, and DPA1*04:01.

[0272] In one embodiment, an endogenous or exogenous gene and an upstream sequence of the gene containing the above-mentioned control sequence or inferred control sequence are inserted. That is, in this embodiment, an endogenous or exogenous gene and the original control sequence of the gene upstream of the gene or its candidate are inserted. In one embodiment, an endogenous or exogenous gene is inserted, and the gene contains more than one intron or all introns. In one embodiment, an upstream sequence of the gene containing a control sequence or inferred control sequence and the above-mentioned gene containing more than one intron or all introns are inserted. In one embodiment, a sequence having a continuous region on the genome is inserted, and the region contains the above-mentioned gene, the upstream sequence of the gene containing a control sequence or inferred control sequence, and all introns. Thus, the influence of the control sequence on gene expression, etc., or the influence of introns on gene expression, etc. can be analyzed. In a preferred embodiment, the above-mentioned gene can be an HLA gene.

[0273] In a preferred embodiment, the gene on the genome corresponding to the HLA gene included in the insertion is deleted. In a preferred embodiment, when the insertion includes the HLA gene, all functional HLA on the genome is deleted. The HLA gene included in the insertion can be a null allele.

[0274] In one embodiment, the inserted gene can be, for example, a chimeric antigen receptor (CAR). The chimeric antigen receptor can, for example, include a single-chain antibody (e.g., scFv) containing heavy and light chains, an extracellular hinge domain (e.g., CD8), a transmembrane domain (e.g., CD8α and CD28), a co-stimulatory molecule signal transduction domain (4-1BB, CD28, and CD137), and an activation signal transduction domain (CD3ζ). When the chimeric antigen receptor thus binds to the target, an activation signal is generated to the cell. The chimeric antigen receptor can bind to an antigen expressed by a cancer cell. Such an antigen can be, for example, one or more selected from the group consisting of CD16, CD19, CD20, CD22, CD123, CD171, epidermal growth factor receptor (EGFR), particularly EGFRvIII, type 3 EGFR, de2-7 EGFR and HER2, carcinoembryonic antigen (CEA), prostate stem cell antigen (PSCA), B cell maturation antigen (BCMA), CS1, NKG2D, NKp30, B7H6, MUC-16 (CA125), orphan receptor 1 for receptor tyrosine kinase (ROR-1), GD3, GM2, phosphatidylinositol proteoglycan-3 (GPC3), mesothelin, IL13R, c-KIT, c-MET, NY-ESO-1, WT1, MAGE-A3, MAGE-A4, MAGE-A10, HPV E6, HPV E7, CMV, AFP, PRAME, SSX2, KRAS, HER2 and PD-L1. The chimeric antigen receptor may also have, for example, protein tag binding properties. The antigen of the scFv may be, for example, a fluorescent protein such as fluorescein isothiocyanate (FITC). This is because by binding an antibody labeled with a protein tag to a cancer antigen on the surface of a cancer cell, and further administering the antibody to cells expressing a chimeric antigen receptor targeting the tag, the cancer cell may be killed.

[0275] In one embodiment, the inserted gene can be, for example, a T cell receptor (TCR). TCR can have antigen specificity. TCR with antigen specificity can, for example, bind to cancer antigens. TCR with antigen specificity can, for example, bind to a selected group of CD16, CD19, CD20, CD22, CD123, CD171, epidermal growth factor receptor (EGFR), particularly EGFRvIII, type 3 EGFR, de2-7EGFR and HER2, carcinoembryonic antigen (CEA), prostate stem cell antigen (PSCA), B cell maturation antigen (BCMA), CS1, NKG2D, NKp30, B7H6, MUC-16 (CA12 5) Receptor tyrosine kinases are bound to one or more of the group consisting of orphan receptor 1 (ROR-1), GD3, GM2, phosphatidylinositol proteoglycan-3 (GPC3), mesothelin, IL13R, c-KIT, c-MET, NY-ESO-1, WT1, MAGE-A3, MAGE-A4, MAGE-A10, HPV E6, HPV E7, CMV, AFP, PRAME, SSX2, KRAS, HER2 and PD-L1. TCRs can be selected in a manner that matches HLA.

[0276] In one embodiment, the inserted gene comprises genes encoding one or more genes selected from the group consisting of immunosuppressive factors, such as CD47, CD24, CD200, PD-L1, IDO1, CTLA4-Ig, C1-inhibitor, IL-10, IL-35, FASL, Serpmb9, CC121 and Mfge8.

[0277] In one embodiment, the inserted gene can be a therapeutic gene. The therapeutic gene can be a gene that produces therapeutic benefit by being expressed in vivo. The therapeutic gene can be an inflammation-inducing protein, such as a cytokine. The therapeutic gene can be an anti-inflammatory protein, such as a cytokine.

[0278] In one embodiment, the inserted gene can be a suicide gene. As suicide genes, for example, thymidine kinase genes, particularly thymidine kinase genes (HSVtk) from herpes viruses, cytotoxic signal receptors (such as diphtheria toxin receptors) and iCas9 can be cited. The thymidine kinase gene phosphorylates ganciclovir to generate cytotoxic ganciclovir triphosphate. In addition, iCas9 (inducible caspase-9) is a protein whose CARD is replaced with FKBP12, and apoptosis is induced in iCas9-expressing cells in the presence of tacrolimus derivatives (such as AP1903). Such suicide genes are beneficial when it is desired to remove immune system escape cells such as universal donor cells (UDC) from the body.

[0279] In this specification, the sequence consistency (or homology) of base sequences or amino acid sequences refers to: introducing intervals and arranging two base sequences or amino acid sequences in a manner that the consistency of the corresponding bases or amino acids is maximized in the part equivalent to the insertion and deletion, and the value obtained in the form of the ratio of the consistent bases or amino acids other than the intervals in the obtained comparison to the whole base sequence or the whole amino acid sequence. The sequence consistency of base sequences or amino acid sequences can be obtained using various homology search software known in the art. The value (consistency value) of the sequence consistency of the base sequence is not particularly limited, for example, it can be obtained based on the BLAT search carried in the UCSC genome browser using the known homology search software.

[0280] [Genome modification method]

[0281] In one embodiment, the present invention provides a genome modification method for modifying two or more alleles of a chromosome genome. The genome modification method comprises the following steps (a) and (b):

[0282] (a) a step of introducing the following (i) and (ii) into a cell containing the above chromosome,

[0283] (i) a genome modification system comprising a sequence-specific nucleic acid cleavage molecule targeting the target region of the chromosome genome or a polynucleotide encoding the sequence-specific nucleic acid cleavage molecule,

[0284] (ii) two or more types of donor DNAs for selection markers, each containing a base sequence of a selection marker gene between an upstream homology arm having a base sequence homologous to a base sequence adjacent to the upstream side of the target region and a downstream homology arm having a base sequence homologous to a base sequence adjacent to the downstream side of the target region, wherein the two or more types of donor DNAs for selection markers have different selection marker genes, and the number of types of the donor DNAs for selection markers is equal to or greater than the number of the alleles to be the subject of genome modification; and

[0285] (b) a step of selecting the above-mentioned cells based on all the selection marker genes possessed by the above-mentioned two or more selection marker donor DNAs after the above-mentioned step (a). In this method, the above-mentioned selection marker gene can be unique to each selection marker donor DNA. In this method, step (b) can also be: after the above-mentioned step (a), different types of selection marker donor DNAs are homologously recombined to the above-mentioned two or more alleles, and different unique selection marker genes that can be distinguished are introduced into the two or more alleles, and the cells expressing all the introduced different selection marker genes that can be distinguished are selected (a step for positive selection). The above-mentioned method can be a method for making cells with two or more alleles of the chromosomal genome modified.

[0286] In this specification, for convenience, when referring to the position of the human genome, the position of the hg38 genome sequence is used as the reference genome. Hg38 is a reference genome released by the University of California, Santa Cruz (UCSC) in December 2013. The reference genome is a genome for reference made by combining various genomes, and does not mean that there is a person with the genome. However, by contrasting the fragmented sequence information decoded by the genomic DNA of an individual with the reference genome, the fragmented sequence information decoded is connected and a continuous sequence is constructed on a computer, whereby the sequence of the genomic DNA of the individual can be inferred. In this way, by establishing a correspondence between the sequence of the genomic DNA of an individual and the reference genome, the genomic DNA of individuals such as an individual can usually be decoded. In addition, the position or region corresponding to the specific position or specific region of the hg38 genome sequence refers to: in the genome of other individuals with different specific sequences, the position or region associated with the specific position or specific region. Specifically, based on sequence consistency, the position or region with the characteristic sequence of the position or region is the position or region corresponding to the specific position or specific region of the hg38 genome sequence. The corresponding position can be determined by the comparison of the partial sequences of 2 genomic DNAs. Even when there are differences in specific sequences, the corresponding relationship of two genomic DNAs can also be determined by comparison with orthologous relationships or with sequence identity. For the region rich in paralogs produced by gene duplication, when the corresponding relationship of sequences is determined based only on simple individual sequences, it is sometimes not enough to determine the true corresponding relationship between two genomes. This increases the difficulty of sequence decoding in the region where similar sequences are gathered. When determining the corresponding sequence, the corresponding relationship between two genomes can be explained by obtaining high sequence identity. In addition, when a specific region is a large region containing more than two genes, homology modules (synteny) can be considered. Homology modules refer to the conservative physical position relationship of orthologous relationships on genomes. Homology modules may be present between individuals and between organisms. Therefore, homology modules can be considered to determine specific regions.

[0287] In one embodiment, a cell containing a genome with a deletion can be provided, wherein the deletion is a deletion of a region in all alleles of the genome (two alleles in the case of diploid) (for example, a deletion of a region within 1 Mb or within 500 kb), and the deletion includes a portion or preferably all of the region containing the MHC similar sequence clustering region of the locus encoding the MHC molecule. This method can improve the readability of the genome and / or improve the targeting efficiency of the genes of the genome (for example, MHC genes) by deleting repeated sequences formed by similar sequences. The cell with the deletion can have an insertion of an endogenous or exogenous gene. The inserted gene is preferably operably connected to a control sequence. In one embodiment, the cell is a human cell, and the deletion includes a portion or preferably all of the region containing the MHC similar sequence clustering region of the locus encoding the HLA molecule.

[0288] In one embodiment, a cell can be provided, which lacks one, two, three or four regions selected from the group consisting of a series of regions from HLA-F to HLA-A (the first HLA similar sequence clustering region), a series of regions from HLA-C to HLA-B (the second HLA similar sequence clustering region), a series of regions from HLA-DRA to HLA-DOB (the third HLA similar sequence clustering region), and a series of regions from HLA-DMB to HLA DPB2 (the fourth HLA similar sequence clustering region) and a portion thereof. In one embodiment, the above-mentioned cell can lack a region containing HLA-E.

[0289] The targeting of the 1st to 4th HLA similar sequence aggregation regions can be performed on the inherent sequences respectively. Thus, unexpected modifications such as cutting caused by off-target can be prevented. Those skilled in the art can understand how to perform targeting to prevent cutting caused by off-target, and can appropriately perform targeting and modification. Even if the modification of each HLA is difficult to perform due to sequence similarity with other HLAs, the region where the inherent sequence is located can be freely set in the large-scale deletion based on the present invention, so the desired large-scale deletion can be made. In one embodiment, the targeting of the 1st to 4th HLA similar sequence aggregation regions is respectively for sequences other than the 1st to 4th HLA similar sequence aggregation regions.

[0290] In one embodiment, the first HLA similar sequence clustering region may exist in chr6:29706837-29956199 of the hg38 genomic sequence. In one embodiment, the first HLA similar sequence clustering region may exist in chr6:29711000-30020000 of the hg38 genomic sequence. In one embodiment, the second HLA similar sequence clustering region may exist in chr6:31225738-31376781 of the hg38 genomic sequence. In one embodiment, the second HLA similar sequence clustering region may exist in chr6:31176000-31534000 of the hg38 genomic sequence. In one embodiment, the third HLA similar sequence clustering region may exist in chr6:32445000-32821000 of the hg38 genomic sequence. In one embodiment, the third HLA similar sequence cluster region may exist in chr6:32445000-32821000 of the hg38 genomic sequence. In one embodiment, the fourth HLA similar sequence cluster region may exist in chr6:32934298-33161621 of the hg38 genomic sequence. In one embodiment, the fourth HLA similar sequence cluster region may exist in chr6:33002000-33147000 of the hg38 genomic sequence.

[0291] In one embodiment, the first HLA similar sequence cluster region may exist in chr6: 29722775-29945870 of the hg38 genomic sequence. In one embodiment, the second HLA similar sequence cluster region may exist in chr6: 31268749-31357179 of the hg38 genomic sequence. In one embodiment, the third HLA similar sequence cluster region may exist in chr6: 32439887-32817002 of the hg38 genomic sequence. In one embodiment, the fourth HLA similar sequence cluster region may exist in chr6: 32934636-33089696 of the hg38 genomic sequence.

[0292] In each of the 1st to 4th HLA similar sequence clustering regions, the minimum region containing HLA to be deleted is determined, and on this basis, the region with a native sequence on the genome is determined on both sides of the region. This determination can be appropriately performed with reference to a genome database, etc. The region with such a native sequence can be used to design homologous arms for genome editing and homologous recombination. The homologous arm is typically designed in a manner that can be homologously recombined with the region having the native sequence (for example, designed to have the same sequence). In a preferred embodiment, the region containing all genes encoding functional HLA is deleted in each of the 1st to 4th HLA similar sequence clustering regions. In a preferred embodiment, the region containing all genes encoding functional HLA is deleted, and the deletion occurs in a manner that does not contain other genes outside the region as much as possible. For example, the deletion occurs in a manner that does not contain more than 5, more than 4, more than 3, more than 2 or more than 1 other genes outside the region. The deletion region depends on the presence of a region with a native sequence on the genome where the homologous recombination arm can undergo homologous recombination. It is expected that human-specific research will be conducted in human conditions, and various non-human species-specific research will be conducted in non-human conditions.

[0293] In one embodiment, the present invention provides a cell comprising genomic DNA having a deletion, wherein the deletion is a deletion of a region including a part or the entirety of an HLA-like sequence cluster region located in one or more chromosomal regions selected from the group consisting of the chromosomal regions specified in the following (i) to (iv):

[0294] (i) Chromosome region corresponding to chr6:29723464-29945455 of hg38 genomic sequence;

[0295] (ii) the chromosomal region corresponding to the chromosomal region of chr6: 31269169-31357158 of the hg38 genomic sequence;

[0296] (iii) a chromosomal region corresponding to the chromosomal region of chr6:32439951-32816951 of the hg38 genomic sequence; and

[0297] (iv) a chromosomal region corresponding to the chromosomal region of chr6: 33006838-33086238 of the hg38 genomic sequence,

[0298] The HLA similar sequence cluster region includes all of the HLA encoding genes and HLA similar sequences respectively contained in the above chromosome region.

[0299] The above-mentioned part contains at least one continuous region, and the above-mentioned one continuous region contains more than 50%, more than 60%, more than 70%, more than 80%, more than 90% or 100% of the genes selected from the group consisting of HLA encoding genes and HLA similar sequences respectively contained in the above-mentioned region. Throughout this specification, the deletion is a deletion in two alleles. In one embodiment, in addition to the above-mentioned region, in the cells of the present invention, in addition to the above-mentioned region, the regions within 20kbp, within 15kbp, within 10kbp, within 9kbp, within 8kbp, within 7kbp, within 6kbp, within 5kbp, within 4kbp, within 3kbp, within 2kbp or within 1kbp can be further deleted independently from both ends to the outside. In addition, in one embodiment, the cells of the present invention may not lack more than one (preferably one) HLA gene located at both ends of the above-mentioned region.

[0300] In one embodiment, the present invention provides a cell comprising genomic DNA having a deletion, wherein the deletion is a deletion of a region including a part or the entirety of an HLA-like sequence cluster region located in one or more chromosomal regions selected from the group consisting of the chromosomal regions specified in the following (i) to (iv):

[0301] (i) Chromosome region corresponding to chr6 of hg38 genome sequence: 29723464-30010618);

[0302] (ii) the chromosomal region corresponding to the chromosomal region of chr6: 31269169-31463338 of the hg38 genomic sequence;

[0303] (iii) a chromosomal region corresponding to the chromosomal region of chr6:32439887-32817002 of the hg38 genomic sequence; and

[0304] (iv) a chromosomal region corresponding to the chromosomal region of chr6: 33006838-33131199 of the hg38 genomic sequence,

[0305] The HLA similar sequence cluster region includes all of the HLA encoding genes and HLA similar sequences respectively contained in the above chromosome region.

[0306] The above-mentioned part contains at least one continuous region, and the above-mentioned one continuous region contains more than 50%, more than 60%, more than 70%, more than 80%, more than 90% or 100% of the genes selected from the group consisting of HLA encoding genes and HLA similar sequences respectively contained in the above-mentioned region. Throughout this specification, the deletion is a deletion in two alleles. In one embodiment, in addition to the above-mentioned region, in the cells of the present invention, in addition to the above-mentioned region, the regions within 20kbp, within 15kbp, within 10kbp, within 9kbp, within 8kbp, within 7kbp, within 6kbp, within 5kbp, within 4kbp, within 3kbp, within 2kbp or within 1kbp can be further deleted independently from both ends to the outside. In addition, in one embodiment, the cells of the present invention may not lack more than one (preferably one) HLA gene located at both ends of the above-mentioned region.

[0307] In one embodiment, the present invention provides a cell comprising genomic DNA having a deletion, wherein the deletion comprises a deletion of a part or the entirety of a region in which an HLA-like sequence cluster is located in one or more chromosomal regions selected from the group consisting of the chromosomal regions specified in (i) to (iv) below:

[0308] (i) Chromosome region corresponding to chr6:29711000-30020000 of hg38 genome sequence;

[0309] (ii) the chromosomal region corresponding to the chr6: 31176000-31534000 chromosomal region of the hg38 genomic sequence;

[0310] (iii) a chromosomal region corresponding to the chr6:32445000-32821000 chromosomal region of the hg38 genomic sequence; and

[0311] (iv) the chromosomal region corresponding to the chr6: 33002000-33147000 chromosomal region of the hg38 genome sequence,

[0312] The HLA similar sequence cluster region includes all of the HLA encoding genes and HLA similar sequences respectively contained in the above chromosome region.

[0313] The above-mentioned part contains at least one continuous region, and the above-mentioned one continuous region contains more than 50%, more than 60%, more than 70%, more than 80%, more than 90% or 100% of the genes selected from the group consisting of HLA encoding genes and HLA similar sequences respectively contained in the above-mentioned region. Throughout this specification, the deletion is a deletion in two alleles. In one embodiment, in addition to the above-mentioned region, in the cells of the present invention, in addition to the above-mentioned region, the regions within 20kbp, within 15kbp, within 10kbp, within 9kbp, within 8kbp, within 7kbp, within 6kbp, within 5kbp, within 4kbp, within 3kbp, within 2kbp or within 1kbp can be further deleted independently from both ends to the outside. In addition, in one embodiment, the cells of the present invention may not lack more than one (preferably one) HLA gene located at both ends of the above-mentioned region.

[0314] In one embodiment, the present invention provides a cell comprising genomic DNA having a deletion, wherein the deletion is a deletion of a region including a part or the entirety of an HLA-like sequence cluster region located in one or more chromosomal regions selected from the group consisting of the chromosomal regions specified in the following (i) to (iv):

[0315] (i) Chromosome region corresponding to chr6:29706837-29956199 of hg38 genomic sequence;

[0316] (ii) the chromosomal region corresponding to the chr6: 31268749-31534000 chromosomal region of the hg38 genomic sequence;

[0317] (iii) a chromosomal region corresponding to the chr6:32439887-32817002 chromosomal region of the hg38 genomic sequence; and

[0318] (iv) the chromosomal region corresponding to the chr6:32934636-33089696 chromosomal region of the hg38 genomic sequence,

[0319] The HLA similar sequence cluster region includes all of the HLA encoding genes and HLA similar sequences respectively contained in the above chromosome region.

[0320] The above-mentioned part contains at least one continuous region, and the above-mentioned one continuous region contains more than 50%, more than 60%, more than 70%, more than 80%, more than 90% or 100% of the genes selected from the group consisting of HLA encoding genes and HLA similar sequences respectively contained in the above-mentioned region. Throughout this specification, the deletion is a deletion in two alleles. In one embodiment, in addition to the above-mentioned region, in the cells of the present invention, in addition to the above-mentioned region, the regions within 20kbp, within 15kbp, within 10kbp, within 9kbp, within 8kbp, within 7kbp, within 6kbp, within 5kbp, within 4kbp, within 3kbp, within 2kbp or within 1kbp can be further deleted independently from both ends to the outside. In addition, in one embodiment, the cells of the present invention may not lack more than one (preferably one) HLA gene located at both ends of the above-mentioned region.

[0321] The chromosome region specified in (i) above includes an HLA similar sequence cluster region containing HLA-F, HLA-G and HLA-A. In addition, in one embodiment, the deletion is a partial or preferably complete deletion of the HLA similar sequence cluster region. Here, a part refers to a region containing at least one HLA and an HLA similar sequence. For example, in one embodiment, the deletion is a deletion of a region containing one or more, preferably all, selected from the group consisting of HLA-F, HLA-G and HLA-A. In one embodiment, the deletion is a deletion of a region containing all HLA similar sequence cluster regions, which is a deletion of a region containing HLA-F, HLA-G and HLA-A.

[0322] In one embodiment, a cell that has lost part or all of HLA may have, for example, an additionally introduced endogenous or exogenous desired gene operably linked to a control sequence. The additionally introduced endogenous or exogenous desired gene operably linked to a control sequence has a naturally occurring sequence in one embodiment, and a sequence that is not naturally occurring or is an artificially designed sequence in another embodiment. The additionally introduced desired gene may, for example, confer additional functions to the cell. The desired gene to be introduced additionally can encode, for example, a factor selected from the group consisting of differentiation promoting factors, differentiation inhibitors, initialization factors (including factors required for initialization to pluripotent cells including Oct4), factors that activate cell-specific functions, factors that inhibit cell-specific functions, signal transduction factors, signal transduction inhibitors, receptors, membrane proteins, enzymes (e.g., metabolic enzymes, phosphorylases, nucleic acid synthetases, telomerases, etc.), growth factors, growth inhibitors, immune activation molecules or immunosuppressive molecules, degrading enzymes (e.g., proteolytic enzymes, nucleic acid degrading enzymes, etc.), secretory factors (e.g., cytokines, hormones, etc.), nuclear proteins, cytoplasmic proteins, mitochondrial proteins, antisense oligonucleotides, siRNA, shRNA, crRNA and trcrRNA, single-stranded gRNA, marker genes (e.g., drug resistance genes, visual marker genes, etc.), inducible suicide genes (e.g., toxins operably connected to inducible promoters, such as diphtheria toxins), and microRNAs. In one embodiment, the control sequence can be a constitutive promoter or an inducible promoter.

[0323] In one embodiment, the cell in which a part of HLA is deleted in (i) above may have (remain) for example, 1 to several (for example, 1 to 4, preferably 3, more preferably 2, and further preferably 1) HLA in (i). In one embodiment, the cell in which a part of HLA is deleted in (ii) above may have (remain) for example, 1 to several (for example, 1 to 4, preferably 3, more preferably 2, and further preferably 1) HLA in (ii). In one embodiment, the cell in which a part of HLA is deleted in (iii) above may have (remain) for example, 1 to several (for example, 1 to 4, preferably 3, more preferably 2, and further preferably 1) HLA in (iii). In one embodiment, the cell in which a part of HLA is deleted in (iv) above may have (remain) for example, 1 to several (for example, 1 to 4, preferably 3, more preferably 2, and further preferably 1) HLA in (iv).

[0324] In one embodiment, the deletion is a deletion of a part or preferably all of the region containing the HLA similar sequence clustering region. In this embodiment, it is preferred to introduce the desired gene into the chromosomal region specified in (i) above. Thus, in this embodiment, although the chromosomal region specified in (i) has deleted all the HLA similar sequence clustering regions, it has the desired gene (endogenous or preferably exogenous gene) or its insertion that is operably connected to the control sequence. In one embodiment, the deletion is a deletion of a part or preferably all of the region containing the HLA similar sequence clustering region. In this embodiment, it is preferred to re-introduce the desired gene into a region other than the chromosomal region specified in (i). Thus, in the above-mentioned genomic DNA, the chromosomal region specified in (i) above has a deletion of a part or preferably all of the HLA similar sequence clustering region, but the region other than the chromosomal region specified in (i) has the desired gene that is endogenous or preferably exogenous that is operably connected to the control sequence. Endogenous means having the same base sequence as the endogenous gene currently or previously possessed by the cell with the deletion, and exogenous means having a base sequence different from the endogenous gene currently or previously possessed by the cell with the deletion. The desired gene is a functional gene. A functional gene means having the original function of the gene. The deletion in (i) includes at least one or both of HLA-A and HLA-F.

[0325] In all modes, the control sequence of the desired gene operably connected to the control sequence is exogenous or endogenous, and the desired gene is exogenous or endogenous. In one mode, the control sequence is endogenous and the desired gene is exogenous. In one mode, the control sequence is endogenous and the desired gene is endogenous. In one mode, the control sequence is exogenous and the desired gene is endogenous. In one mode, the control sequence is exogenous and the desired gene is exogenous. In one mode, the control sequence is exogenous and the desired gene is exogenous. In one mode, the control sequence is endogenous and the desired gene is endogenous, but a series of sequences containing the control sequence and the desired gene are endogenous or exogenous as a whole. As the control sequence, various known control sequences such as enhancer and promoter can be listed.

[0326] The chromosome region specified in (ii) above includes an HLA-like sequence cluster region containing HLA-C, HLA-B, MICA and MICB. In addition, in one embodiment, the deletion is a part or preferably all of the HLA-like sequence cluster region. Here, a part refers to a region containing at least one HLA and an HLA-like sequence. For example, in one embodiment, the deletion is a deletion of one or more, preferably all, of the region selected from the group consisting of HLA-C, HLA-B, MICA and MICB.

[0327] The chromosome region specified in (iii) above includes an HLA-like sequence cluster region containing HLA-DRB5, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DQA2, HLA-DQB2 and HLA-DOB. In addition, in one embodiment, the deletion is a part or preferably all of the HLA-like sequence cluster region. Here, a part refers to a region containing at least one HLA and HLA-like sequence. For example, in one embodiment, it is a deletion of more than one, preferably all, of the region selected from the group consisting of HLA-DRB5, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DQA2, HLA-DQB2 and HLA-DOB.

[0328] The chromosome region specified in (iv) above includes an HLA-like sequence cluster region containing HLA-DOA, HLA-DPA1 and HLA-DPB1. In addition, in one embodiment, the deletion is a part or preferably all of the HLA-like sequence cluster region. Here, a part refers to a region containing at least one HLA and an HLA-like sequence. For example, in one embodiment, it is a deletion of one or more, preferably all, of the region selected from the group consisting of HLA-DOA, HLA-DPA1 and HLA-DPB1.

[0329] In view of the gist of the present invention, the deletion of the region specified in (i) above may be a deletion of all regions except for the region containing only one of HLA and the HLA similar sequence in the HLA similar sequence clustering region.

[0330] In one embodiment, the deletion of the region specified in (ii) above may be a deletion of all regions except for the region containing only one of HLA and the HLA similar sequence in the HLA similar sequence clustering region.

[0331] In one embodiment, the deletion of the region specified in (iii) above may be a deletion of all regions except for the region containing only one of HLA and the HLA similar sequence in the HLA similar sequence clustering region.

[0332] In one embodiment, the deletion of the region specified in (iv) above may be a deletion of all regions except for the region containing only one of HLA and the HLA similar sequence in the HLA similar sequence clustering region.

[0333] In one embodiment, the deletion is a deletion of the region specified in (i), and the other regions of (i) to (iv) do not have a deletion of part or all of the HLA similar sequence clustering region. In one embodiment, the deletion is a deletion of the region specified in (ii), and the other regions of (i) to (iv) do not have a deletion of part or all of the HLA similar sequence clustering region. In one embodiment, the deletion is a deletion of the region specified in (iii), and the other regions of (i) to (iv) do not have a deletion of part or all of the HLA similar sequence clustering region. In one embodiment, the deletion is a deletion of the region specified in (iv), and the other regions of (i) to (iv) do not have a deletion of part or all of the HLA similar sequence clustering region.

[0334] In one embodiment, the deletion is a deletion of the region specified in each of (i) to (iv).

[0335] In one embodiment, more than one gene can be inserted (knocked in) in the region with the above-mentioned deletion. The inserted gene can be a selection marker (such as a drug resistance marker and a visualization marker) and a target gene with a physiological function. The inserted gene is preferably operably connected to a control sequence. In a preferred embodiment, the gene insertion position is any one of the above (i) to (iv). In a preferred embodiment, the gene insertion position is not any one of the above (i) to (iv). In a preferred embodiment, the gene insertion position is in the region of (ii). In a preferred region, the region of (ii) has a deletion (preferably the deletion specified above) and has the insertion of more than one gene. In one embodiment, there is no insulator at either or both of the upstream and downstream of the inserted gene. The insulator is a cis-regulatory element, for example, having the following effects: preventing an enhancer at a distant position from acting on a promoter, or preventing the adjacent heterochromatin from expanding and silencing the same chromatin. As insulators, CTCF insulators, gypsy insulators and β-globin insulators can be listed. The insulator has a length of about 200 to 1000 bp. The insulator can inhibit PCR amplification across the insulator, etc. In one embodiment, the region of (ii) above has a deletion (preferably the deletion specified above) and has an insertion of the above-mentioned one or more genes, and the above-mentioned one or more genes do not have an insulator at any one or both of their centromere side and telomeric side (or upstream and downstream). In one embodiment, the region with the deletion does not have an insertion of a new sequence. In one embodiment, the region with the deletion does not have site-specific recombinase recognition sequences such as loxP or FRT (flip enzyme recognition target) and variants thereof.

[0336] In one embodiment, the above-mentioned deletion, in particular, the deletion of the region specified in the above (i) may be a deletion of part or preferably all of a series of regions containing HLA-F, HLA-G and HLA-A (for example, a chromosomal region corresponding to chr6:29723464-29945455, preferably chr6:29723464-30010618 of the hg38 genome sequence). In one embodiment, the above-mentioned deletion, in particular, the deletion of the region specified in the above (i) is a deletion of a specific sequence (first sequence) in the chromosomal region of chr6:29701000 to 29723464 (for example, Chr6:29709000-29711000) having one end and chr6:29945455-3003000 0 (e.g., the chromosomal region of Chr6: 30020000-30020000 and chr6: 30021500-30022800) has a deletion of a region at the other end in a unique sequence (second sequence) in the chromosomal region of chr6: 30020000-30020000. This is because the first sequence and the second sequence contain a genome-specific sequence (single sequence), and therefore, when genome modification is performed by homologous recombination using a donor DNA described later, the upstream homologous arm (e.g., the telomere-side homologous arm) and the downstream homologous arm (e.g., the centromere-side homologous arm) are used as targets, and selectively bind to the above-mentioned inherent sequence (single sequence), so that genome modification can be achieved according to the target. The above-mentioned deletion is a deletion of about 300 kb, and as a method for efficiently producing such a huge deletion, the following method can be preferably used.

[0337] In one embodiment, the above-mentioned deletion, in particular the deletion of the region specified in the above (ii), is a deletion of part or preferably all of a series of regions containing HLA-C and HLA-B (for example, a chromosomal region corresponding to the chromosomal region of chr6:31269169-31357158, preferably chr6:31269169-31463338 of the hg38 genome sequence). In one embodiment, the deletion, particularly the deletion of the region specified in (ii) above, is a deletion of a region having one end in a unique sequence (third sequence) in a chromosome region of chr6:31166000 to 31269169 (e.g., Chr6:31174000 to 31177000) and the other end in a unique sequence (fourth sequence) in a chromosome region of chr6:31357158 to 31544000 (e.g., Chr6:31534000 to 31538000). The third sequence and the fourth sequence contain a unique sequence (a single sequence, in other words, a unique sequence in which no other similar sequence exists) that is unique to the genome, and therefore, when genome modification is performed by homologous recombination using a donor DNA described later, the upstream homology arm (e.g., the telomere-side homology arm) and the downstream homology arm (e.g., the centromere-side homology arm) are used as targets, and selective binding to the above-mentioned unique sequence (single sequence) can be achieved to achieve genome modification according to the target. The above deletion is a deletion of about 360 kb, and the following method can be preferably used as a method for efficiently generating such a large deletion.

[0338] In one embodiment, the above-mentioned deletion, in particular the deletion of the region specified in the above (iii), is a deletion of part or preferably all of a series of regions containing HLA-DRA, HLA-DRB5 and HLA-DRB1 (for example, a chromosomal region corresponding to the chromosomal region of chr6:32445000-32816951, preferably chr6:32439951-32817002 of the hg38 genome sequence). In one embodiment, the above-mentioned deletion, in particular the deletion of the region specified in the above (iii), is a deletion of a region having one end in a specific sequence (5th sequence) in the chromosome region of chr6:32416000-33445000, for example, chr6:32420000-33445000, for example, chr6:32429000-33445000 (for example, Chr6:32446000-32448500), and having the other end in a specific sequence (6th sequence) in the chromosome region of chr6:32439951-32831000 (for example, Chr6:32820500-32822500). The 5th sequence and the 6th sequence contain the inherent sequence of the genome (single sequence, in other words, a unique sequence without other similar sequences). Therefore, when the genome is transformed by homologous recombination using the donor DNA described later, the upstream homology arm (e.g., telomere homology arm) and the downstream homology arm (e.g., centromere homology arm) are used as targets, and selectively bind to the above-mentioned inherent sequence (single sequence), so that the genome transformation can be achieved according to the target. The above-mentioned deletion is a deletion of about 380kb. As a method for efficiently generating such a huge deletion, the following method can be preferably used.

[0339] In one embodiment, the above-mentioned deletion, in particular the deletion of the region specified in the above (iv), can be a deletion of part or all of a series of regions containing HLA-DOA, HLA-DPA1 and HLA-DPB1 (for example, a chromosomal region corresponding to the chromosomal region of chr6:33006838-33086238, preferably chr6:33006838-33131199 of the hg38 genome sequence). In one embodiment, the deletion, in particular, the deletion of the region specified in (iv) above, is a deletion of a region having one end in a specific sequence (seventh sequence) in a chromosome region of chr6:32924000 to 33006838 (e.g., Chr6:32999500 to 33002500) and the other end in a specific sequence (eighth sequence) in a chromosome region of chr6:33086238 to 33165000 (e.g., Chr6:33147500 to 33150500). The seventh sequence and the eighth sequence contain a specific sequence (a single sequence, in other words, a specific sequence in which no other similar sequence exists) that is a specific sequence of the genome, and therefore, when genome modification is performed by homologous recombination using a donor DNA described later, the upstream homology arm (e.g., the telomere-side homology arm) and the downstream homology arm (e.g., the centromere-side homology arm) are used as targets, and selective binding to the above-mentioned specific sequence (single sequence) can be achieved to achieve genome modification according to the target. The above-mentioned deletion is a deletion of about 150 kb, and the following method can be preferably used as a method for efficiently generating such a large deletion.

[0340] In one embodiment, the cell having the deletion contains genomic DNA having the deletion, wherein the deletion is a deletion of a region including a part or the entirety of an HLA-like sequence cluster region located in all chromosomal regions selected from the group consisting of the chromosomal regions specified in the following (i) to (iv):

[0341] (i) a region containing HLA-F, HLA-G and HLA-A (e.g., a chromosomal region corresponding to chr6:29723464-29945455, preferably chr6:29723464-30010618 of the hg38 genomic sequence);

[0342] (ii) a region containing a series of HLA-C and HLA-B (e.g., a chromosomal region corresponding to chr6:31269169-31357158, preferably chr6:31269169-31463338 of the hg38 genomic sequence);

[0343] (iii) a region containing HLA-DRA, HLA-DRB5 and HLA-DRB1 (e.g., a chromosomal region corresponding to chr6:32445000-32816951, preferably chr6:32439951-32817002 of the hg38 genomic sequence); and

[0344] (iv) a region containing HLA-DOA, HLA-DPA1 and HLA-DPB1 (e.g., a chromosomal region corresponding to the chromosomal region of chr6:33006838-33086238, preferably chr6:33006838-33131199 of the hg38 genomic sequence),

[0345] The HLA similar sequence cluster region includes all of the HLA encoding genes and HLA similar sequences respectively contained in the above chromosome region.

[0346] The above-mentioned part contains at least one continuous region, and the above-mentioned one continuous region contains more than 50%, more than 60%, more than 70%, more than 80%, more than 90% or 100% of the genes selected from the group consisting of HLA encoding genes and HLA similar sequences respectively contained in the above-mentioned region.

[0347] In one embodiment, the cell having a deletion contains genomic DNA having a deletion, and the deletion is a deletion including all chromosomal regions selected from the group consisting of chromosomal regions specified in the following (i) to (iv):

[0348] (i) a region containing HLA-F, HLA-G and HLA-A (e.g., a chromosomal region corresponding to chr6:29723464-29945455, preferably chr6:29723464-30010618 of the hg38 genomic sequence);

[0349] (ii) a region containing a series of HLA-C and HLA-B (e.g., a chromosomal region corresponding to chr6:31269169-31357158, preferably chr6:31269169-31463338 of the hg38 genomic sequence);

[0350] (iii) a region containing HLA-DRA, HLA-DRB5 and HLA-DRB1 (e.g., a chromosomal region corresponding to chr6:32445000-32816951, preferably chr6:32439951-32817002 of the hg38 genomic sequence); and

[0351] (iv) a region containing HLA-DOA, HLA-DPA1 and HLA-DPB1 (e.g., a chromosomal region corresponding to the chromosomal region of chr6:33006838-33086238, preferably chr6:33006838-33131199 of the hg38 genomic sequence),

[0352] Preferably, there is further deletion of a series of regions containing HLA-E, and further deletion of a series of regions containing HLA-DMB, a series of regions containing MICA and MICB, and a series of regions containing HLA-DMA.

[0353] In one embodiment, when the above (i) has a deletion, the above (i) having the deletion does not have a repetitive sequence in its chromosomal region. In one embodiment, when the above (ii) has a deletion, the above (ii) having a deletion does not have a repetitive sequence in its chromosomal region. In one embodiment, when the above (iii) has a deletion, the above (iii) having a deletion does not have a repetitive sequence in its chromosomal region. In one embodiment, when the above (iv) has a deletion, the above (iv) having a deletion does not have a repetitive sequence in its chromosomal region. The repetitive sequence is, for example, a continuous sequence that is difficult to sequence. The repetitive sequence is, for example, a continuous sequence that induces off-target to the homologous arm of the donor DNA. The repetitive sequence contains, for example, a repetition of a 0.5kb to 2kb sequence.

[0354] In one embodiment, the human cells with the above-mentioned deletion have a gene encoding a functional β2 microglobulin (B2M). In one embodiment, the human cells with the above-mentioned deletion have a gene encoding a functional class II tumor tissue compatibility gene complex transactivator (CIITA). In one embodiment, the human cells with the above-mentioned deletion have a gene encoding a functional B2M and a gene encoding a functional CIITA. Thus, it is possible to prevent the unexpected functional modification that may be produced by the cell by making B2M and CIITA missing. Nevertheless, in one embodiment, the cell surface of the human cells with the above-mentioned deletion does not substantially express HLA class I and / or HLA class II.

[0355] In one embodiment, the deletion may be greater than 100 kb, greater than 150 kb, greater than 200 kb, greater than 250 kb, greater than 300 kb, greater than 350 kb, or greater than 400 kb. In one embodiment, the deletion may be less than 400 kb, less than 350 kb, less than 300 kb, less than 250 kb, less than 200 kb, less than 150 kb, or less than 100 kb. In one embodiment, the deletion may be between 100 kb and 400 kb.

[0356] In one embodiment, the cells may be differentiated cells or precursor cells for introduction of further modifications.

[0357] Hereinafter, as Cell Examples 1 to 4, examples of cells that can be used as useful cells themselves and are also useful as precursor cells for introduction into further transformation are listed. Cell Examples 1 to 4 lack at least one HLA-like sequence aggregation region, thus solving the problem of hindering genome sequence decoding or gene targeting due to the presence of repeated sequences. As a result, transformation becomes easy and decoding of the transformed sequence becomes easy, so it can be more reliably applied to genetic engineering.

[0358] Cell Example 1

[0359] In one embodiment, the cell has a deletion in (i) above. In a preferred embodiment, the deletion can be a deletion of the entire HLA similar sequence aggregation region. In one embodiment, the deletion in (i) above can be a deletion caused by replacement with DNA containing one or more desired genes or their insertions. In one embodiment, the desired gene can be a selection marker gene. The selection marker gene preferably contains a positive selection marker gene, and more preferably contains both a positive selection marker gene and a negative selection marker gene, or contains a marker gene that can be used for either positive selection or negative selection. In one embodiment, the cell has a deletion in (i) above and does not have a deletion in (ii) to (iv) above. Cell Example 1 is a cell that lacks HLA-A and F and is useful in itself, for example, it can be used to make cell examples 2 to 4.

[0360] Cell Example 2

[0361] In one embodiment, the cell has a deletion in (i) above and has a desired gene or an insertion thereof operably linked to a control sequence. In a preferred embodiment, the deletion in (i) above is a deletion of the entire region containing HLA similar sequence aggregation. In one embodiment, the deletion in (i) above can be a deletion caused by replacement with DNA containing one or more desired genes or insertions thereof. In one object, the desired gene can be a molecule that inhibits immunity against cells having the deletion, for example, it can be a gene encoding an immunosuppressive molecule. In one embodiment, the region with the deletion contains a selection marker gene. The selection marker gene preferably contains a positive selection marker gene, more preferably contains both a positive selection marker gene and a negative selection marker gene, or contains a marker gene that can be used for either positive selection or negative selection. In one embodiment, the cell with the deletion has the desired gene in a region other than (i) above. Cell Example 2 is a cell that is useful in itself, for example, it can be used to make Cell Examples 3 to 4.

[0362] Cell Example 3

[0363] In one embodiment, the cell has a deletion in (i) and (iii) and / or (iv) and has a desired gene or an insertion thereof operably connected to a control sequence. In a preferred embodiment, the cell has a deletion in (i), (iii) and (iv) and has a desired gene or an insertion thereof operably connected to a control sequence. In a preferred embodiment, the deletions in (i), (iii) and (iv) are respectively deletions of the entire HLA similar sequence aggregation region containing the region. In one embodiment, the deletion in (i) can be a deletion caused by replacement with DNA containing one or more desired genes or their insertions. In one object, the desired gene can be a molecule that suppresses immunity against cells having the deletion, for example, a gene that encodes an immunosuppressive molecule. In one embodiment, the cell has a deletion in (i), (iii) and / or (iv) and any one or more or all of the deleted regions contain a selection marker gene. The selective marker gene preferably contains a positive selective marker gene, more preferably contains both a positive selective marker gene and a negative selective marker gene, or contains a marker gene that can be used for either positive selection or negative selection. In a preferred embodiment, none of the above (i), the above (iii) and the above (iv) have insertions of desired genes such as marker genes or new genes. In one embodiment, the cell does not have a deletion in the above (ii). Cell Example 3 is a cell useful in itself, for example, it can be used to make Cell Example 4.

[0364] Cell Example 4

[0365] In one embodiment, the cell has a deletion in all of the above (i) to (iv) and has an insertion of a desired gene or its insertion operably connected to a control sequence. In a preferred embodiment, the deletion in (i) can be a deletion caused by replacement with DNA containing one or more desired genes or their insertions. In an object, the desired gene can be a molecule that suppresses immunity to cells having the deletion, for example, a gene encoding an immunosuppressive molecule. In a preferred embodiment, the deletion in (ii) can be a deletion caused by replacement with DNA containing one or more desired genes. In a preferred embodiment, the desired gene can be a selection marker gene. The selection marker gene preferably contains a positive selection marker gene, more preferably contains both a positive selection marker gene and a negative selection marker gene, or contains a marker gene that can be used for either positive selection or negative selection. In a preferred embodiment, neither (iii) nor (iv) has an insertion of a desired gene such as a marker gene or a new gene. Cell Example 4 is a cell that is useful in itself, for example, it can be used to further replace the DNA portion containing one or more desired genes or their insertions in (ii) with other DNA. For example, the marker gene can be removed or other desired genes can be introduced on the basis of removing the marker gene. According to genome analysis, the region of (ii) is a transcriptional activation region, and it can be expected that the desired gene can be well expressed by introducing the desired gene. In a preferred embodiment, the desired gene is inserted into the region of (ii) above, and there is no insulator at any one or both of the centromere side and the telomeric side of the gene.

[0366] In one embodiment, the cell having the deletion does not have at least HLA-A. In one embodiment, the cell having the deletion does not have at least HLA-A and F. On the other hand, the cell having the deletion may have one or more or all selected from the group consisting of HLA-B, C, E, G, H, J and W; MICA and MICB; and HLA-DRA, DRB1, DRB5, DRB6, DRB9, DQA1, DQA2, DQB1, DPA1, DPB1, DMB, DOA and DOB.

[0367] The above is the description of Cell Examples 1 to 4. As described above, in cells with HLA deletion, the HLA region can be replaced with a marker gene or with a desired gene (target gene). The marker gene and the target gene are operably linked to a control sequence.

[0368] In all embodiments, the cell having the deletion has the deletion in both alleles, and thus the expression of the deleted gene is lost.

[0369] In one embodiment, the cell having the deletion may be an isolated cell or a cell line.

[0370] In one embodiment, the cells with the above-mentioned deletion can avoid the cell killing effect brought by T cell natural killer cells (NK cells). In one embodiment, the cells with the above-mentioned deletion can not induce immune rejection against the cells even if they are administered to allogeneic individuals. Thus, for example, cells that can be preferably used for hematopoietic stem cell transplantation, organ transplantation, cell transplantation or tissue transplantation can be provided.

[0371] In one embodiment, the cells with the above-mentioned deletion can be frozen in a cell cryoprotectant. In one embodiment, the cell cryoprotectant containing the cells with the above-mentioned deletion can be provided in a non-frozen state or preferably in a frozen state. The cell cryoprotectant containing the cells with the above-mentioned deletion in a frozen state (also referred to as a "frozen reserve") can be used as a research cell bank (RCB), a mother cell bank (MCB) or a working cell bank (WCB). Therefore, the present invention can provide a research cell bank (RCB), a mother cell bank (MCB) or a working cell bank (WCB) containing the above-mentioned frozen reserve. The above-mentioned genomic DNA with deletion can be subjected to whole genome sequencing. In addition, in one embodiment, reference genome data is prepared by the above-mentioned whole genome sequencing. In the case where the repetitive sequences in the above-mentioned (i) to (iv) have been removed, the preparation of the reference genome data becomes easier. The cells with the above-mentioned genomic DNA with deletion can be further subjected to genome modification and the modification of the modification site can be confirmed based on the reference genome. Thus, the above-mentioned cells with deletion can be easily or reliably subjected to further genome modification, and the sequence of the obtained modified genome can be easily determined.

[0372] As the above-mentioned cells, for example, pluripotent cells (for example, pluripotent stem cells such as embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells)), hematopoietic stem cells, hematopoietic precursor cells, bone marrow cells, spleen cells, common precursor cells of the bone marrow system, immune cells (for example, T cells, B cells, NK cells, NKT cells, macrophages, monocytes, neutrophils, eosinophils, basophils), erythrocytes, megakaryocytes, cardiac cells, cardiomyocytes, cardiac fibroblasts, pancreatic β cells, corneal cells (for example, corneal epithelial cells and corneal endothelial cells), epidermal cells, dermal cells, adipocytes, chondrocytes, osteocytes, osteoclasts, osteoblasts, mesenchymal stem cells (for example, from fat, from bone marrow, from placenta and from umbilical cord), dental pulp cells, tendon cells, ligament cells, neural cells (for example, cone cells, astrocytes and granule cells), glial cells, Purkinje cells, retinal ganglion cells, retinal cells, optic nerve cells and neural stem cells can be listed. In a preferred embodiment, the cells can be primary cells. In a preferred embodiment, the cells may be immortalized cells or cell lines.

[0373] The cells with the above-mentioned deletion can form cell clumps such as organoids. The cells with the above-mentioned deletion can form cell sheets. The cells with the above-mentioned deletion can form the whole or partial structure of an organ or tissue.

[0374] In one embodiment, a composition (e.g., a pharmaceutical composition or a cell preparation) containing the above-mentioned cells with deletions can be provided. The above-mentioned composition can be used for medical purposes. In addition to containing cells, the above-mentioned composition can also contain a pharmaceutically acceptable carrier and / or additive. As a pharmaceutically acceptable carrier, for example, water and physiological saline can be mentioned. As a pharmaceutically acceptable additive, for example, salt, pH buffer and isotonic agent can be mentioned. A preferred embodiment of the above-mentioned composition can be serum-free.

[0375] The method described below (e.g., UKiS; see International Publication No. 2021 / 206054) is useful as a method for simultaneously and efficiently introducing the same modification into two or more alleles of a chromosome genome, for example, suitable for making a deletion of about 100 kb to 500 kb in a sequence-specific manner in a target chromosome region, and can be preferably used to make the above-mentioned cells. The method can also be used to transform haploid cells. The method can also be applied to cells with only one allele in the HLA gene region on the genomic DNA.

[0376] In one embodiment, the present invention may be a method for producing a cell in which two or more alleles of a chromosome genome are modified, comprising:

[0377] (a) a step of introducing the following (i) and (ii) into a cell containing two or more alleles to introduce a selectable marker gene into each of the two or more alleles,

[0378] (i) a genome modification system comprising a sequence-specific nucleic acid cleavage molecule or a polynucleotide encoding the sequence-specific nucleic acid cleavage molecule that can target and cleave a target region in two or more alleles of the above-mentioned chromosomal genome,

[0379] (ii) two or more types of donor DNAs for selection markers, each of which has an upstream homology arm having a base sequence capable of homologously recombination with a base sequence on the upstream side of the target region and a downstream homology arm having a base sequence capable of homologously recombination with a base sequence on the downstream side of the target region, and contains a base sequence of a selection marker gene between the upstream homology arm and the downstream homology arm, the two or more types of donor DNAs for selection markers respectively have different selection marker genes that can be distinguished from each other, the selection marker gene is unique to each type of donor DNA for selection markers, and the number of types of donor DNA for selection markers is greater than or equal to the number of alleles to be the subject of genome modification; and

[0380] (b) After the above step (a), a step is performed in which different unique selectable marker genes that can be distinguished are introduced into the two or more alleles respectively by homologously recombinating the two or more alleles with different types of selectable marker donor DNAs, and cells expressing all the introduced different selectable marker genes that can be distinguished are selected (a step for positive selection).

[0381] (Step (a))

[0382] In step (a), the above (i) and (ii) are introduced into cells containing chromosomes.

[0383] The cells used in the genome modification method of the present embodiment are not particularly limited, and can be cells having a haploid or 2-ploid chromosome genome or more. The cell can be 2-ploid, 3-ploid, or 4-ploid or more. As cells, there are no particular restrictions, and eukaryotic cells can be listed. The cell can be a plant cell, an animal cell, or a fungal cell. Animal cells are not particularly limited, and can be a cell of any one of a human, a mammal other than a human (e.g., non-human primates such as monkeys, dogs, cats, cattle, horses, sheep, goats, llamas, rodents, etc.), birds, reptiles, amphibians, fish, and other vertebrates.

[0384] The target region as the object of genome modification can be set to any region on the genome with more than one pair of alleles. The size of the target region is not particularly limited. The genome modification method of the present embodiment can modify a larger region than in the past. The target region can, for example, be more than 10kbp. The target region can, for example, be more than 100bp, more than 200bp, more than 400bp, more than 800bp, more than 1kbp, more than 2kbp, more than 3kbp, more than 4kbp, more than 5kbp, more than 8kbp, more than 10kbp, more than 20kbp, more than 40kbp, more than 80kbp, more than 100kbp, more than 200kbp, more than 300kbp, more than 400kbp, more than 500kbp, more than 600kbp, more than 700kbp, more than 800kbp, more than 900kbp or more than 1Mbp or any of the above values ​​below. In one embodiment, the target region is missing in the modified cell.

[0385] <(i) Genome modification system>

[0386] The "genome modification system" refers to a molecular mechanism capable of modifying a desired target region. The genome modification system contains a sequence-specific nucleic acid cleavage molecule targeting a target region of a chromosomal genome or a polynucleotide encoding the sequence-specific nucleic acid cleavage molecule.

[0387] The sequence-specific nucleic acid cleavage molecule is not particularly limited as long as it is a molecule with sequence-specific nucleic acid cleavage activity, and can be a synthetic organic compound or a biopolymer compound such as a protein. As a synthetic organic compound with sequence-specific nucleic acid cleavage activity, for example, pyrrole imidazole polyamides can be cited. As a protein with sequence-specific site cleavage activity, for example, a sequence-specific endonuclease can be cited.

[0388] Sequence-specific endonucleases are enzymes that can cut nucleic acids at a specified sequence. Sequence-specific endonucleases can cut double-stranded DNA at a specified sequence. As sequence-specific endonucleases, there are no particular restrictions, and examples thereof include zinc finger nucleases (Zinc finger nuclease (ZFN)), TALEN (Transcription activator-like effector nuclease), Cas proteins, etc., but are not limited to these.

[0389] ZFN is an artificial nuclease containing a nucleic acid cleavage domain that is bound to a binding domain containing a zinc finger array. As the cleavage domain, the cleavage domain of the type II restriction enzyme FokI can be cited. The design of a zinc finger nuclease that can cleave a target sequence can be performed by a known method.

[0390] TALEN is an artificial nuclease that contains a DNA binding domain of a transcription activator-like (TAL) effector in addition to a DNA cleavage domain (e.g., FokI domain). The design of TALE constructs capable of cleaving a target sequence can be performed by known methods (e.g., Zhang, Feng et al. (2011) Nature Biotechnology 29 (2)).

[0391] When using Cas protein as a sequence-specific nucleic acid cleavage molecule, the genome modification system contains a CRISPR / Cas system. That is, the genome modification system preferably contains a Cas protein and a guide RNA having a base sequence homologous to the base sequence in the target region. The guide RNA contains a sequence homologous to the sequence (target sequence) in the target region as a spacer sequence. As long as the guide RNA can bind to the DNA in the target region, it is not necessary to have a sequence that is exactly the same as the target sequence. The binding can be formed under physiological conditions in the nucleus. The guide RNA may contain, for example, 0 to 3 base mismatches relative to the target sequence. The number of the above-mentioned mismatches is preferably 0 to 2 bases, more preferably 0 to 1, and further preferably has no mismatches. The design of the guide RNA can be based on a known method. The genome modification system is preferably a CRISPR / Cas system, preferably containing a Cas protein and a guide RNA. The Cas protein is preferably a Cas9 protein.

[0392] Sequence-specific endonucleases can be introduced into cells in the form of proteins, or in the form of polynucleotides encoding sequence-specific endonucleases. For example, the mRNA of the sequence-specific endonuclease can be introduced, or the expression vector of the sequence-specific endonuclease can be introduced. In the expression vector, the coding sequence of the sequence-specific endonuclease (sequence-specific endonuclease gene) and the promoter can be functionally connected. The promoter is not particularly limited, for example, various pol II promoters can be used. As pol II promoters, there are no particular restrictions, and examples thereof include CMV promoter, EF1 promoter (EF1α promoter), SV40 promoter, MSCV promoter, hTERT promoter, β-actin promoter, CAG promoter, CBh promoter, etc.

[0393] The promoter can be an inducible promoter. An inducible promoter is a promoter that can induce the expression of a polynucleotide that can be functionally connected to the promoter only in the presence of an inducing factor for driving the promoter. As an inducible promoter, a promoter that induces gene expression by heating, such as a heat shock promoter, can be cited. In addition, as an inducible promoter, a promoter in which the inducing factor for driving the promoter is a drug can be cited. As such a drug-inducible promoter, for example, a Cumate operator sequence, a λ operator sequence (for example, 12×λOp), a tetracycline-based inducible promoter, etc. can be cited. As a tetracycline-based inducible promoter, for example, a promoter that drives gene expression in the presence of tetracycline or its derivatives (for example, doxycycline) or a reverse tetracycline-controlled transactivator (rtTA) can be cited. As a tetracycline-based inducible promoter, for example, a TRE3G promoter can be cited.

[0394] The expression vector can use a known expression vector without particular limitation. As an expression vector, for example, a plasmid vector and a viral vector can be cited. When the sequence-specific nuclease is a Cas protein, the expression vector may contain a guide RNA coding sequence (guide RNA gene) in addition to the coding sequence (Cas protein gene) of the Cas protein. In this case, the guide RNA coding sequence (guide RNA gene) is preferably functional with a pol III promoter. As a pol III promoter, for example, mouse and human U6-snRNA promoters, human H1-RNase PRNA promoters, human valine-tRNA promoters, etc. can be cited.

[0395] <(ii) Donor DNA for selection marker>

[0396] The donor DNA for selection marker is a donor DNA for knocking the selection marker into the target region. The donor DNA for selection marker contains the base sequence of one or more selection marker genes between the upstream homology arm having the homologous base sequence of the base sequence adjacent to the upstream side of the target region and the downstream homology arm having the homologous base sequence of the base sequence adjacent to the downstream side of the target region.

[0397] The donor DNA for selection marker is not particularly limited, and may have a length of, for example, 1 kb or more, 2 kb or more, 3 kb or more, 4 kb or more, 5 kb or more, 6 kb or more, 7 kb or more, 8 kb or more, 9 kb or more, 9.5 kb or more, or 10 kb or more. The donor DNA for selection marker is not particularly limited, and may have a length of, for example, 50 kb or less, 45 kb or less, 40 kb or less, 35 kb or less, 30 kb or less, 25 kb or less, 20 kb or less, 15 kb or less, 14 kb or less, 13 kb or less, 12 kb or less, 11 kb or less, 10 kb or less, 9 kb or less, 8 kb or less, 7 kb or less, 6 kb or less, 5 kb or less, or 4 kb or less.

[0398] "Selection marker" refers to a protein that can select cells based on the presence or absence of its expression. The selection marker gene is a gene that encodes a selection marker. When selecting cells expressing the selection marker in a cell population in which cells expressing the selection marker and cells that do not express the selection marker are mixed, the selection marker is referred to as a "positive selection marker" or a "selection marker for positive selection". When selecting cells that do not express the selection marker in a cell population in which cells expressing the selection marker and cells that do not express the selection marker are mixed, the selection marker is referred to as a "negative selection marker" or a "selection marker for negative selection". Selection markers that are different from each other refer to being able to distinguish from each other (e.g., being different), for example, refer to being able to distinguish from each other in terms of physiological properties such as the drug resistance properties given to cells into which the selection markers are introduced or other physicochemical properties. That is, selection markers that are different from each other refer to: two or more different selection markers can be detected separately from other selection markers, or can be selected for agents separately from other selection markers. In addition, the selection marker gene is unique to each selection marker donor DNA, which means that the selection marker gene possessed by one selection marker donor DNA is not contained in the selection marker donor DNA of the types other than the above; or, when the selection marker gene possessed by one selection marker donor DNA is contained in a plurality of donor DNAs, it is not simultaneously expressed by two or more donor DNAs. In this case, the two or more donor DNAs may be identical except for the selection marker, or may differ in sequence and / or composition other than the selection marker.

[0399] The positive selection marker is not particularly limited as long as cells expressing the marker can be selected. Examples of the positive selection marker gene include drug resistance genes, fluorescent protein genes, luminescent enzyme genes, and color development enzyme genes.

[0400] Negative selection markers are not particularly limited as long as they can select cells that do not express the marker. As negative selection marker genes, for example suicide genes (thymidine kinase, etc.), fluorescent protein genes, luminescent enzyme genes, color development enzyme genes, etc. can be cited. When the negative selection marker gene is a gene (such as a suicide gene) that has a negative impact on cell survival, the negative selection marker gene can be functionally connected to an inducible promoter. By being functionally connected to an inducible promoter, the negative selection marker gene can be expressed only when the cells with the negative selection marker gene are removed. When the negative selection marker gene is a marker gene (visual marker gene; visible marker gene) that can be detected by optical methods such as fluorescence, luminescence and color development, etc., in the case where the negative impact on cell survival is small, it can be stably expressed.

[0401] Examples of drug resistance genes include, but are not limited to, puromycin resistance gene, blasticidin resistance gene, geneticin resistance gene, neomycin resistance gene, tetracycline resistance gene, kanamycin resistance gene, zeocin resistance gene, hygromycin resistance gene, and chloramphenicol resistance gene.

[0402] Examples of fluorescent protein genes include green fluorescent protein (GFP) gene, yellow fluorescent protein (YFP) gene, and red fluorescent protein (RFP) gene, but are not limited thereto.

[0403] Examples of luminescent enzyme genes include luciferase genes, but are not limited thereto.

[0404] Examples of the chromogenic enzyme gene include, but are not limited to, a β-galactosidase gene, a β-glucuronidase gene, and an alkaline phosphatase gene.

[0405] Examples of suicide genes include herpes simplex virus thymidine kinase (HSV-TK) and inducible caspase 9, but are not limited thereto.

[0406] The selectable marker gene contained in the selectable marker donor DNA is preferably a positive selectable marker gene. That is, cells expressing the selectable marker can be selected as cells into which the selectable marker gene has been knocked in.

[0407] The upstream homology arm has a base sequence that can be homologously recombined with the base sequence on the upstream side of the target region in the genome of the object of transformation, for example, a base sequence homologous to the base sequence adjacent to the upstream side of the target sequence. The downstream homology arm has a base sequence that can be homologously recombined with the base sequence on the upstream side of the target region in the genome of the object of transformation, for example, a base sequence homologous to the base sequence adjacent to the downstream side of the target sequence. As long as the upstream homology arm and the downstream homology arm can be homologously recombined with the surrounding area of ​​the target region, their length and sequence are not particularly limited. As long as the upstream homology arm and the downstream homology arm can be homologously recombined, it is not necessary to be completely consistent with the upstream side sequence or the downstream side sequence of the target region. For example, the upstream homology arm can be a sequence having a sequence identity (homology) of more than 90% with the base sequence adjacent to the upstream side of the target region, preferably having a sequence identity of more than 92%, more than 93%, more than 94%, more than 95%, more than 96%, more than 97%, more than 98% or more than 99%. For example, the downstream homology arm can be a sequence having more than 90% sequence identity (homology) with the base sequence adjacent to the downstream side of the target region, preferably having more than 92%, more than 93%, more than 94%, more than 95%, more than 96%, more than 97%, more than 98% or more than 99% sequence identity. In addition, when at least any one of the upstream homology arm and the downstream homology arm is closer to the cutting position in the target region, the transformation efficiency of the allele can be further improved. Here, "close" can refer to a distance of less than 100bp, less than 50bp, less than 40bp, less than 30bp, less than 20bp or less than 10bp between the two sequences.

[0408] In the donor DNA for selection marker, the selection marker gene is located between the upstream homology arm and the downstream homology arm. Thus, when the donor DNA for selection marker is introduced into the cell together with the genome modification system of (i) above, the selection marker gene is introduced into the target region through HDR (when the gene is destroyed thereby, it is called gene knockout, and when the desired gene is introduced thereby, it is called gene knock-in, and other genes can also be knocked in while knocking out the gene).

[0409] The selectable marker gene is preferably functionally connected to a promoter in a manner that is expressed under the control of a suitable promoter. The promoter can be appropriately selected according to the type of cell into which the donor DNA is introduced. As promoters, for example, SRα promoter, SV40 early promoter, LTR of retrovirus, CMV (cytomegalovirus) promoter, RSV (Rous sarcoma virus) promoter, HSV-TK (herpes simplex virus thymidine kinase) promoter, EF1α promoter, metallothionein promoter, heat shock promoter, etc. can be cited. The selectable marker donor DNA can have any control sequence such as enhancer, poly A addition signal, terminator, etc.

[0410] The donor DNA for selective marker can have an insulator sequence. "Insulator" refers to a sequence that blocks or weakens the influence of adjacent chromosome environment, guarantees or improves the independence of the transcriptional regulation of the DNA clamped in this region. Insulators can be defined by the inhibitory effect of enhancer blocking effect (the effect of the influence of enhancer on promoter activity by being inserted between enhancer and promoter) and position effect (the effect of the influence of the position of the gene being inserted into the genome by clamping the two sides of the gene with insulators). The donor DNA for selective marker can have an insulator sequence between the upstream arm and the selective marker gene (or between the upstream arm and the promoter controlling the selective marker gene). The donor DNA for selective marker can have an insulator sequence between the downstream arm and the selective marker gene.

[0411] The donor DNA for selective marker can be linear or circular, preferably circular. The donor DNA for selective marker is preferably a plasmid. In the donor DNA for selective marker, in addition to containing the above sequence, any sequence can also be contained. For example, a spacer sequence can be contained in all or part of each sequence between the upstream homology arm, the insulator, the selective marker gene and the downstream homology arm.

[0412] In step (a), the same or more types of donor DNA for selective markers as the number of alleles as the object of genome modification are introduced into cells. Different types of donor DNA for selective markers have different (distinguishable) types of selective marker genes. In one embodiment, different types of donor DNA for selective markers do not have exactly the same selective marker gene or its set. That is, the first donor DNA for selective markers has the first selective marker gene, and the second donor DNA for selective markers has the second selective marker gene. The third donor DNA for selective markers has the third selective marker gene, and the same is true for more types of donor DNA for selective markers. When the alleles as the object of genome modification are 2, the type of donor DNA for selective markers is more than 2. When the alleles as the object of genome modification are 3, the type of donor DNA for selective markers is more than 3. In one embodiment, one selection marker donor DNA may have two or more different (distinguishable) selection markers (in this case, different types of selection marker donor DNAs must also have different (distinguishable) types (e.g., unique) selection marker genes). In one embodiment, the selection marker donor DNA does not have a recombination sequence of a site-specific recombinase (e.g., a loxP sequence and its variants that are recombined by the Cre recombinase). In addition, in one embodiment, the method of the present invention does not use a site-specific recombinase and its recombination sequence (e.g., a loxP sequence and its variants that are recombined by the Cre recombinase). If a site-specific recombinase is used, a recombination sequence of a site-specific recombinase will usually remain in the edited genome. In contrast, in one embodiment, the modified genome of the cell obtained by the method of the present invention does not have a recombination sequence (exogenous sequence) of a site-specific recombinase.

[0413] As long as the number of types of the donor DNA for selection markers is greater than or equal to the number of alleles as the object of genome modification, the upper limit is not particularly limited. By using the donor DNA for selection markers whose number of types is greater than or equal to the number of alleles as the object of genome modification, more than two alleles can be stably modified. From the viewpoint of the selection operation in the step (b) described later, the number of types of the donor DNA for selection markers is preferably equal to or more than 1 to 2 kinds of the number of alleles as the object of genome modification, and more preferably equal to the number of alleles as the object of genome modification.

[0414] The method of importing the above-mentioned (i) and (ii) into cells is not particularly limited, and known methods can be used without particular restrictions. As the method of importing (i) and (ii) into cells, for example, viral infection method, lipofection method, microinjection method, calcium phosphate method, DEAE-dextran method, electroporation method, gene gun method, etc. can be cited, but it is not limited to these. By importing the above-mentioned (i) and (ii) into cells, after the DNA of the target region is cut using the sequence-specific nucleic acid cleavage molecule of the above-mentioned (i), the selection marker in the donor DNA of (ii) is knocked into the target region by HDR. At this time, when the upstream homology arm and the downstream homology arm of each of the two or more selection marker donor DNAs are consistent, it can be randomly knocked into more than two alleles in the target region. However, as long as two or more selection marker donor DNAs respectively have base sequences of homologous arms having base sequences that can be homologously recombined with the upstream sequences and downstream sequences of the target regions of the two or more alleles, the two or more alleles can be transformed respectively, and therefore, there is no need to have base sequences of completely identical homologous arms. In one embodiment, in two or more selection marker donor DNAs, the base sequences of the upstream and downstream homologous arms can have base sequences with higher consistency with the upstream and downstream sequences of the target regions of each allele (for example, it can be optimized in this manner).

[0415] In one embodiment, the selective marker donor DNA may have an upstream homology arm and a downstream homology arm, and between the upstream homology arm and the downstream homology arm, there is a selective marker gene, preferably also having a target sequence of an endonuclease (base sequence specific nucleic acid cleavage molecule) such as a cleavage site of a meganuclease. In a preferred embodiment of the method, the selective marker contains a selective marker gene for positive selection and a marker gene for negative selection. In another preferred embodiment, the selective marker may contain a selective marker for positive selection without containing another negative selection marker gene. In a preferred embodiment, the selective marker gene for positive selection may also be used for negative selection, and as such a marker gene, a visual marker gene may be enumerated.

[0416] More than 2 selection marker donor DNA groups are combinations of the above selection marker donor DNAs, and each has a selection marker gene that can be distinguished from each other for positive selection. The above group may also have a target sequence for an endonuclease (base sequence specific nucleic acid cleavage molecule) such as a cleavage site of a meganuclease, and the target sequence may be different from each other, but preferably the same (or can be cut by the same base sequence specific nucleic acid cleavage molecule). The length of the selection marker donor DNA is as described above, for example, can be more than 5 kbp, more than 8 kbp or more than 10 kbp.

[0417] (Step (b))

[0418] Step (b) is performed after the above step (a). In step (b), for cells into which different selectable marker genes or combinations thereof that can be distinguished are respectively introduced into more than two alleles, selection is performed based on the expression of the different selectable marker genes that can be distinguished. More specifically, in step (b), different unique selectable marker genes that can be distinguished are respectively introduced into the more than two alleles by making different types of selectable marker donor DNAs carry out homologous recombination on the more than two alleles, and cells expressing all the different selectable marker genes that can be distinguished that are introduced are selected. In one embodiment, in step (b), based on the expression of all selectable marker genes that are integrated into the chromosome genome as the selectable marker genes possessed by the more than two selectable marker donor DNAs, cells that have been transformed by introducing different selectable marker donor DNAs are selected. In one embodiment, in step (b), cells are selected based on all selectable marker genes possessed by the more than two selectable marker donor DNAs. In one embodiment, in step (b), based on the expression of all the selection marker genes (marker genes for positive selection) integrated into the chromosome genome as the selection marker genes possessed by the above-mentioned two or more selection marker donor DNAs, cells that have been transformed by introducing distinguishable selection marker donor DNAs are selected. In one embodiment, the cells obtained in step (b) have marker genes for positive selection that are different for each allele. In one embodiment, the cells obtained in step (b) have marker genes for positive selection that are common to each allele. Here, in one embodiment, single cell cloning is not performed in step (b) {however, step (b) may or may not include: single cell cloning is performed after selecting cells that have been transformed with more than two alleles}. In one embodiment, in step (b), the selection of cells is performed based on the expression of two or more distinguishable marker genes for positive selection introduced into each allele. In one embodiment, step (b) is a method in which the number of transformed alleles is not inferred based on the expression intensity of a single selection marker gene (e.g., the expression intensity or fluorescence intensity of a fluorescent protein). This is because, when cells are selected by inferring the number of modified alleles based on the strength of the expression of a single selection marker gene, the gene expression level of each cell will fluctuate, making it difficult to completely separate cells that have been modified with more than two alleles from cells that have been modified with one allele. Therefore, single-cell cloning is required in step (b).

[0419] In step (b), cells can be appropriately selected according to the type of selection marker gene used in step (a). In this case, cells are selected based on the expression of all the selection marker genes used in step (a).

[0420] For example, when the selection marker gene is a positive selection marker gene, cells expressing all the selection marker genes to be integrated (or integrated) into the chromosome genome of the object to be transformed can be selected, for example, cells expressing the positive selection marker equal to the number of alleles of the object to be transformed can be selected. When the positive selection marker gene is a drug resistance gene, cells expressing the above-mentioned positive selection marker can be selected by culturing cells in a culture medium containing the agent. When the positive selection marker gene is a fluorescent protein gene, a luminescent enzyme gene or a color developing enzyme gene, cells expressing the above-mentioned positive selection marker can be selected by selecting cells that exhibit fluorescence, luminescence or color development caused by fluorescent protein, luminescent enzyme or color developing enzyme. In this step, when a selection marker donor DNA equal to the number of alleles to be transformed is introduced into the genome, the alleles of the number are transformed. In nploid cells, the number of alleles to be transformed is n or less than n, and when a selection marker donor DNA of more than this number and less than n is introduced into the genome, at least the alleles (more than 2 alleles) to be transformed are transformed. In one embodiment, the number of alleles to be transformed is n, and the number of donor DNAs for selection markers is introduced into the chromosome genome, and all alleles are transformed. In one embodiment, in this step, since the number of donor DNAs for selection markers is greater than or equal to the number of alleles to be transformed, the number of positive selection markers expressed by the cell indicates that the number of alleles has been transformed. From the perspective of improving the selection efficiency of the cells in step (b), the number of alleles to be transformed is preferably the same as the number of donor DNAs for selection markers.

[0421] As described above, in the genome modification method of the present embodiment, by inducing HDR using n kinds of selection marker donor DNA in order to modify n alleles in nploid cells, cells with all the alleles possessed by the cells can be efficiently obtained. In addition, since cells with all the alleles can be obtained, even if the size of the target region is large (e.g., more than 10 kbp), cells with the target region modified can be efficiently obtained. Therefore, large-scale genome modification can also be performed.

[0422] In one embodiment, in step (b), the modified cells can be selected from the cell pool containing the cells obtained in step (a) without cloning the cells. By omitting the cloning step, the time required for the step can be shortened. In one embodiment, the cell pool can contain 10 5 More than 10 6 More than 10 7 More than 10 8 More than one cell.

[0423] (Optional Step)

[0424] The genome modification method of this embodiment may also have optional steps in addition to the above steps (a) and (b). As optional steps, for example, the following steps (c) and (d) may be cited:

[0425] (c) after the above step (b), a step of introducing into the above cell a donor DNA for recombination containing a desired base sequence between an upstream homology arm having a homologous base sequence adjacent to the upstream side of the above target region and a downstream homology arm having a homologous base sequence adjacent to the downstream side of the above target region; and

[0426] (d) After the above step (c), a step of selecting cells that do not express the above negative selection marker.

[0427] In one embodiment, the genome modification method of the present embodiment may have an optional step in addition to the above steps (a) and (b). In one embodiment, in the genome modification method of the present embodiment or the method for obtaining a cell with a modified genome, two or more selection marker donor DNAs respectively have a selection marker gene for positive selection, another marker gene for negative selection, and a target sequence between the upstream homology arm and the downstream homology arm. Here, when the selection marker gene can be used for both positive selection and negative selection, the other selection marker gene for negative selection may not be present, and for example, the following steps (c) and (d) may be present:

[0428] (c) after the above step (b), the step of introducing the following (iii) and (iv) into the selected cells to introduce the donor DNA for recombination into the above two or more alleles,

[0429] (iii) a genome modification system comprising a sequence-specific nucleic acid cleavage molecule that can target and cleave the above-mentioned additional target sequence or a polynucleotide encoding the above-mentioned sequence-specific nucleic acid cleavage molecule

[0430] (iv) a donor DNA for recombination containing a desired base sequence, the donor DNA for recombination comprising an upstream homology arm having a base sequence capable of homologously recombination with a base sequence on the upstream side of the target region and a downstream homology arm having a base sequence capable of homologously recombination with a base sequence on the downstream side of the target region {the donor DNA for recombination may contain the desired base sequence between the upstream homology arm and the downstream homology arm, or may not contain any base sequence}; and

[0431] (d) After the above step (c), a step of selecting cells that do not express the above marker gene for negative selection (a step for negative selection).

[0432] <Step (c)>

[0433] After step (b), step (c) may be performed. In one embodiment, in step (c), a donor DNA for recombination containing or not containing a desired base sequence between an upstream homology arm and a downstream homology arm is introduced into the cell selected in step (b). In one embodiment, in step (c), a donor DNA for recombination containing a desired base sequence between an upstream homology arm having a homologous base sequence adjacent to the upstream side of the target region and a downstream homology arm having a homologous base sequence adjacent to the downstream side of the target region is introduced into the cell selected in step (b).

[0434] 《Donor DNA for Recombination》

[0435] The donor DNA for recombination can contain the desired base sequence to be knocked in. The above-mentioned desired base sequence is not particularly limited. For example, when the genome modification target is to knock out the function of the gene contained in the target region, the base sequence after a part or all of the base sequence in the target region is deleted can be used as the desired base sequence. In addition, when an exogenous gene is integrated into the target region, the base sequence containing the gene can be used as the desired base sequence. The size of the desired base sequence is not particularly limited and can be set to any size. The desired base sequence can be, for example, set to more than 10bp, more than 20bp, more than 40bp, more than 80bp, more than 200bp, more than 400bp, more than 800bp, more than 1kbp, more than 2kbp, more than 3kbp, more than 4kbp, more than 5kbp, more than 6kbp, more than 7kbp, more than 8kbp, more than 9kbp, more than 10kbp, more than 15kbp, more than 20kbp, more than 40kbp, more than 80kbp, more than 100kbp or more than 200kbp, etc. The method of the present embodiment can efficiently select the cell that has knocked into the desired base sequence in more than 2 alleles. Therefore, it is also possible to knock into the large-sized DNA of, for example, more than 5kbp, more than 8kbp or more than 10kbp. The length of the recombinant donor DNA can, for example, be shorter than the selective marker donor DNA.

[0436] The upstream homology arm and downstream homology arm possessed by the donor DNA for recombination may be the same as or different from those possessed by the donor DNA for the above-mentioned selection marker. For convenience, the upstream homology arm and downstream homology arm contained by the donor DNA for selection marker are sometimes referred to as "the first upstream homology arm" and "the first downstream homology arm", and the upstream homology arm and downstream homology arm contained by the donor DNA for recombination are referred to as "the second upstream homology arm" and "the second downstream homology arm". The second upstream homology arm and the second downstream homology arm, for example, as long as they can carry out homologous recombination with the first upstream homology arm or its upstream region and can carry out homologous recombination with the first downstream homology arm or its downstream region, their length and sequence are not particularly limited (in one embodiment, as long as they can carry out homologous recombination with the peripheral region of the target region, their length and sequence are not particularly limited). After utilizing the recombinant donor DNA for recombination, it is acceptable that a part of the base sequence of the selective marker donor DNA remains on the genome, but the base sequence of the selective marker donor DNA can be completely removed from the genome by recombination with the recombinant donor DNA. Various genes carried in the selective marker donor DNA can be removed by recombination utilizing the recombinant donor DNA. Thus, in one embodiment, more than two alleles of a cell can be replaced by the recombinant donor DNA, respectively. In one embodiment, the recombinant donor DNA can have a desired base sequence, and thus, a cell having modified more than two alleles has the desired base sequence on the modified allele.

[0437] In the donor DNA for recombination, the desired base sequence is located between the second upstream homology arm and the second downstream homology arm. When the donor DNA for recombination contains an exogenous gene, the exogenous gene is preferably functionally connected to a promoter. The donor DNA for recombination may have any control sequence such as an enhancer, a poly A addition signal, a terminator, etc. In addition, when the donor DNA for recombination contains an exogenous gene, the donor DNA for recombination may have an insulator sequence upstream and downstream of the exogenous gene. In one embodiment, the donor DNA for recombination contains a spacer sequence between the second upstream homology arm and the second downstream homology arm. In one embodiment, when removing cells having a negative selection marker gene possessed by the donor DNA for selection marker, if the donor DNA for recombination expresses a gene identical to (or indistinguishable from) the gene under conditions where its toxicity can be exerted, it is impossible to select cells that have produced homologous recombination using the donor DNA for recombination. Therefore, the donor DNA for recombination is constituted in such a manner that, when cells having the negative selection marker gene possessed by the donor DNA for selection marker are removed, a gene identical to (or indistinguishable from) the gene is not expressed under conditions where its toxicity can be exerted. For example, in one embodiment, the donor DNA for recombination does not have the negative selection marker gene and the second target sequence between the second upstream homology arm and the second downstream homology arm.

[0438] The donor DNA for recombination is preferably introduced into the cell together with the above (i). By introducing the donor DNA for recombination into the cell together with the above (i), after the DNA of the target region is cut by the sequence-specific nucleic acid cleavage molecule of the above (i), the desired base sequence in the donor DNA for recombination is knocked into the target region by HDR. The cell to be introduced into the donor DNA for recombination in this step is the cell selected in step (b), so the base sequence of the donor DNA for selection marker is knocked into the target region. Therefore, the target sequence of the genome modification system of (i) is the base sequence contained in the target region after the donor DNA for selection marker is knocked in. For convenience, the target sequence of the genome modification system in step (a) is sometimes referred to as "the first target sequence", and the target sequence of the genome modification system in step (c) is referred to as "the second target sequence". The second target sequence can use any sequence contained in the target region of the cell after step (b). In one embodiment, the second target sequence in the donor DNA for selection marker can be a sequence that does not exist in the genome of the cell. In one embodiment, the second target sequence in the selection marker donor DNA is a sequence that does not exist on the genome of the cell, and is a sequence that is different from other sequences to the extent that other sequences on the genome are not cut due to off-target. In one embodiment, the second target sequence in the selection marker donor DNA can be a cleavage site for a meganuclease that does not exist on the genome. In one embodiment, the second target sequence is a region other than the negative selection marker gene in step (d). Of course, the recombinant donor DNA is constructed in a manner that does not significantly inhibit homologous recombination using the recombinant donor DNA. In the case where the first target sequence remains in the target region of the cell after step (b) or the first target sequence is reintroduced by the selection marker donor DNA, the second target sequence may be the same as or different from the first target sequence.

[0439] The donor DNA for recombination may not contain a base sequence between the upstream homology arm and the downstream homology arm, and may also contain a base sequence of less than 10 bp, less than 20 bp, less than 30 bp, less than 40 bp, less than 50 bp, less than 60 bp, less than 70 bp, less than 80 bp, less than 90 bp, less than 100 bp, less than 200 bp, less than 300 bp, less than 400 bp, less than 500 bp, less than 600 bp, less than 700 bp, less than 800 bp, less than 900 bp or less than 1 kbp between the upstream homology arm and the downstream homology arm. The donor DNA for recombination may contain a base sequence of more than 1 kbp, more than 2 kbp, more than 3 kbp, more than 4 kbp, more than 5 kbp, more than 6 kbp, more than 7 kbp, more than 8 kbp, more than 9 kbp or more than 10 kbp between the upstream homology arm and the downstream homology arm.

[0440] Between the upstream homology arm and the downstream homology arm of the donor DNA for recombination, it may contain one or more or all of the group consisting of a selection marker gene, a target sequence of a site-specific recombinase, a gene encoding a factor with physiological activity, a gene encoding a factor with cytotoxicity and a promoter sequence, or it may not contain one or more or all of the group consisting of the above group.

[0441] In step (c), the donor DNA for recombination is introduced into the cells selected in step (b). The cells selected in step (b) have a selection marker gene knocked into the target region. Step (c) can also be referred to as a step of removing or replacing the selection marker gene knocked into the above-mentioned target region with a desired base sequence.

[0442] (Step (d))

[0443] Step (c) may be followed by step (d). In step (d), cells that do not express the negative selection marker are selected.

[0444] In the case of performing step (d), in step (a), the donor DNA for selection marker can use DNA containing positive selection marker gene and negative selection marker gene respectively. That is, the donor DNA for selection marker used in step (a) can contain positive selection marker gene and negative selection marker gene between upstream homology arm and downstream homology arm. The positional relationship between positive selection marker gene and negative selection marker gene is not particularly limited, and the positive selection marker gene can be upstream of the negative selection marker gene, or vice versa. In the case where the donor DNA for selection marker has positive selection marker gene and negative selection marker gene, a base sequence encoding a self-cleaving peptide or an IRES (internal ribozyme entry site, internal ribozyme entry site) sequence, etc. can be sandwiched between the positive selection marker gene and the negative selection marker gene. By sandwiching these sequences, the positive selection marker gene and the negative selection marker gene can be expressed independently using 1 promoter. Examples of 2A peptides include 2A peptide (F2A) from foot-and-mouth disease virus (FMDV), 2A peptide (E2A) from equine rhinitis virus (ERAV), 2A peptide (P2A) from porcine teschovirus (PTV-1), and 2A peptide (T2A) from Thosea asigna virus (TaV).

[0445] Alternatively, the same selection marker gene can be used as a positive selection marker in step (a) and as a negative selection marker in step (d). For example, when the selection marker gene is a marker gene (visual marker gene) related to the color development of fluorescence or pigments, such as a fluorescent protein gene, a luminescent enzyme gene or a chromogenic enzyme gene, cells expressing fluorescence, luminescence or color development caused by the fluorescent protein, luminescent enzyme or chromogenic enzyme can be selected in step (a), and cells in which these fluorescence, luminescence or color development have disappeared can be selected in step (c). The situation in which the same selection marker gene serves as both a positive selection marker and a negative selection marker is also included in the situation in which the selection marker donor DNA has a positive selection marker and also has a negative selection marker.

[0446] The negative selection marker gene may be different for each selection marker donor DNA, or may be the same. By using a universal negative selection marker gene, the cell selection operation in step (d) can be simplified.

[0447] In step (d), cells can be appropriately selected according to the type of negative selection marker gene used in step (a). In this case, cells that do not express any of the negative selection marker genes used in step (a) are selected.

[0448] For example, when negative selection marker gene is a visualization marker gene such as a fluorescent protein gene, a luminescent enzyme gene or a color developing enzyme gene, select the cells in which visualization markers such as fluorescence, luminescence or color development have disappeared. In addition, when negative selection marker gene is a suicide gene, cells that do not express the above-mentioned negative selection marker can be selected by using a culture medium cell containing a medicament that shows toxicity due to the expression of the suicide gene. For example, when using a thymidine kinase gene as a suicide gene, cells can be cultured in a culture medium containing ganciclovir. The disappearance of the expression of the negative selection marker gene means that the negative selection marker gene that is integrated into the target region in step (a) is replaced with a polynucleotide containing the desired base sequence of a recombinant donor DNA. At this point, it is believed that the replacement of polynucleotides occurs in the base sequence overall knocked in step (a). Therefore, by selecting the cell in which the expression of the negative selection marker gene has disappeared, the cell in which the base sequence knocked in step (a) is replaced by the desired base sequence of a recombinant donor DNA can be efficiently selected. Negative selection marker genes such as suicide genes can be functionally linked to an inducible promoter, and cells can be cultured in the presence of a drug that drives the inducible promoter in a manner that the negative selection marker gene is expressed under conditions that can exert its toxicity, thereby selecting cells that do not express the negative selection marker. In this case, the negative selection marker gene can be a gene encoding a cytotoxin (such as ricin and diphtheria toxin) that is toxic to cells only when it is expressed.

[0449] In one embodiment, step (d) can select cells modified with two or more alleles (cells without negative selection marker genes) from a cell pool containing cells obtained in step (c) without cloning cells. 5 More than 10 6 More than 10 7 More than 10 8 More than one cell.

[0450] As described above, by performing steps (c) and (d), it is possible to efficiently obtain cells in which all alleles possessed by cells are transformed into cells of desired sequences. In addition, since it is indeed possible to obtain cells in which all alleles have been transformed, even if the size of the desired base sequence is large (e.g., more than 10kbp), it is possible to efficiently obtain cells in which the base sequence has been knocked into the target region. In one embodiment, by performing steps (c) and (d), the target region is missing in all alleles possessed by cells, and its front and back (i.e., the sequence in which homologous recombination occurs respectively in the upstream homologous arm and the downstream homologous arm) are seamlessly connected in a manner that is not selected from the group consisting of the insertion, displacement and deletion of free bases, more than one (e.g., the insertion, displacement and deletion of no bases). In one embodiment, in the obtained cell, the base sequence of the upstream side and the downstream side of the defective region is seamlessly connected.

[0451] It should be noted that when the number of surviving cells obtained by step (b) is small or when no surviving cells are obtained, it is indicated that the target region removed from the genome by homologous recombination with the upstream homologous arm and the downstream homologous arm contains a gene that affects the proliferation or survival of the cell. Therefore, it is possible to investigate whether the target region contains a gene that affects the proliferation or survival of the cell. In addition, in this case, the design position of the upstream homologous arm and the downstream homologous arm can be changed to transform the gene that disappears from the genome due to homologous recombination, thereby determining the gene that affects the proliferation or survival of the cell. Therefore, in the present invention, step (e) can be performed after step (b). That is, step (e) includes: when the number of surviving cells in step (b) is small or when no surviving cells are obtained, the target region is made smaller and the gene that disappears from the genome is reduced, thereby determining the gene that affects the proliferation or survival of the cell. When the target region contains only 1 gene, it is indicated that the gene is a gene that affects the proliferation or survival of the cell. Then, in the case of determining the gene that affects the proliferation or survival of the cell, step (f) can be performed. Step (f) includes: knocking the determined gene affecting the proliferation or survival of the cell into other regions of the genome to be transformed (such as safe harbor regions, etc.) {recombination donor DNA can be used when knocking in}. Thus, the region removed by the method of the present invention can be expanded (the target region is extended upstream and / or downstream). The small number of surviving cells can be confirmed by comparing the number of cells obtained when implementing steps (a) and (b) with the region that does not affect the survival and proliferation of the cell. In one embodiment, the region that causes the proliferation and survival of the cell to disappear may not be used as the target region in step (a). The present invention includes, for example, the following steps: for the genomic DNA of the cell having a deletion in the chromosome region of (i), knocking in the desired gene in the chromosome region of (i) or in the region outside (i) (such as a safe harbor region, etc.). Such a cell has a genome having a deletion in the chromosome region of (i) and a gene encoding a desired gene in the chromosome region of (i) or in the region outside (i) (such as the region and safe harbor region of the above-mentioned (ii) with a deletion, etc.).

[0452] [Genome modification kit]

[0453] In one embodiment, the present invention provides a genome modification kit for modifying two or more alleles of a chromosome genome. The genome modification kit comprises the following (i) and (ii):

[0454] (i) a genome modification system comprising a sequence-specific nucleic acid cleavage molecule targeting the target region of the chromosomal genome or a polynucleotide encoding the sequence-specific nucleic acid cleavage molecule; and

[0455] (ii) two or more types of donor DNAs for selection markers, which contain the base sequence of a selection marker gene between a downstream homology arm having a homologous base sequence to the base sequence adjacent to the upstream side of the above-mentioned target region and a downstream homology arm having a homologous base sequence to the base sequence adjacent to the downstream side of the above-mentioned target region, wherein the above-mentioned two or more types of donor DNAs for selection markers have different selection marker genes, and the number of types of the above-mentioned donor DNAs for selection markers is greater than or equal to the number of the above-mentioned alleles to be the object of genome modification.

[0456] In one embodiment, the present invention is a genome modification kit for modifying two or more alleles of a chromosomal genome comprising the following (i) and (ii):

[0457] (i) A genome modification system comprising a sequence-specific nucleic acid cleavage molecule that can target and cleave the target region of the chromosome genome or a polynucleotide encoding the sequence-specific nucleic acid cleavage molecule

[0458] (ii) Two or more donor DNAs for selection markers, which have an upstream homologous arm having a base sequence that can undergo homologous recombination with the base sequence on the upstream side of the above-mentioned target region and a downstream homologous arm having a base sequence that can undergo homologous recombination with the base sequence on the downstream side of the above-mentioned target region, and the base sequence of the selection marker gene is contained between the upstream homologous arm and the downstream homologous arm. The above-mentioned two or more donor DNAs for selection markers have selection marker genes that can be distinguished from each other, and the number of types of the above-mentioned donor DNAs for selection markers is greater than or equal to the number of the above-mentioned alleles as the object of genome modification. In this method, the above-mentioned selection marker gene can be unique to each donor DNA for selection markers. The above-mentioned kit can be used in the method of the present invention. The above-mentioned kit can be used in a method for preparing cells in which two or more alleles of a chromosomal genome have been modified.

[0459] (i) and (ii) contained in the kit of this embodiment are the same as (i) and (ii) described in the above section [Genome modification method]. By using the kit of this embodiment, the above genome modification method can be easily performed.

[0460] In one embodiment, the present invention provides cells that have been modified with more than two alleles of a chromosome genome, and in which the more than two alleles have different (distinguishable) selection marker genes. In one embodiment, the cell can be a cell of a unicellular organism. In one embodiment, the cell can be a cell after separation. In one embodiment, the cell can be a cell selected from a group consisting of pluripotent cells and pluripotent stem cells (embryonic stem cells and induced pluripotent stem cells, etc.). In one embodiment, the cell can be a tissue stem cell. In one embodiment, the cell can be a somatic cell. In one embodiment, the cell can be a reproductive series cell (such as a reproductive cell). In one embodiment, the cell can be a cell strain. In one embodiment, the cell can be an immortalized cell. In one embodiment, the cell can be a cancer cell. In one embodiment, the cell can be a non-cancerous cell. In one embodiment, the cell can be a cell of a disease patient. In one embodiment, the cell can be a cell of a healthy person. In one embodiment, the cell can be an animal cell (e.g., a human cell), for example, a cell selected from the group consisting of insect cells (e.g., silkworm cells), HEK293 cells, HEK293T cells, Expi293F (trademark) cells, FreeStyle (trademark) 293F cells, Chinese hamster ovary cells (CHO cells), CHO-S cells, CHO-K1 cells, and ExpiCHO cells, and cells derived from these cells. In a preferred embodiment, all alleles of the target region of the chromosome genome in the above-mentioned cell are modified, and the modified regions respectively have different (distinguishable) selection marker genes.

[0461] In one embodiment, a method for culturing cells in which two or more alleles of a chromosome genome are modified and each of the two or more alleles has a different (distinguishable) selection marker gene. When the selection marker gene is a drug resistance marker gene, the culture can be carried out in the presence of a drug for each drug resistance marker gene. The culture can be carried out under conditions suitable for the maintenance or proliferation of the cells.

[0462] In one embodiment, the present invention provides a non-human organism having a chromosomal genome modified with two or more alleles, and each of the two or more alleles has a different (distinguishable) selection marker gene. In one embodiment, the cell can be a cell of a unicellular organism. In one embodiment, the non-human organism can be a yeast (e.g., a fission yeast or a budding yeast, for example, selected from the genus Saccharomyces cerevisiae, Saccharomyces carlsbergensis, Saccharomyces fragilis, Saccharomyces rouxii, etc.; Candida utilis, Candida tropicalis, etc. tropicalis) and other Candida species; organisms in the group consisting of Pichia, Kluyveromyces, Yarrowia, Hansenula, Endomyces and other yeasts. In one embodiment, the non-human organism can be a filamentous fungus (e.g., Aspergillus, Trichoderma, Humicola, Acremonium, Fusarium and Penicillium species). In one embodiment, the non-human organism can be a multicellular organism. In one embodiment, the non-human organism can be a non-human animal. In one embodiment, the non-human organism can be a plant. In a preferred embodiment, in the above-mentioned non-human organism, all alleles of the target region of the chromosomal genome are modified, and the modified regions respectively have different (distinguishable) selection marker genes.

[0463] In the above-mentioned cells, one or more desired genes such as genes necessary for cell survival and proliferation may be included or concentrated in other regions of the chromosome genome. Other regions may be, for example, safe harbor regions (e.g., AAVS1 regions, etc.). Other regions may be, for example, regions of the above-mentioned (ii) that have deletions.

[0464] Example

[0465] Example 1: Search results of homologous sequences

[0466] Using each HLA as a query, a Blat search was performed on the human genome sequence (hg38 genome sequence). HLA-A, B, C, E, F, G, H, J, and W; MICA and MICB; and HLA-DRA, DRB1, DRB5, DRB6, DRB9, DQA1, DQA2, DQB1, DPA1, DPB1, DMB, DOA, and DOB were searched as queries. The results are as follows: Figures 1 to 25 shown.

[0467] like Figures 1 to 25 As shown, more than two similar sequences clustered in the region of (i) chr6:29711000-30020000, (ii) chr6:31176000-31534000b, (iii) chr6:32445000-32821000, and (iv) chr6:33020000-33147000. Fig.26 A summary of the results is summarized. Fig.26 (i) to (iv) in the above regions correspond to the above regions, respectively. More specifically, two or more similar sequences exist in (i) a chromosomal region corresponding to the chromosomal region of chr6: 29723464-29945455 of the hg38 genomic sequence, (ii) a chromosomal region corresponding to the chromosomal region of chr6: 31269169-31357158 of the hg38 genomic sequence, (iii) a chromosomal region corresponding to the chromosomal region of chr6: 32439951-32816951 of the hg38 genomic sequence, and (iv) a chromosomal region corresponding to the chromosomal region of chr6: 33006838-33086238 of the hg38 genomic sequence.

[0468] One of the reasons why sequence decoding of the HLA locus is difficult is the aggregation of more than two similar sequences. Therefore, even if you want to selectively destroy one gene in any region of (i) to (iv), the genome editing method containing CRISPR / Cas9 is also likely to apply modifications to other similar sequences on the basis of applying modifications to the targeted gene. In addition, it is difficult to perform sequence decoding of the destroyed region due to the presence of repeated similar sequences, so it is also difficult to investigate the impact on the surrounding similar sequences. Therefore, the present invention provides cells that are missing at least one, preferably two, more preferably three, and further preferably four of (i) to (iv). At least one HLA of such a cell is missing, and the sequence decoding of the surrounding of the missing region is easy. Therefore, it is suitable for clarifying whether further editing is successful by sequence decoding.

[0469] According to International Publication No. 2021 / 206054, a technology (UKiS) is disclosed for efficiently making a specific region of hundreds of kb deleted simultaneously on two alleles in diploid cells. Common genome editing can efficiently edit the unilateral allele in diploid cells, but the efficiency of editing two alleles simultaneously is extremely low. UKiS technology significantly improves the efficiency of editing two alleles simultaneously, and is suitable for this knockout purpose. In International Publication No. 2021 / 206054, a donor DNA having an upstream homology arm and a downstream homology arm adjacent to the region to be deleted and a selection marker that can be distinguished from each other between the upstream homology arm and the downstream homology arm is contacted with any one of the first genomic DNA part hybridized with the upstream homology arm and the second genomic DNA part hybridized with the downstream homology arm or preferably both of them has a genomic DNA cut, thus, the genomic DNA region present between the first genomic DNA part and the second genomic DNA part is deleted, and is replaced with a sequence (the third sequence) between the upstream homology arm and the downstream homology arm. In International Publication No. 2021 / 206054, a genomic DNA can be obtained in which the third sequence can also be removed from the genomic DNA and the first genomic DNA portion and the second genomic DNA portion are seamlessly connected. In addition, in International Publication No. 2021 / 206054, the same modification can be achieved simultaneously on two alleles. In this way, by using a genome modification technology such as the technology disclosed in International Publication No. 2021 / 206054, the HLA region with many repetitive sequences can be completely deleted from the genomic DNA.

[0470] According to the present embodiment, the regions of (i) to (iv) are considered to be regions where sequence decoding is difficult. Therefore, by deleting at least one of the regions that are considered to be difficult to sequence decode, sequence decoding becomes easy for the region with the deletion. In addition, by deleting the repetitive sequence, the risk of off-target modification caused by the target of genome editing appearing in other unexpected repetitive sequences can also be reduced. Moreover, the sequence decoding of the modified genomic DNA is easy, so it is possible to confirm whether the modification has been carried out according to the target.

[0471] Therefore, it can be understood that according to the present invention, in principle, UkiS can be used to produce cells that are deficient in at least one, preferably two, more preferably three, and further preferably four of (i) to (iv). In order to apply the UKiS technology, a single sequence on the genome is required. By targeting the single sequence, sequence-specific deletions can be introduced. In the case of small regional deletions, due to repetitive sequences, the sequence that serves as the target of homologous recombination constitutes a repetitive sequence, making it difficult to perform accurate homologous recombination. When the above-mentioned large region is deleted, a single sequence on the genome can be selected as the target sequence for homologous recombination and appropriately performed.

[0472] Figures 27 to 34 The results of the search performed to determine the telomere-side boundary and the centromere-side boundary for the above (i) to (iv) are shown in FIG. Fig. 27 Region 1 and region 2 have similar sequences and therefore cannot be targeted. In contrast, region 3 is a single sequence that does not have a similar sequence and therefore can be a candidate for a targetable sequence.

[0473] Example 2: Preparation of HLA-deficient cells

[0474] In this example, the technique of the present invention was applied to cells to induce HLA deficiency. As cells, iPS cells having the ability to differentiate into various cells were used.

[0475] (1) Introduction of UKiS mark

[0476] Preparation of cells: 1.25×10 cells were cultured in each well of a 24-well plate pre-coated with iMatrix-511 diluted 150-fold with DPBS. 5 iPS cells were seeded with 10 cells per well. StemFit AK02N (10 μM Y-27632) was used as the culture medium.

[0477] Insertion of marker: Mix 50 μL of OptiMEM, 300 ng of gRNA / Cas9 expression plasmid for marker insertion sequence cutting, 100 ng of donor plasmid (GFP-Puro), 100 ng of donor plasmid (RFP-Blst), and 2 μL of Lipofectamine stem cell transfection reagent, incubate at room temperature for 5 minutes, and add the resulting transfection solution to a 24-well plate seeded with cells. The donor plasmid (GFP-Puro) has genes encoding green fluorescent protein (GFP) and a puromycin resistance gene (Puro) as a drug resistance gene operably linked to the EF1 promoter. GFP and Puro are connected via the T2A sequence. The donor plasmid (RFP-Blst) has genes encoding red fluorescent protein (RFP) and a blasticidin resistance gene (Blst) as a drug resistance gene operably linked to the EF1 promoter. RFP and Blst are connected via the T2A sequence. Details are described in Examples 1 and 2 of WO2021 / 206054. Figure 1 In this specification, the marker carried by the donor plasmid is referred to as the UKiS marker, and the cells introduced with the UKiS marker are referred to as UKiS marker-introduced cells. In addition, the UKiS marker-introduced cells are also referred to as UKiS stage 1 cells.

[0478] Drug selection and expanded culture: The obtained cells are sown in 6-well plates, and the cells are selected for drug in the presence of puromycin and blasticidin. As a medium for drug selection, StemFitR AK02N (containing 1 μM puromycin, 10 μM blasticidin) is used. Thus, the surviving cells after drug selection are resistant to both drugs, i.e., cells having both puromycin resistance genes and blasticidin resistance genes. In theory, such cells are produced when a puromycin resistance gene is introduced into a monoallele in the region targeted by gRNA and a blasticidin resistance gene is introduced into another allele. The surviving cells are expanded and cultured to obtain cells with a UKiS marker. Cells with a UKiS marker are cloned as needed. The cells are cloned by cloning and recovering the surviving cells after drug selection one by one and causing the cells to proliferate.

[0479] (2) Cutting at two sites on the genome and flow cytometry

[0480] Preparation of cells: 1.25×10 cells were cultured in each well of a 24-well plate pre-coated with iMatrix-511 diluted 150-fold with DPBS. 5 iPS cells were seeded with 10 cells per well. StemFit AK02N (10 μM Y-27632) was used as the culture medium.

[0481] Introduction of gRNA / Cas9: Prepare two gRNAs in such a way that both ends of the region to be deleted are targeted. Mix solution 1 (OptiMEM 25μL, CRISPRMAX 1.5μL) and solution 2 (OptiMEM 25μL, gRNA (left side) 62.5ng, gRNA (right side) 62.5ng, Cas9 protein 750μg, Cas9 plus 1.2μL), incubate at room temperature for 5 minutes, and add the resulting transfection solution to the 24-well plate seeded with cells. Replace the culture medium after 24 hours.

[0482] Flow cytometry: After culturing, GFP-negative and RFP-negative cells are selected using a flow cytometer, and the cells are seeded one by one in a 96-well plate to allow the cells to proliferate. In this way, cells in which the region containing the UKiS marker introduction region is deleted in both alleles can be obtained.

[0483] (3) Genotyping PCR

[0484] Genome purification: recovery of about 2×10 5 The mutations were introduced into cells and the genomes were purified.

[0485] As primers for genotyping, the primers shown in the following Table 1 were used. PCR was carried out according to a conventional method.

[0486] [Table 1]

[0487] Table 1: Primers for genotyping

[0488]

[0489] [Table 2]

[0490] Table 2: gRNAs for genome cleavage

[0491]

[0492] (4) Further transformation of cloned UKiS-labeled cells

[0493] The introduction of UKiS markers into cells becomes a platform for various further transformations. The introduction of UKiS markers into cells is provided for further transformation, and the region into which the UKiS marker is inserted (the UKiS marker insertion region) is cut so that it contacts a further donor DNA, whereby the UKiS marker introduction region can be replaced with the sequence of the further donor DNA. For example, cells (i.e., UKiS marker introduction cells) into which different UKiS markers that can be distinguished are introduced are prepared. By selectively cutting an allele in the UKiS marker insertion region, the one allele can be transformed. Another allele can also be transformed in the same manner.

[0494] Specifically, OptiMEM 50 μL, UKiS marker insertion region cutting gRNA / Cas9 expression plasmid (GFP allele or RFP allele) 400 ng, mutation introduction donor plasmid 100 ng, Lipofectamine stem cell transfection reagent 2 μL were mixed, incubated at room temperature for 5 minutes, and the resulting transfection solution was added to the 24-well plate seeded with cells. GFP-negative cells or RFP-negative cells were recovered by flow cytometry and the cells were allowed to proliferate.

[0495] The cells obtained in this way indeed lacked the following four regions: chr6: 29706837-29956199, chr6: 31225738-31376781, chr6: 32421257-32820167 and chr6: 32934298-33161621.

[0496] (5) Evaluation of HLA expression

[0497] The cells were dissociated into single cells using TrypLE, washed with PBS containing 0.5% BSA, and exposed to anti-HLA-A antibody, anti-HLA-B antibody, and anti-HLA-C antibody (BioLegend 311413; 200-fold dilution), and analyzed using flow cytometry after washing.

[0498] (6) Evaluation of the expression of pluripotent stem cell markers

[0499] Fix the cells with PBS containing 4% paraformaldehyde. After washing the cells with PBS, add PBST and let stand at room temperature for 30 minutes. Let stand at room temperature for 1 hour in PBST containing 1% bovine serum albumin (BSA). React the cells with primary antibodies (anti-OCT4 antibody, anti-NANOG antibody, anti-SSEA4 antibody). Wash and react the cells with secondary antibodies. Then stain the nuclei with DAPI. Observe the stained cells under a confocal microscope.

[0500] result

[0501] The region between HLA-G and HLA-A of the cell was targeted with gRNA and cleaved with Cas9 to integrate the UKiS marker into the region (refer to Fig.36 ). The cells obtained by drug selection in the presence of Puro and Blst were targeted with gRNA outside the HLA-F to HLA-A region and cleaved with Cas9 to obtain cells in which the entire HLA-F to HLA-A region was deleted (clones 27 and 29) (refer to Fig.36 ).

[0502] Then, the region between HLA-C and HLA-B of clone 27 was targeted with gRNA and cleaved with Cas9 to integrate the UKiS marker into the region (refer to Fig.37 ). The outer side of the HLA-F to HLA-A region of the clone obtained by drug selection in the presence of Puro and Blst was targeted with gRNA and cleaved with Cas9 to obtain cells (clone 6) in which the entire HLA-F to HLA-A region was deleted (refer to Fig.37 ).

[0503] For clone 6, the expression of HLA-A, HLA-B, and HLA-C was confirmed by flow cytometry. Fig.28 As shown, almost all cells before transformation (iPS 771-3G WT) were positive for at least one of HLA-A, HLA-B and HLA-C, whereas the expression of HLA-C was completely lost in clone 6 obtained by transformation.

[0504] Then, the expression of pluripotent stem cell markers in the transformed cells (clone 6) was confirmed. Fig.39As shown, the transformed cells (clone 6) expressed pluripotent stem cell markers comparable to those of the iPS cells before transformation, indicating that the large-scale deletion of the HLA region did not significantly affect cell proliferation and pluripotency.

[0505] Furthermore, the region containing HLA-E was targeted with gRNA from clone 6 and cleaved with Cas9 to integrate the UKiS marker into the region (refer to Fig.40 As a result, 8 clones with UKiS markers replacing the HLA-E region were obtained (refer to Fig.40 ).

[0506] From one of the eight clones obtained, the UKiS marker was removed one by one (refer to Fig.41 As a result, 13 clones were obtained in which the region containing HLA-E was completely deleted (refer to Fig.41 ).

[0507] The HLA class II region was further deleted in clone 6. Specifically, HLA-DQB1 of clone 6 was targeted with gRNA and cleaved with Cas9 to integrate the UKiS marker into this region (see Fig.42 ). Then, the outside of the series of regions from HLA-DRA to HLA-DOB was targeted with gRNA and cut with Cas9 to obtain cells (clone 2) in which the series of regions were deleted (refer to Fig.42 ).

[0508] The other regions of HLA class II were further deleted in clone 6. Specifically, HLA-DOA of clone 6 was targeted with gRNA and cleaved with Cas9, and the UKiS marker was integrated into this region (see Fig.43 ). Then, the outside of a series of regions containing HLA-DMB to HLA-DPB2 was targeted with gRNA and cut with Cas9 to obtain cells (clones 9 and 13) in which the above series of regions were deleted ( Fig.43 ). Furthermore, in Fig.42 Among the clones obtained in Fig.44 The HLA region was deleted by the scheme. As a result, clones 6 to 9 ( Fig.44 ).

[0509] It can be seen from this that according to the present invention, the HLA aggregation region can be edited or deleted, and two or more HLA aggregation regions can be deleted.

[0510] Furthermore, various foreign genes can be introduced into any region (e.g., the HLA-E locus). Fig.45The diagram shows a scheme for introducing a foreign gene into cells in which HLA-E is deleted from cells (HLA-A to C, F, and G are deleted) and a UKiS marker is introduced into the region instead. Fig.45 In the present invention, HLA-E (MAVMAPRTLLLLLSGALALTQTWAGSHSLKYFHTSVSRPGRGEPRFISVGYVDDTQFVRFDNDAASPRMVPRAPWMEQEGSEYWDRETRSARDTAQIFRVNLRTLRGYYNQSEAGSHTLQWMHGCELGPDRRFLRGYEQFAYDGKDYLTLNEDLRSWTAVDTAAQISEQKSNDASEAEHQRAYLEDTCVEWLHKYLEKGKETLLHLEPPKTHVTHHPISDHEATLRCWALGFYPAEITLTWQQDGEGHTQDTELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPVTLRWKPASQPTIPIVGIIAGLVLLGSVVSGAVVAAVIWRKKSSGGKGGSYSKAEWSDSAQGSESHSL) artificially linked with a signal sequence was integrated into the above locus. The signal sequence used was a sequence corresponding to the amino acids 2 to 15 of HLA-A (AVMAPRTLLLLLSG). Fig.45 As shown, foreign genes were successfully introduced into 6 / 7 clones.

[0511] Furthermore, HLA-A to C and E as foreign genes are introduced into any region (for example, the locus of HLA-E). Fig.46 The diagram shows a scheme for introducing a foreign gene into cells in which HLA-E is deleted from cells (HLA-A to C, F, and G are deleted) and a UKiS marker is introduced into the region instead. Fig.46 In the experiment, HLA-A, HLA-B, HLA-C and HLA-E were integrated into the above loci as exogenous electrons. These genes respectively include the upstream of the protein coding region to the downstream of the stop codon, and each gene also includes all the introns naturally contained. Specifically, HLA-A includes the upstream 2.3kbp to the downstream 1.1kbp of the coding region, HLA-B includes the upstream 2.1kbp to the downstream 1.1kbp of the coding region, HLA-C includes the upstream 2.2kbp to the downstream 1.1kbp of the coding region, and HLA-E includes the upstream 2.6kbp to the downstream 2.2kbp of the coding region. The results are as follows. Fig.47 and 48As shown, the desired foreign gene was successfully integrated into the desired allele. The expression of the introduced foreign gene in the obtained cells was confirmed by flow cytometry. As antibodies for cell detection, antibodies that bind to HLA-A, B and C (Biolegend, Manufacturing No.: 311413) were used. HLA expression was observed in the original iPS cells, but the genes encoding these HLAs were missing in the modified cells (LxUDC (1.0)), and the cell surface expression of HLA actually disappeared (refer to Fig.49 ). In contrast, HLA cell surface expression was confirmed in cells that integrated HLA-A and B (refer to Fig.49 ). HLA cell surface expression was also confirmed in cells that integrated HLA-C and E (refer to Fig.49 ). Thus, according to the method of the present invention, the desired gene can be integrated into each monoallelic gene. For example, by introducing natural HLA into HLA-deficient cells in a manner including control sequences and introns as in this embodiment, the expression level and functional evaluation of the introduced HLA can be evaluated. Therefore, it is considered to be useful in the expression analysis and functional evaluation of HLA-like sequences and each polymorphism.

[0512] It was confirmed that the above UDC can prevent T cell cell killing. iPS cells (wild type), LxUDC (1.0)_E-Del, or β2-microglobulin (B2M) knockout cells were mixed with T cells at a ratio of 1:1, 1:3, 1:5, or 1:10, and T cell cytotoxicity was confirmed. The results are as follows Fig.50 As shown, LxUDC(1.0)_E-Del was more strongly protected from cell killing than B2M knockout.

[0513] Contents of the sequence listing

[0514] Serial number: 1 cttcatctcc gtcggctacg 20

[0515] Serial number: 2 atgatggaaa actcgatggg 20

[0516] Serial number:3 tggaatccgg tataggcgcc 20

[0517] Serial number: 4 tgagtgaccc gataaaactc 20

[0518] Serial number:5 tcttaaaaac ttctatatcg 20

[0519] Serial number: 6 gtgcaactcc cgaataggct 20

[0520] Serial number:7 tgggccttat catccgtcaa 20

[0521] Serial number:8 tgggtctgtc gagcacaagg 20

[0522] Serial number: 9 ggtcaaatgc cttgtactcg 20

[0523] Serial number: 10 gggagggccg gtaccgttga 20

[0524] Serial number: 11 atagctaacg tcactattgc 20

[0525] Serial number:12 cgttctcagc gcgggcacta 20

[0526] Serial number:13 gccgctgccg ctctacgctt 20

[0527] Serial number: 14 cagaaagggt aagcgcacag 20

[0528] Serial number:15 ggcgcaacgc gatcgcgtaa 20

[0529] Serial number:16 gacgccagtg cattcgacga 20

[0530] Serial number: 17 ggcgcaacgc gatcgcgtaa 20

[0531] Serial number:18cctcaccttcccctcttttc20

[0532] Serial number:19 accttcccct gtgacttgtg 20

[0533] Serial number:20 ctcaccttcc cttcctttcc 20

[0534] Serial number:21 accttcccct gtgatttgtg 20

[0535] Serial number:22 ccaccaccct gtctttgact 20

[0536] Serial number:23 tgtcacccct tccttacctg 20

[0537] Serial number:24 gaggcagaaa ggcacacata 20

[0538] Serial number:25 agcctctcct tcccattctt 20

[0539] Serial number:26 tccatcaacc tctcatagca aa 22

[0540] Serial number:27 acttctggaa attccttttg g 21

[0541] Serial number:28 gatggcccat gtgtggat 18

[0542] Serial number:29 ttatcccagg tgcctgtgtc 20

[0543] Serial number:30 ttcccactta cagccagacc 20

[0544] Serial number:31 tacgggaggt agccagtgtt 20

[0545] Serial number:32 tgggaagtgg tcaggagata a 21

[0546] Serial number:33 ggccttccat ctgttgct 18

[0547] Serial number:34 gacatcggca aggtgtgg 18

[0548] Serial number:35 gtggtggagt gaacggaga 19

[0549] Serial number:36 tgggaagtgg tcaggagata a 21

[0550] Serial number:37 tgtaatcttc tctgtcgcta cttc 24

[0551] Serial number:38 tgcaccagat tgttttgtgt 20

[0552] Serial number:39 gtggtggagt gaacggaga 19

[0553] Serial number:40 ccaccttagc ctcctcctct 20

[0554] Serial number:41 aaagcatatt tgggcactct g 21

[0555] Serial number:42 agacaagttc accccaccag 20

[0556] Serial number:43 tcacctccat gtgccttaca 20

[0557] Serial number:44 acagagagaa gggcacagga 20

[0558] Serial number:45 catcagcaga agggaggaag 20

[0559] Serial number:46 aacatgcaaa ggggattctg 20

[0560] Serial number:47 tggaagtggc ttttggtttc 20

[0561] Serial number:48 tggatttcat gcctcacaaa 20

[0562] Serial number:49 ttcctcttgt ctccccagaa 20

[0563] Serial number:50 caccatcacc cttcttccac 20

[0564] Serial number:51 tgcttcctct tcccagctaa 20

[0565] Serial number:52 caccatcacc cttcttccac 20

[0566] Serial number:53 tgcttcctct tcccagctaa 20

[0567] Serial number:54 gcagagagtg ggaccaagag 20

[0568] Serial number:55 tgctaattct ggggagatgg 20

[0569] Serial number:56 tccatcaggg tcttctggtc 20

[0570] Serial number: 57 tttttaaccg gctctggatg 20

[0571] Serial number:58 gagagccctt agctggtgtg 20

[0572] Serial number:59 gtgcagtttg tccacccttt 20

[0573] Serial number:60 tgggaagtgg tcaggagata a 21

[0574] Serial number: 61 gtctgggtaa gggccagggc ccccgagagt agcaggagga 40

[0575] Serial number:62 acgtagggtc cttcatcctg 20

[0576] Serial number: 63 gtggtggagt gaacggaga 19

[0577] Serial number:64 tgggaagtgg tcaggagata a 21

[0578] Serial number: 65 agacaactgc caaggacacc 20

[0579] Serial number:66 gtggtggagt gaacggaga 19

[0580] Serial number:67 ccctgtgtga gtccagaaca 20

[0581] Serial number:68 tgggaagtgg tcaggagata a 21

[0582] Serial number:69 ccctgtgtga gtccagaaca 20

[0583] Serial number:70 gtggtggagt gaacggaga 19

[0584] Serial number:71 ccctgtgtga gtccagaaca 20

[0585] Serial Number:72

[0586] MAVMAPRTLL LLLSGALALT QTWAGSHSLK YFHTSVSRPG RGEPRFISVG YVDDTQFVRF 60

[0587] WMHGCELGPD RRFLRGYEQF AYDGKDYLTL NEDLRSWTAV DTAAQISEQK SNDASEAEHQ 180

[0588] WQQDGEGHTQ DTELVETRPA GDGTFQKWAA VVVPSGEEQR YTCHVQHEGL PEPVTLRWKP 300

[0589] L 361

[0590] Serial number:73AVMAPRTLLL LLSG 14

Claims

1. A cell comprising genomic DNA having a deletion, wherein the deletion is a deletion of a region including a part or the entirety of an HLA-like sequence cluster region respectively located in one or more chromosomal regions, wherein the one or more chromosomal regions are selected from the group consisting of the chromosomal regions specified in (i) to (iv) below: (i) A series of regions containing HLA-F, HLA-G, and HLA-A; (ii) a series of regions containing HLA-C and HLA-B; (iii) a series of regions containing HLA-DRA, HLA-DRB5, and HLA-DRB1; and (iv) a series of regions containing HLA-DOA, HLA-DPA1 and HLA-DPB1, The HLA similar sequence clustering region contains all of the HLA encoding genes and HLA similar sequences respectively contained in the chromosome region, The portion contains at least one continuous region, and the one continuous region contains 50% or more of genes selected from the group consisting of HLA encoding genes and HLA similar sequences respectively contained in the region.

2. The cell according to claim 1, in, The genomic DNA contains no or only one endogenous HLA and HLA-like sequence in any one or preferably all of the deletions (i) to (iv) specified in claim 1.

3. The cell according to claim 1 or 2, in, The genomic DNA does not contain any one or preferably all of the deletions (i) to (iv) specified in claim 1 and does not contain endogenous HLA and HLA-like sequences.

4. The cell according to any one of claims 1 to 3, comprising (i) genomic DNA in which the entire HLA-like sequence cluster region in a series of regions containing HLA-F, HLA-G, and HLA-A is deleted.

5. The cell according to any one of claims 1 to 4, comprising (ii) genomic DNA in which the entire HLA-like sequence cluster region in a series of regions containing HLA-C and HLA-B is deleted.

6. The cell according to any one of claims 1 to 5, comprising (iii) genomic DNA in which the entire HLA-like sequence cluster region in the chromosome region corresponding to chr6:32445000-32821000 is deleted. 7 . The cell according to claim 1 , comprising (iv) genomic DNA in which the entire HLA-like sequence cluster region in a series of regions containing HLA-DOA, HLA-DPA1, and HLA-DPB1 is deleted.

8. The cell according to any one of claims 1 to 7, in, The deletion is a deletion of a region having the other end in a unique sequence (second sequence) in the chromosome region corresponding to chr6:29701000-29723464 of the hg38 genome sequence.

9. The cell according to any one of claims 1 to 8, in, The genomic DNA comprises an insertion of an endogenous or exogenous desired gene operably linked to a control sequence, and the insertion is located in any region of (i) to (iv) or in a region outside of (i) to (iv).

10. The cell according to any one of claims 1 to 9, in, The deletion is a deletion of a region having one end in a unique sequence (third sequence) in the chromosome region corresponding to chr6:31166000-31269169 of the hg38 genome sequence and the other end in a unique sequence (fourth sequence) in the chromosome region corresponding to chr6:31357158-31544000 of the hg38 genome sequence.

11. The cell according to any one of claims 1 to 10, in, The deletion is a deletion of a region having one end in a unique sequence (5th sequence) in the chromosome region corresponding to chr6:32416000-33445000 of the hg38 genome sequence and the other end in a unique sequence (6th sequence) in the chromosome region corresponding to chr6:32439951-32831000 of the hg38 genome sequence.

12. The cell according to any one of claims 1 to 11, in, The deletion is a deletion of a region having one end in a unique sequence (sequence 7) in the chromosome region corresponding to chr6:32924000-33006838 of the hg38 genome sequence and the other end in a unique sequence (sequence 8) in the chromosome region corresponding to chr6:33086238-33165000 of the hg38 genome sequence.

13. The cell according to any one of claims 1 to 12, in, The (i) to (iv) having deletions do not have a repetitive sequence in the chromosomal region. The cell according to any one of claims 1 to 13, which has either or both of functional β2 microglobulin and functional CIITA.

15. The cell according to any one of claims 1 to 14, in, HLA class I and / or HLA class II are not substantially expressed on the cell surface.

16. The cell according to any one of claims 1 to 15, in, The deletions ranged in size from 100 kb to 400 kb.

17. A composition comprising the cell according to any one of claims 1 to 16.

18. A cell comprising a genome having a deletion, wherein the deletion is a deletion of a region in all alleles of the genome, and the deletion comprises a portion or preferably the entire region of a locus encoding an MHC molecule containing a clustered region of MHC-like sequences.

19. The cell according to claim 18, in, Each MHC similar sequence cluster region contains less than one gene encoding an MHC molecule.

20. The cell according to claim 18, in, Each MHC similar sequence cluster region contains no more than 4 genes encoding MHC molecules.

21. The cell according to claim 18, in, Each MHC similar sequence cluster region does not contain genes encoding MHC molecules.

22. The cell according to claim 18, in, The deletion is a deletion of a region of the locus encoding the MHC molecule that contains all MHC-like sequence clusters.

23. The cell according to claim 22, in, It also contains control sequences and the desired gene operably linked to the control sequences.

24. The cell according to claim 23, in, The control sequences and the desired gene operably linked to the control sequences have sequences that are not found in their entirety in nature.

25. The cell according to claim 23, in, The control sequences and the desired gene operably linked to the control sequences have naturally occurring sequences.